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ABSTRACT 
Until recently, meta-analyses have usually been performed based on 
summary data methods. Individual patient data methods are 
becoming more popular, but the advantages of using these methods 
have not been fully investigated with regards to assessing and 
exploring heterogeneity. 
This thesis has assessed whether there are any clinically important 
differences in the results from analysing data from three meta-
analyses of randomised controlled trials in the area of stroke 
medicine, using summary and individual patient data methodologies. 
Blood pressure ill Acute Stroke Collaboration (BAS C) 
The management of blood pressure during the acute phase of stroke 
remains an enigma, therefore a systematic review and meta-analysis 
of existing randomised controlled trials was conducted to assess the 
effects of vasoactive drugs on outcome. Trends towards an increase 
in the risk of death, and death or dependency at the end of trial were 
found in patients randomised to a vasoactive drug as compared to 
those randomised to control. When baseline systolic blood pressure 
was taken into account in the analyses, patients randomised to a 
vasoactive drug had a significantly higher risk of death at the end of 
trial. Analyses also indicated that patients recruited early and within 
48 hours has significant increases in the risk of death at the end of 
trial. However, no significant effects were seen for early change in 
systolic blood pressure. 
9 . 
Community occupational therapy in stroke patients 
An evaluation of the efficacy of occupational therapy given in the 
community to stroke patients was performed using a systematic 
review and meta-analysis of randomised controlled trials. At the end 
of intervention, patient randomised to occupational therapy had 
significantly higher scores for extended and personal activities of daily 
living, and non-significantly higher scores for leisure participation. 
These effects appeared to be maintained over time. No effects were 
seen between the groups for death or minor psychiatric disorders as 
measured in patients or their carers. Subgroup analyses revealed that 
the benefits of occupational therapy were greatest when targeted 
interventions were used. Also, being male or independent at baseline 
was found to be important predictor of extended activities of daily 
living scores. 
Dipyridamole in Stroke Collaboration (DISC) 
Results from randomised controlled trials of dipyridamole, given with 
and without aspirin, for secondary prevention after stroke or transient 
ischaemic attack have given conflicting results; therefore, we 
performed a systematic review and meta-analysis. The risk of 
subsequent fatal or non-fatal stroke was reduced using the dual 
treatment of aspirin and dipyridamole as compared to either aspirin 
alone, dipyridamole alone, or control. Additionally, the dual treatment 
lowered the risk of non-fatal stroke, and subsequent vascular events 
defined by a composite outcome (non-fatal stroke, non fatal 
myocardial infarction, or vascular death). Analyses indicated that 
10 
these results were independent of method of formulation of 
dipyridamole, dose of aspirin, type of qualifying event, and gender of 
the patients. However, increasing age was found to be an important 
predictor of subsequent stroke. 
These systematic reviews demonstrate that collaborations within the 
area of stroke medicine can be successful and much data can be 
shared. The findings from meta-analyses can be informative about 
the effectiveness of particular treatment and about which patients 
should be targeted for treatment; and may help steer the direction of 
future trials. 
Although summary data meta-analyses are practically easier to 
perform, it is important that assessments and explorations of 
heterogeneity should always be performed. Meta-analyses based on 
individual patient data may be needed to allow for more in depth 
investigations of heterogeneity, especially of patient characteristics. 
However, they themselves are not the panacea to all difficulties since 
they are subject to particular problems, mainly related to obtaining 
individual patient data to enable these in depth analyses to be 
performed. 
11 
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CHAPTER 1 
AN INTRODUCTION TO SYSTEMATIC REVIEWS 
AND META-ANALYSIS 
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1.1 Introduction 
In the world of healthcare research, there is a vast quantity of 
subjective and evidence based knowledge. As researchers, we 
attempt to make sense of the evidence based knowledge which can 
be difficult especially if the findings are conflicting. How do we decide 
which of the results do we give more credibility to, and how do we 
form an overall conclusion of the findings? 
This chapter describes how research evidence may be combined in a 
narrative manner, and using statistical methodology. This chapter 
also stresses the importance of identifying all of the available 
evidence based knowledge, and then describes the problems that are 
associated with reviews and the types of bias that may be present. 
1.2 Combining sources of evidence 
Within a research area, many clinical trials and studies may have 
been performed. Some of these studies may show positive 
intervention effects or associations, others may be inconclusive or 
show negative effects or associations. This variation may be related 
to differences in the characteristics of the participants under 
assessment within the studies, known as sampling variation; or 
possibly related to the stUdies using different measures to assess the 
outcome of interest. Alternatively, some studies may have been 
unable to detect a significant difference or association because they 
were too small and hence under-powered. 
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The overall conclusion from all of these studies may be difficult to 
interpret as they stand therefore methods have been devised to help 
combine the primary knowledge, and give a more representative and 
clearer understanding of the intervention/association. 
1.3 Literature and systematic reviews 
One technique used for combining the sources of evidence is called a 
literature review. Historically, literature reviews have been used to 
pool the evidence in a narrative manner and have been largely 
unsystematic, possibly resulting in many relevant trials or studies 
being ignored. In light of the disadvantages of this method, review 
methods were developed in the 1970s which systematically examined 
all the current evidence from primary studies in a narrative manner; 
known as systematic reviews. These methods reduce the chance of 
studies being missed by identifying more relevant studies, which in 
turn should lead to a clearer and more balanced view of the current 
evidence being achieved. 
1.4 Statistically combining the current evidence 
A technique was designed to critically evaluate and statistically 
combine results from the primary trials and studies to yield 
quantifiable intervention estimates. Glass first referred to this 
systematic method of reviewing current literature and knowledge as 
'meta-analysis' (Glass 1976); Huque describes the term 'meta-
analysis' better as " ... a statistical analysis that combines or 
19 
integrates the results of several independent clinical trials considered 
by the analyst to be combinable" (Huque 1988). 
Meta-analysis has been shown to be a powerful tool, since it allows 
for quantification of an intervention or association to be estimated, 
which is not possible in literature or systematic reviews. Maximising 
the number of studies through a comprehensive literature search will 
improve statistical power in the analyses, which should in turn 
improve the estimates yielded for the effect size of an intervention or 
association. 
However, it must also be stressed that meta-analyses may also be 
used in epidemiological areas where an association may be of 
interest between two variables. The advantages and disadvantages 
of using meta-analyses are relevant for a clinical or an 
epidemiological setting. 
The numbers of meta-analyses annually published have grown 
dramatically (Easterbrook et al. 1991) and it has been clearly 
established that they have the potential to change patient care (Lau et 
al. 1992). 
1.5 Identifying eligible studies 
A critical part to any systematic review, and hence meta-analysis; is 
the identification of primary studies. Strict inclusion and exclusion 
criteria need to be formulated each time a review is performed. If all 
of the relevant studies are not identified then the result from the 
systematic review could be biased and not truly represent the 
intervention effect or association. Many biases may enter in the early 
20 
stage of a meta-analysis which could potentially affect the 
interpretation of the results and hence conclusions from the meta-
analysis. Therefore a thorough search programme needs to be well 
documented at the protocol stage to attempt to identify all of the 
available knowledge and literature. 
This programme must not just rely on identifying studies through an 
electronic search engine but must also involve searching non English 
written journals, reference lists, and through contacting authors. The 
Cochrane Collaboration (The Cochrane Collaboration 2003) and the 
NHS Centre for Reviews and Dissemination (Deeks et al. 1996) have 
published guidelines which may be followed when conducting 
systematic reviews. Both of these guidelines are similar in the 
structuring and content formats, which involve how to identify relevant 
studies and the search procedures one may use to achieve this. They 
imply that the search should be exhaustive and attempts should be 
made to identify every study that has been performed in the particular 
area of interest by using specified search strategies using search 
engines such as MEDLlNE, EMBASE and Web of Knowledge. They 
also stress the importance of hand searching reference lists and 
sifting through grey material such as dissertations, reports and 
conference proceedings. 
1.6 Biases associated with systematic reviews 
Systematic reviews are vulnerable to several problems, all of which 
may contribute to invalidating the generalisability of the results of the 
meta-analysis. As described earlier in this chapter, biased results 
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may be yielded when an inadequate search strategy has been 
performed where not all eligible studies are identified. Other sources 
of bias maybe related to publication bias, selection bias, missing data 
bias, English language bias, multiple publication bias and study 
quality bias. 
1.6.1 Publication bias 
Electronic databases such as MEDLINE or PUBMED are not 
sufficient to be the sole sources used to search for studies or trials. 
These databases only contain a selection of all medical journals. 
Another limitation is that they only contain published studies, 
therefore any unpublished data or data published as abstracts will be 
missed. This may introduce a type of bias known as publication bias 
into the meta-analysis (Easterbrook et al. 1991). 
It is generally acknowledged that studies which show a benefit with 
regards to the efficacy of an intervention, are more likely to get 
published than studies which fail to detect a benefit (Song et al. 
2000). In contrast, studies which fail to detect a benefit are more likely 
to be underpowered from using smaller sample sizes; which may lead 
to smaller studies being published in lower impact journals which 
themselves are less likely to be included in the electronic database 
(Gotzche 1987). 
A variety of statistical methods may be used to assess publication 
bias; the most common methods used include 8egg's funnel plot, 
8egg and Mazumdar's rank correlation test, and Egger's asymmetry 
test; these methods will be described and discussed in section 2.13. 
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1.6.2 Inclusion of unpublished data 
There is a debate as to whether unpublished studies should be 
included in a meta-analysis. The Cochrane Collaboration generally 
includes unpublished material in their systematic reviews, since it is 
assumed that the results from an unpublished study are comparable 
to those obtained from published studies; and excluding the study 
may invalidate the generalisability of the results from the systematic 
review. Conversely, unpublished material is likely to be of inferior 
quality and bias may be increased through including unpublished 
work in the review. However, it is possible for a sensitivity analysis to 
be performed to assess the effect of including the unpublished 
studies. The interpretation should be that if a difference is seen when 
these studies are included then it is questionable whether 
unpublished data should be excluded. 
1.6.3 Missing data bias 
Missing data can lead to bias in the results from a meta-analysis. 
Data which is missing at study level, where the study did not record 
the variable of interest, is unique to meta-analyses (Sutton et al. 
1998) and can be problematic since studies may not be included in 
the adjusted analyses. leading to a situation analogous to publication 
bias. 
Data from studies may be included in a meta-analysis at the 
individual participant level and analyses may proceed which are 
similar to those used to analyse multi-centre studies. However. data 
may be missing at the individual participant level where a person in a 
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study does not have a recorded value. If this is related to either the 
study design or the intervention under investigation. concerns are 
raised since the exclusion of these participants may over-estimate the 
efficacy of the intervention (Sutton et al. 1998). 
1.6.4 English language bias 
Studies performed in a country where English is not the first language 
are more likely to be published in non-English language journals if the 
results are inconclusive whereas studies which show benefit towards 
an intervention are more likely to be published in an English language 
journal (Moher et al. 1996). This finding is known as English language 
bias. which can lead to data being missed through inadequate search 
methods. This type of bias needs to be minimised by searching 
journals irrespective of their publication language; however. this may 
not always be achieved since many of the electronic databases are 
predominately English language based. 
1.6.5 Multiple publication bias and selection bias 
Two other types of publication bias exist; the first relates to multiple 
publication bias. which can be a serious problem in meta-analysis. It 
occurs when a study is included in the meta-analysis more than once 
because it has been published in different forms. Sometimes it may 
be unclear as to whether the identified paper is an offshoot of the 
main paper. 
The second type of bias is known as selection bias which occurs 
when only a selection of the relevant studies are chosen and their 
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inclusion is dependent upon their results, for example, only studies 
with beneficial effects are included. 
In light of these potential biases which can exist in any meta-analysis, 
it has been recommended that at least two independent reviewers 
should decide which studies are included following a thorough 
literature search; similarly, the data should be extracted from the 
primary studies to minimise errors (Deeks et a/. 1996). 
1.6.6 Assessment of study quality 
Issues relating to the quality of each study included in the meta-
analysis is an important factor to assess, since the quality of the 
studies have been found to have an impact on the results generated 
from a meta-analysis (Chalmers et a/. 1981; Schulz et a/. 1995). 
Unfortunately at present, there is no consensus on how to determine 
the quality of a trial; various checklists have been published (Moher et 
a/. 1995; 8egg et a/. 1996) although they do not give consistent 
results with each other. The scales differ considerably in the 
components they include to assess quality and in the weights they 
assign to each component. 
An example of this is a scale developed by Jadad and colleagues. 
This scale tends to gives more weight to how well the results were 
reported rather than to the methodological quality of the design of 
each study (Jadad et al. 1996). Therefore, this would imply that a 
well-designed randomised clinical trial that is poorly reported will 
receive relatively less weight than an inadequately designed study 
that mentions a statement about withdrawals and dropouts but does 
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not analyse the data according to the intention-to-treat principle, 
which is clearly debatable. 
It has been also suggested (Schulz et a/. 1995) that only double-blind 
randomised controlled trials should be included in systematic reviews 
(and meta-analyses) to improve the quality of included studies. 
However, this would imply that the results from these studies are 
more reliable than single- or un-blinded studies. Excluding these 
studies may invalidate the results; however, including these studies 
may produce biased results if the studies are of low quality. Similarly, 
it has been suggested that meta-analysis should only include trials 
which have used the intention to treat principle, since withdrawals and 
dropouts may be related to the treatment or intervention received in 
the trial. 
The Cochrane collaboration have devised recognised criteria to 
assess the quality of randomised controlled trials (The Cochrane 
Collaboration 2003). These criteria are based on assessing whether 
there is a low, moderate or high risk of bias which could invalidate the 
results from the study. Biases can be grouped into four main areas; 
selection bias, performance bias, attrition bias, and detection bias. 
Selection bias deals with whether there were systematic differences 
between how the participants were selected for inclusion into the 
study and what method was used to conceal the allocation of 
treatment. Adequate methods used for concealment of allocation 
include centralised randomisation; pre-coded identical containers 
administered directly to participants; protected onsite computer 
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system; and sequentially numbered sealed opaque envelopes. 
However, methods which include alternation, e.g. using case records 
numbers or dates of birth, are inadequate since the investigators will 
be aware of which patient received which intervention. Double 
blinding of the investigator and patients to the intervention 
assignment is the gold-standard although this can not always be 
achieved. For example, in the case of investigating the efficacy of a 
surgical intervention compared to non-surgical intervention, the 
patient and investigator will be aware of which they 
received/administered. 
Performance bias is related to whether there were differences in the 
standard of care or treatment between the two groups external to the 
intervention under study. The levels of care between the two groups 
should remain comparable so that the efficacy of the intervention can 
be studied. Attrition bias deals with whether there were differences in 
the rates of drop-outs between the two groups. Obviously, if the drop 
out rate is large for those receiving the active intervention, then this 
has implications for the practical application of the intervention. 
Lastly, detection bias deals with how the assessments were 
conducted and whether they were consistent between the two 
intervention groups. The outcome assessor should be blinded to the 
allocation of intervention to ensure that measurement of the outcome 
is not biased by prior knowledge. 
It has been found that the results of a study lacking adequate 
concealment of allocation and double blinding may result in an over-
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estimate the intervention efficacy (The Cochrane Collaboration 2003). 
However, these criteria rely on the publication giving sufficient details 
with regards to these areas; where insufficient details are given the 
investigators should be contacted for more details. 
Incorporating only randomised controlled trials in meta-analyses may 
eliminate the majority of known biases associated with study designs; 
however, other biases such as performance and attrition bias may be 
present. 
Smaller studies are usually conducted and analysed with less 
methodological rigour than larger studies and tend to show larger 
effects than would be seen with the larger studies (Kjaergard et a/. 
2001). Therefore, it has been proposed that the sample sizes of the 
studies could be categorised and analyses could be presented 
stratified by the variable to allow for an adjustment for quality (Bath et 
a/. 1998). 
1.6.7 Misleading meta-analyses 
Misleading meta-analyses have been published identifying a 
beneficial intervention effect which has not been replicated in 
subsequent clinical trials. 
An example is a meta-analysis of clinical trials which assessed the 
efficacy and safety of magnesium infusions in acute myocardial 
infarction (Yusuf et a/. 1993). The meta-analysis concluded that 
magnesium reduced all cause mortality. From these conclusions a 
large randomised controlled trial was instigated called the 181S-4 trial 
(ISIS-4 (Fourth International Study of Infarct Survival) Collaborative 
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Group 1995). The beneficial treatment effect seen in the meta-
analysis was not apparent in this subsequent clinical trial. 
A review of these findings suggests that the results from this 
misleading meta-analysis were subject to selection bias and possible 
heterogeneity (Egger 1998). It was thought that the studies included 
in the meta-analysis were not representative of all available evidence, 
e.g. publications that were inconclusive or found a detrimental 
treatment effect were under-represented. Misleading meta-analyses 
may also result from inappropriately combining heterogeneous 
studies; and it has been suggested if the studies are too 
heterogeneous, a meta-analysis should be avoided. 
1.7 Aims of the thesis 
Although meta-analyses can suffer from several problems, this has 
not prevented them from being performed widely. Until recently, many 
meta-analyses have used summary data extracted from publications 
or, where data were not extractable, supplied by the authors of the 
study. Meta-analyses were then performed using data at summary 
level. Occasionally, further more in-depth analyses have been 
performed to ascertain why there are differences between the results 
from each study by assessing the effect predictors may have on the 
results. This was achieved by ~ i t h e r r grouping the studies into 
categories, such as high versus low study quality; or by modelling a 
predictor using simple linear regression techniques, such as average 
age of patients in the study. 
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More recently, meta-analyses have been performed which use the 
raw data from the studies. The analyses used are similar to those 
performed in multicentre studies, where the data are stratified by 
study. This type of model may allow for in-depth analyses to be 
performed to assess which predictors; either at the patient level 
and/or the study level, influence the efficacy of the intervention using 
mUltivariate regression analyses. 
However, the majority of the published meta-analyses only present 
the overall efficacy results for an intervention. Although it is now 
becoming more common for additional analyses to be performed 
which investigate why there are differences between the results from 
the studies, it is still rare for them to assess the level of unexplained 
variation between the results. 
This thesis will describe the types and models that can be used in 
meta-analyses both at summary and individual patient level (Chapter 
2 and 3). These models will be exemplified using data from three 
meta-analyses of randomised controlled trials in stroke medicine 
(Chapter 4). 
The first meta-analyses is concerned with assessing the efficacy of 
vasoactive drugs in acute stroke to see whether altering blood 
pressure in patients with acute stroke is safe and effective in reducing 
the risk of death, and death or dependency; and to determine the 
effects of vasoactive drugs on systolic blood pressure (Chapter 5). 
The next meta-analysis is concerned with assessing the efficacy of 
occupational therapy in the community setting to see whether giving 
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occupational therapy in this setting is associated with a range of 
functional scores, such as extended activities of daily living and 
leisure participation; and to assess whether the differences between 
the findings of the individual trials are related to trial and/or patient 
level factors (Chapter 6). The final meta-analysis is concerned with 
assessing whether the combination of aspirin and dipyridamole given 
to stroke patients as a secondary prevention treatment is more 
effective in reducing vascular events than compared to the mono 
therapies of dipyridamole alone or aspirin alone; and also to identify 
which patients should be targeted for the combination treatment 
(Chapter 7). 
Next, this thesis aims to assess whether there are clinically important 
differences between the results from using methodologies based on 
summary and individual patient data within these meta-analyses; and 
whether there are distinct advantages to using individual patient data 
as compared to summary data methods. 
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CHAPTER 2 
SUMMARY DATA AND INDIVIDUAL PATIENT 
DATA METHODOLOGIES IN META .. ANALYSIS 
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2. 1 Introduction 
A variety of mathematical methods may be employed to combine data 
from different sources depending on the type of outcome data 
available. These methods range from being very simple to perform 
through to requiring complicated mathematics. This chapter will 
provide an overview of simple techniques for combining data; and 
describe how data from studies can be summarised and combined 
together to yield an overall result. A variety of statistical methods 
which combine data from studies using summary and individual 
patient data methodologies will be described from both classical and 
Bayesian perspectives. Additionally, several methods for assessing 
publication bias will also be described and discussed. 
2.2 Simple methods for combining studies 
Very simple methods exist for combining the conclusions from 
studies; these include methods such as vote counting and combining 
p values. Vote counting is a technique where the direction of the 
result from each study is considered. The magnitude of the result is 
not taken into account and it is usual for the Significance of the result 
to be ignored as well. It has been commented that this method can 
lead to extremely misleading results due to a lack of power 
(Greenland 1987), and can miss important sources of why the studies 
yield differing results. Therefore it has been suggested that these 
methods be used only as a prelude to a more detailed analysis 
(Greenland 1987). 
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An alternative method involves combining the significance level of the 
effect estimate ( p value) from each study. Both this method and the 
vote counting method are easy to employ but suffer from common 
problems. Specifically, these methods do not yield an estimate for the 
overall intervention effect. Therefore these methods are rarely used 
unless other more complicated methods are not possible, which is 
usually related to a lack of available data required for the other 
techniques. 
The more complicated techniques used in conventional meta-
analyses have the advantage over these simpler methods in that they 
yield an overall estimate for the intervention effect. Also, the precision 
with which this result is estimated may be presented in the form of 
confidence intervals. Conventionally 95% confidence intervals are 
presented with the point estimate. 
2.3 Single study effect estimation 
In conventional meta-analyses the data from each study is 
summarised into a single summary measure. This thesis will 
concentrate on dichotomous outcomes and continuous outcomes as 
they are pertinent to the examples used in the exemplified meta-
analyses. 
2.3.1 Dichotomous outcome measures 
The most commonly used outcome measure for summarising 
dichotomous data is the odds ratio (OR); other outcome measures 
that may be used for dichotomous data are the risk difference and the 
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risk ratio (relative risk). The odds ratio is used in a wide range of 
studies and trials; additionally it may be used in retrospective and 
cross-sectional studies which aim to assess associations rather than 
differences. The odds ratio has mathematical advantages over the 
other two measures which include symmetry with respect to 
'successes' and 'failures', and the values it takes are unrestricted 
between zero and infinity (Engels et al. 2000). Also for more 
complicated analyses such as logistic regression the odds ratios is 
the only measure of association that can be used which does not 
require special assumptions. However, the main disadvantage of the 
measure is that it is quite complicated to interpret, even using the 
simplest analyses, as compared to the relative ease of interpretation 
for the risk difference and risk ratio. However, if the outcome measure 
is rare then the odds ratio may be interpreted as a risk ratio thereby 
simplifying the interpretation of the odds ratio. Although the examples 
used within this thesis will estimate the effects using odds ratios, 
these will be interpreted as risk ratios since the outcome measures 
used are relatively rare within each of the studies. 
The risk difference (RD) is the simplest measure to use and interpret 
since an estimate of the percentage of patients who would directly 
benefit from the intervention or treatment may be calculated. It is 
appealing to a wide range of researchers since it reflects both the 
underlying risk of the control group and the reduction in risk 
associated with the intervention. However, it does not give an 
estimate that is relative (Engels et al. 2000) which is problematic 
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since it has been found that relative effect measures give more 
consistent results than absolute measures (The Cochrane 
Collaboration 2003). Additionally, the RD has been found to give 
more emphasis to the results from the studies with lower prevalence 
rates, when used in a meta-analysis. 
The risk ratio (RR) gives an estimate of relative benefit of effect; this 
outcome measure is intuitively appealing since it compares the 
probabilities from two groups in terms of their proportionate difference 
(Fleiss et 81. 1994). It is commonly used in observational studies such 
as case-control and cross-sectional studies, but is also used in 
clinical trials due to its simple interpretation. However, caution must 
be used in its interpretation since its value is asymmetrical meaning 
that the reciprocal of the RR for benefit is not equal to the relative risk 
for harm. 
The remainder of this section will focus on the methods for the odds 
ratio due to its advantages. 
2.3.1.1 Example of calculating the odds ratio 
Data from a single two-armed study may be grouped into a 2x2 table 
for each dichotomous outcome measure. 
Intervention Group 
Control Group 
Event 
Table 2.1 Binary data from the lth study 
Event free 
From Table 2.1, if we assume there are two treatment groups. The 
number of patients having an event is (a j + cj ) and the number of 
patients whom are event free is (b j + dJ. The odds ratio (OR) is the 
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ratio of the odds of an event from each group and may be calculated 
using a maximum likelihood estimate (Equation 2.1 ). 
(2.1 ) 
The estimate of the odds ratio is usually expressed in logarithmic 
form since this should provide a measure that is normally distributed 
and symmetrical about its null value (Fie iss et al. 1994). An 
asymptotic estimate of the large sample variance of the logarithm of 
the odds ratio may be estimated as shown in Equation (2.2). 
( ~ ) ) 1 111 Var InOR j =-+-+-+-
a j bj Cj d j 
(2.2) 
A 95% confidence interval may be calculated by assuming that the 
estimate of the log odds ratio is normally distributed (Equation 2.3). 
(2.3) 
It has been found that these methods of calculating the odds ratio 
work well however, sparse data in the 2x2 table can cause instability 
in the estimates yielded (Sankey et al. 1996). Also, where zero events 
are seen in either the control group or in both the intervention and the 
control groups; this leads to the study being excluded from the meta-
analysis since an estimate can not be calculated. Whitehead and 
Whitehead comment that it is appropriate for the study to be dropped 
from the meta-analysis since the data does not provide information on 
the magnitude of the intervention effects (Whitehead et al. 1991). 
However, this does not take into account the size of the study where 
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the information yielded from a small study with no events is not 
equivalent to that from a large study with a zero event rate. Therefore, 
it has become common for studies with sparse event data or where 
groups have zero events for an arbitrary value of 0.5 to be added to 
each of the cells in the 2x2 table. Adding an arbitrary value to each of 
the cells has been shown to reduce bias in the estimation of the odds 
ratio (Sankey et a/. 1996). 
2.3.1.2 Other methods for estimating the odds ratios 
Adaptations to the maximum likelihood estimate for the odds ratio 
have been developed to handle different types of problems within the 
data sets. The Mantel-Haenszel method (Mantel et al. 1959) was 
initially designed to calculate the odds ratio for individual case-control 
studies; subsequently it has been shown that it can be applied to 
most data sets (Robins et al. 1986a; Robins et al. 1986b; Hasselblad 
et a/. 1995). However, the Mantel-Haenszel method has been found 
to not compensate for sparse data within the 2x2 table and in the 
case of zero cells or very small frequencies this method should not be 
used. 
An adaptation by Peto and colleagues was devised, which is based 
on a modified likelihood, to overcome the problems associated with 
the Mantel-Haenszel method where sparse data exist (Peto et al. 
1977; Yusuf et al. 1985). This method however, can produce biased 
estimates for the intervention effect when the odds ratio is very large 
in magnitude, or when there is a serious imbalance in the numbers 
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between the intervention and control groups and hence should not be 
used in these circumstances (Fleiss 1993). 
Other more complicated techniques also exist for calculating the odds 
ratio which includes a method which uses the maximum likelihood 
method to yield an unconditional estimate using iterative formulae 
(Emerson 1994). 
2.3.2 Continuous outcome measures 
Continuous data from an individual study may be summarised; the 
most common methods include the absolute difference in means and 
the standardised difference between means. 
2.3.2.1 Absolute difference in means 
An estimate of absolute difference in means may be calculated when 
a common normally distributed outcome measure is used across the 
studies. The difference in means estimate for each study, JiWEI ' is a 
maximum likelihood estimate of the absolute difference between the 
means for the control, PCI' and intervention, P,I , group for each study 
(Equation 2.4). 
J. = Jl - II lWEI Ii rCt (2.4) 
The variance for the absolute difference in means may be estimated 
using Equation (2.5) where 0-; is the individual study variance and 
nCt and ni, are the sample sizes in the control and intervention 
groups, respectively. 
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(2.5) 
The individual study variance, a}, may be estimated using a variety 
of methods. The most common method assumes a common variance 
and uses the pooled within-group variance, Sj (Shadish et al. 1994). 
Where SCI and SII are the standard deviations for the control and 
intervention groups, respectively (Equation 2.6). 
Sj = (2.6) 
95% confidence intervals for the effect estimate may be calculated as 
described in Equation (2.7). 
(2.7) 
The absolute difference in means is used when the a/l the studies 
have assessed an outcome measure using the same scale and units, 
and therefore has an advantage that the estimate for the intervention 
effect may be described in the same units as it was measured and 
the interpretation of the estimate may be applied directly to the 
outcome measure. 
2.3.2.2 Standardised difference between means 
The standardised mean difference may be used when different 
measures have been used to assess the outcomes of the patients 
across the studies. The maximum likelihood estimate of the 
40 
standardised difference between means, 5" ,is given in Equation 
STD 
(2.8). 
(2.8) 
The standard deviation OJ is a maximum likelihood estimate, 
however, this estimate is known to be biased and therefore 
alternative sources have been suggested. Glass recommends using 
the standard deviation from the control group (Glass 1976), however 
this has also been found to be biased (Hedges et al. 1985). If it is 
reasonable to use a common variance for the standardised mean 
difference (when the variance between the two groups are similar 
within a study), Hedges and Olkin recommend using the unbiased 
estimate for the standard deviation, Sj (Equation 2.6) (Hedges et al. 
1985). 
If the variances in the active and control groups can not be assumed 
to be similar then Rosenthal suggest transforming the data using logs 
or square roots; to attempt to make the variances more similar, 
however this assumes that the original data is available (Rosenthal 
1994). 
The variance for the standardised difference between means may be 
estimated using various formulae. If the underlying data can be 
assumed to be normally distributed then the most robust method is 
the overall conditional variance, Var(5
iSTD
) (Shadish et al. 1994). 
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"2 
(" ) nl + n O. V Ii ,c, 'srD 
ar iSTD = n n + 2{n + n ) 
I, C, I, C, 
(2.9) 
The standardised mean difference method may be used if the data 
are approximately normally distributed, therefore transformations of 
the outcome data may be required to achieve normality. 
Interpreting the standardised difference between means is difficult 
because a common unit has not been used across all of the studies 
and the effect estimate was transformed to be dimensionless; hence 
the confidence intervals of the intervention effect are used primarily to 
assess significance of the effect. 
The outcome measure may be transformed to achieve approximate 
normality if there is evidence of non-normality for the absolute 
difference in means or the standardised difference between means. It 
has been suggested that the logarithm of the outcome measure may 
be used where there is evidence that the outcome measure is not 
normally distributed (Hasselblad et al. 1995), however in practice this 
is rarely performed. 
2.4 Classical approaches to meta-analysis using 
summary data 
The choice of model for the analysis is dependent upon the question 
that is being investigated. Most meta-analyses attempt to answer how 
well an intervention works mainly because this is what the individual 
trials were assessing. In this case, where the question is whether the 
intervention could ever achieve benefit then a model should be used 
which evaluates a single underlying effect estimate (Petitti 2001). This 
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model assumes that the studies included in the meta-analysis are 
homogeneous in nature designed to answer the same question using 
patients from the same population (Lau et al. 1998). 
However, if the question is related to whether the intervention will 
produce benefit "on average" then a model should be used which 
allows for the studies to be heterogeneous in their study design and 
patient populations. This allows for the intervention effect estimate to 
have extra variability and yield a global effect estimate (Petitti 2001). 
2.4.1 Fixed effect methods 
A fixed effect model will estimate the single true underlying effect by 
assuming that the variation in the intervention estimates from the 
trials are due to sampling variation alone (Fleiss 1993). When 
combining effect estimates from k individual studies, there will almost 
certainly be some degree of difference between the point estimates. If 
the point estimates vary by a small measure, then the studies are 
homogeneous and it may be appropriate to consider using a fixed 
effect model (Equation 2.10); where e is the true underlying 
intervention effect, OJ is an estimate of the underlying intervention 
effect associated with the i'th study where i = 1, .... ,k; and the error 
terms are normally distributed random variables with a mean zero 
and variance qj2; and it is assumed that q/ is equal to Var{Oi) 
(2.10) 
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An interaction between the study and the intervention effects could be 
included in the fixed effect model. This term would allow for the 
intervention effects to vary between studies and is included in the 
model as a fixed effect. However, there is usually a lack of power to 
be able to estimate the effect size of the interaction term especially 
when a small number of studies are present in the meta-analysis and 
so is rarely used in practice. 
Several methods have been proposed which combine the estimated 
effect sizes from the individual studies. The most common method 
used is weighted least squares regression, the weightings for this 
method are calculated using the inverse variance method (Birge 
1932; Cochran 1937). 
2.4.1.1 Weighted least squares regression 
In an ordinary least squares regression the observations are not 
weighted, therefore this assumes that a constant weight is given to 
each study, thereby implying that each study is of equal importance. 
The method also assumes that a common variance exists across 
studies, this is referred to as homoscedasticity (Neter et al. 1977). In 
practice this may be unreasonable, since it is inevitable that a meta-
analysis will include studies with differences in design, sample size 
and patient population. Therefore, if the intervention estimates were 
combined and the average taken, misleading results would arise, 
since the estimates would have varying degrees of precision due to 
different sample sizes. The precision to which a study estimates its 
own variation depends on the sample size of the study, each study 
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will have its own sampling error (DerSimonian et al. 1986). Generally, 
larger studies will have a more precise estimate of the intervention 
effect than smaller studies; therefore ordinary least squares 
regression method will be inadequate to incorporate the non-constant 
variances across the studies. 
The weighted least squares regression allows for non-constant 
variance across the studies (Neter et al. 1977). As the name 
suggests, this method incorporates a weighting function into the 
regression model, where a specific weight is assigned to each study 
which reflects the level of the precision the study provides. The 
weights assigned to each of the studies can vary depending on which 
assumptions are made. A conventional method of weighting that is 
used is called the inverse variance method (Birge 1932; Cochran 
1937). 
2.4.1.2 Inverse variance method 
The inverse-weighted method, sometimes referred to as Woolfs 
method, was first described in the 1930's (Birge 1932; Cochran 1937) 
and remains the most commonly used method due to its relative 
simplicity (Woolf 1955). This method may be used to combine 
summary measures whilst weighting the results of each trial, denoted 
by Wi. The weight is conventionally the reciprocal of the variance 
associated with the individual study, Var(Oi) (Equation 2.11). 
(2.11 ) 
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Describing the weighting in this manner gives more weight to larger 
studies than smaller stUdies. This seems intuitively correct since 
larger studies will generally have a smaller within-study variance, than 
compared to smaller studies, hence will tend be more precise in their 
estimation of the intervention effect size. 
A pooled estimate of the intervention effect, 0, may be calculated 
using the following Equation (2.12), where 0; is an estimate of the 
intervention effect from the i'th study. 
k 
LWjO; 
O = . . ; . . ; = . . : . . . . ~ - -
LW; 
;=1 
(2.12) 
The large sample asymptotic variance of the pooled estimate for the 
intervention effect may be estimated as the reCiprocal of the sum of 
the weights calculated from the studies. 
(2.13) 
It is assumed that the asymptotic pooled variance is normally 
distributed, however the estimate for the variance may be imprecise if 
the number of studies included in the meta-analysis is small (Li et a/. 
1994). 
Li and colleagues have found that the weights used in the above 
method are sensitive to unequal variances between intervention 
groups from each study, and become biased when the sample sizes 
in each study are not large (Li et al. 1994). They proposed a method 
for calculating the pooled sample variance based on the sample size 
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for each study which takes into account the total number of patients in 
the studies. This method was found to be more robust than previous 
methods with regards to the variation of the sample variances and the 
sample sizes within the studies, and is not sensitive to any individual 
result estimate from a particular study. It has also been suggested 
that the method based on sample size should be used when the 
sample variances are not homogeneous within a study (U et a/. 
1994). 
Potential problems may result if fixed effects models are used; there 
are concerns that the simple weighting scheme may overweight the 
results from the larger studies and not truly reflect the differences 
between the studies (Pocock et a/. 1981). Also, the results from the 
analysis can only be applied to the studies used in the meta-analysis. 
It may be undesirable to use a fixed effect model if there is a 
considerable degree of disagreement between the estimates for the 
intervention effect from the studies. This type of disagreement 
between the study estimates is called heterogeneity. An assessment 
of heterogeneity should be performed to ascertain whether there 
appears to be statistical variation between the studies. 
2.4.2 Random effects methods 
When there is a considerable difference in the estimates for the 
intervention effect between the k studies, (O' ....... Ok)' it may be more 
appropriate to compensate for the variation by assuming that they are 
a sample of independent observations from N(O, r2) and using a 
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random effect model (DerSimonian et al. 1986); where the U j are the 
random effect terms with mean zero with a variance of l"2 for 
i = l, ...... ,k ; and uj and Gj are assumed independently distributed. 
(2.14) 
The random effects model allows estimates for the intervention effect 
to vary from study to study; where the studies are assumed to be 
from a random sample of studies which follow a specified distribution. 
Conventionally the normal distribution has been used to 
accommodate the variation (Sutton et al. 1998). In the random effect 
model, the estimated variances of the intervention effects for the 
individual studies, Var{Oj)' contain two components, an estimate of 
the conditional variation, ~ / , , and an estimate of the random variation, 
f2 (Equation 2.15). 
(2.15) 
When performing a random effects analysis where the outcome is a 
dichotomous measure, the standard error for the intervention effect 
will be too conservative (Greenland 1987) unless an adjustment is 
made to fix the residual variance at one. This ensures that the 
residual heterogeneity is accounted for in the model as an additive 
effect, and not a multiplicative effect (Thompson et a/. 1999). 
The additive effect for the random effect is incorporated into the 
analysis through the weights; this allows for the more variation to be 
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estimated between the studies than would be seen using a fixed 
effect model. However, this has been criticised since a large value for 
the additive effect would result in larger studies having a smaller 
relative weight in a random effects model than a fixed effect model; 
and in contrast, the relative weights given to the results from the 
smaller sized studies will be larger (Leonardi-Bee 2000). Since there 
is the tendency for these studies to yield outlying results; these two 
issues could overtly influence the pooled intervention estimate and 
lead to a spurious result. 
The concept of allowing for the intervention effect estimates to vary 
according to a predetermined distribution means that the results can 
be generalised to other trials. However, if each study estimated 
exactly the same true effect size, then the estimated random effects 
variance would be equal to zero. The variation between the effect 
sizes across all of the studies would be attributed to sampling 
variance only; and the model would then reduce to the fixed effect 
model. 
As mention previously, an estimate of the heterogeneity, denoted as 
';2, is required; a variety of classical techniques have been proposed, 
these include the method of moments based on weighted and un-
weighted least squares regression methods, the maximum likelihood 
method and the restricted maximum likelihood method. 
2.4.2.1 Method of moments, un-weighted and weighted 
Two non-iterative methods for estimating the between study 
heterogeneity in a simple model have been proposed (DerSimonian 
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et al. 1986); which are based on using the method of moments 
approach and are relatively simple to calculate. The first uses an un-
weighted approach (DerSimonian et al. 1986; Shad ish et al. 1994), 
and so can be thought of as allowing all of the studies to have equal 
sampling variances and thus equal weightings. The methodology for 
calculating the estimate of heterogeneity is divided into three parts. 
Firstly, an ordinary un-weighted estimate of the variance for the effect 
size, S2(OUNW)' is calculated as shown in Equation (2.16), where there 
are k studies included in the meta-analysis where i = 1, ....... ,k; OJ is 
the estimate of the intervention effect, and OUNW is the un-weighted 
k A 
. L ~ ~
estimate for the intervention effect, and is specified as j = ~ ~ • 
(2.16) 
Equation (2.16) can be rearranged to form Equation (2.17). 
(2.17) 
The un-weighted sample estimate of the variance for the effect size is 
an unbiased estimate of the expectation (Equation 2.18). 
(2.18) 
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substituting an estimate of the Var(OJ for 0"2(0; IOJ and rearranging 
yields an estimate for the between study heterogeneity (Equation 
2.19). 
(2.19) 
The estimate for Var{Oi) is dependent on which effect estimate is 
chosen. In the case where the log odds ratio is used the large sample 
variance is commonly used (Equation 2.2). For the case where the 
mean difference is used, it is based on using a common variance, 0";2 
(Equation 2.5). 
The second method is known as the weighted method of moments 
(DerSimonian et a/. 1986; Shad ish et al. 1994) since it uses the 
estimate for the unconditional sample variance from a weighted 
regression and an estimate from Cochran's homogeneity statistic, Q. 
The expectation for Q is described in Equation (2.20). 
2 
(2.20) 
Substituting Q for its expectation and rearranging yields an estimate 
for 1'2 as shown in Equation (2.21). If Q is less than k -1 then ;2 is 
replaced with zero, so that the magnitude of the random effect for the 
summary estimate will not exceed the magnitude of the fixed effect 
(Higgins et al. 2002). 
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f2 = Q-(k-l) 
k (2.21) 
k LW;2 
L ;=1 W.---I k 
;=1 " L.J W; 
;=1 
Both of these estimators have not been fully studied with regards to 
their advantages (Shad ish et al. 1994). Even though the weighted 
method appears to be less complex to calculate than iterative 
methods, it only produces non-zero estimates for the between study 
heterogeneity when the value for Q is greater than the critical value 
of %2 on k-1 degrees of freedom, as detailed under the null 
hypothesis. 
2.4.2.2 Maximum likelihood methodology 
The method of maximum likelihood may be used to estimate the 
between study variability, where an iterative scheme is implemented 
(Hardy et al. 1996). A conventional weighted least squares regression 
is performed where the estimate for the heterogeneity is set to zero to 
yield an initial estimate for the pooled intervention effect. Then, e is 
fixed and an initial estimate for the heterogeneity is calculated 
(Equation 2.22). 
A2 t.w;[(O; -OJ -var(oJ] 
T = k 
LW,2 
i ~ l l
(2.22) 
The initial estimate of f2 is then used to re-calcu/ate the weights 
(Equation 2.23). 
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(2.23) 
The cycle is then repeated to generate new estimates for the 
summary statistic parameter using a weighted least squares 
regression where the weights wi are replaced with W;2. The values 
are then inputted into Equation (2.22) and a new estimate of f2 is 
calculated. The cycle is repeated until f2 converges. 
This method has been found to yield results which are smaller in 
magnitude for the between trial heterogeneity as compared to other 
methods (Turner et al. 2000), since this method uses the 
observations to calculate the log-likelihood function and is not based 
on the residual terms. The process of convergence may be slow for 
this estimator and the reliability may be poor in practice (Thompson et 
al. 1999). Therefore the maximum number of iterations specified in 
the program needs to be large enough to ensure that convergence 
has been reached and has not stopped prematurely due to the 
maximum number of iterations being exceeded. 
2.4.2.3 Restricted maximum likelihood methodology 
Restricted maximum likelihood may be used to estimate 
heterogeneity (Thompson et al. 1999). The scheme used to estimate 
the heterogeneity is similar to the method used in ML where an 
iterative cycle is used to achieve convergence. Equation (2.22) is 
slightly modified to partially allow for the pooled intervention effect 
and heterogeneity being estimated from the data (Equation 2.24). 
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The REML method has been found to be less biased than ML since 
REML uses a modified likelihood equation to estimate heterogeneity 
and the fixed effects (Brown et al. 1994). The difference in magnitude 
for the between trial heterogeneity between the ML and REML 
methods has been estimated about 10% (Turner et al. 2000); in 
contrast, REML and weighted MM techniques have been found to 
yield similar results for the heterogeneity, hence also the fixed effects, 
since the weighted MM also yields an unbiased estimate 
(DerSimonian et al. 1986). 
Both the ML and REML approaches are based on the assumption of 
normality of the random effects. However, the two methods are not 
sensitive to moderate deviations from normality (Raghunathan et a/. 
1993). Specifying the random effects distribution as non normal has 
been studied using a simulation study. Both the t- and log normal 
distributions produced similar estimates for the intervention effect 
however, the confidence intervals were slightly more conservative for 
small values of heterogeneity (Raghunathan et al. 1993). 
2.5 Meta-analysis using individual patient data 
Conventionally, data from a meta-analysis are analysed using 
summary statistics estimated from each of the studies; however it is 
possible to use the individual data from each participant within a 
study. 
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Meta-analyses which use individual patient data (IPO) have been 
quoted as the yardstick against which the quality of other systematic 
reviews of randomised controlled trials should be measured 
(Chalmers et al. 1993). The techniques used when performing IPO 
meta-analyses allow for many of the problems associated with using 
data from published articles, and a few of the problems associated 
with using summary data to be overcome. These include allowing for 
detailed data checking to be performed on each study and for 
analyses of data to be performed using consistent methods across all 
of the studies. 
However, there are some disadvantages associated with using IPO. 
These mainly include problems with obtaining the raw data from the 
investigators who are unwilling or unable to supply the data. It has 
been suspected that some trialists may not want to share their data in 
a meta-analysis because it may dilute their results of a positive 
intervention effect (Sutton et al. 1999). It has also been 
acknowledged that high costs and time are involved in building a 
database (Stewart et al. 1995). It has been estimated that a meta-
analysis based on IPO costs at least five time more than a meta-
analysis based on summary data (Steinberg et al. 1997). 
At present there appears to be little evidence that the gains from 
performing a meta-analysis based on individual patient data are 
worthwhile and justified (Sutton et al. 1999). Although since the late 
eighties, much collaboration has been achieved between 
investigators and much individual patient data has been shared to try 
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to answer pressing questions that could not be answered alone from 
using meta-analysis with summary data. 
2.6 Classical approaches to meta-analysis using 
individual patient data 
Several approaches have been advocated to analyse data in a meta-
analysis of individual patient data. A simple but na"ive method has 
been used where the data are analysed without adjusting for study 
effects (Man-Son et al. 1995). This simple method does not allow for 
the patients to be clustered within their study and hence the variability 
between the studies is not adequately described. 
An alterative simple method has involved adjusting for confounding 
factors using regression techniques within each study, followed by a 
conventional meta-analysis on the adjusted summary estimates 
(Nicolucci et al. 1996). This method is inefficient but does allow for 
problems associated with missing variables within studies to be 
overcome, since each study may be adjusted for the covariates 
recorded, and the covariates may vary between studies. 
Traditional mixed effect models (Searle 1971) or multilevel models 
(Goldstein et al. 2000) may be used to analyse IPD meta-analyses. 
Within the individual patient data meta-analysis, the study may be 
specified as either a fixed effect or a random effect; where the choice 
of method depends on the question to be answered (see Section 2.4). 
2.6.1 Fixed effect methods 
The methodology used for analysing individual patient data meta-
analysis depends on the type of outcome data and in the case where 
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either dichotomous or continuous data is used; the analysis 
performed is similar to a conventional regression analysis. 
2.6.1.1 Dichotomous outcome measures 
The outcome for a patient is denoted as Y if and is from a random 
variable Yij which has a binomial distribution with parameter trij and a 
denominator of 1. If tr ij is the probability of an event for patient j in 
study i where i = (l •....• k), then Yij =1 if the event occur and 0 if they 
are event-free (Equation 2.25). 
(2.25) 
Using a logit link function leads to a linear regression model where 
the parameter a is the intercept, POi is the study effect which is 
constrained so that POk is equal to zero, zij is a dummy variable for 
intervention assignment, and PI is the pooled log odds ratio of an 
event on intervention as compared to control (Equation 2.26). 
(2.26) 
A logistic regression analysis is performed to provide a maximum 
likelihood estimate of the intervention effect. Unlike the methods used 
when the summary outcome is based on dichotomous data where an 
assumption of normality is required for the log odds ratio; this method 
allows for the data in its binomial form to be used directly to estimate 
the log odds ratio. 
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Whitehead has compared using individual patient data as compared 
to combining summaries. and has found that the results from the two 
methods were similar and any differences in the estimates of the 
parameters were due to the normality assumption of the log odds 
ratio from the summary data model (Whitehead 2002). 
Turner and colleagues have investigated the advantages of analysing 
the log odds ratio using summary and individual patient data analysis 
methods using two examples (Turner et al. 2000). In their first 
example. they found similar odds ratios and identical standard errors 
for the intervention effects were yielded from the summary and 
individual patient data methods. 
The slight difference in the estimates for the intervention effect may 
be related to the summary data method inadequately estimating the 
parameters due to a lack of events in some of the trials. which 
required adding an arbitrary value of 0.5 to the cells within the trials 
(Turner et a/. 2000). This was exemplified in Turner and colleagues 
second example. where smaller differences between the intervention 
estimates and its standard errors for the two methodologies were 
seen. since the included trials within this meta-analysis had larger 
sample sizes and adequate numbers of events within each 
intervention group (Turner et al. 2000). 
2.6.1.2 Continuous outcome measures 
A linear model may be used to analyse data from an individual patient 
data meta-analysis based on continuous outcome data (Whitehead 
2002). Within this model. the outcome relating to patient j from study 
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i, where i = (l, .... ,k); may be denoted by Yif' The outcome Yif is from 
a random variable Yif with a Normal distribution (Equation 2.27). 
Yif - N(Pij' 0'2 ) (2.27) 
A linear model may be described where a. is the intercept, POi is 
study effect and is constrained so that POk is equal to zero, zij is a 
dummy variable relating to the intervention assignment, and PI is the 
intervention effect for the intervention group as compared to the 
control group (Equation 2.28). A common variance for the error terms 
is assumed across the studies (Whitehead 2002). 
(2.28) 
A linear regression analysis is then performed to estimate the 
parameter for the intervention effect. 
Whitehead has compared the estimates and standard errors obtained 
from modelling IPD and combining summaries (Whitehead 2002). 
The methods were found to give identical results for the intervention 
estimate. However, the standard error for the intervention estimate 
varied between the two methods where a larger estimate was seen 
from the individual patient data method as compared to the summary 
data method. The difference in the estimates is attributed to how the 
variance for each of the trials was calculated. In the summary data 
model the variances are allowed to vary across the trials, however the 
IPD model used in Equation (2.28) assumes a common variance 
59 
across all of studies. The difference in how the models are specified 
impact of the results since the estimate for the standard error of the 
intervention effect depends upon the estimates for the common 
variances (Whitehead 2002). 
2.6.2 Random effect methods 
If there are concerns using a fixed effect model where heterogeneity 
may be present then a random effect model could be considered. 
Recently. articles have been published which detail the 
implementation of multilevel models in individual patient data meta-
analyses using dichotomous, continuous or ordinal outcome 
measures (Turner et al. 2000; Higgins et al. 2001; Whitehead et al. 
2001; Whitehead 2002) although traditional mixed models can be 
used. Unlike the fixed effect model that can be performed using basic 
software, a random effect model requires the use of more expert 
software. The analyses of classical and Bayesian IPO models used in 
the examples in this thesis (Chapters 5, 6 and 7) have been 
performed using SAS for Windows (SAS Institute Inc) and WinBUGS 
(Spiegel halter et al. 2003), respectively. 
2.6.2.1 Random treatment by trial effects model 
For comparability with the models described in section 2.4.2, fixed 
effects may be specified for the intervention and study effects and a 
random effect for interaction between the intervention effect and 
study effect, thereby allowing the intervention to vary randomly across 
the studies. 
60 
2.6.2.1.1 Dichotomous outcome variables 
The model used for analysing dichotomous outcome measures is an 
extension to the fixed effect model (Equation 2.25 and 2.26) where a 
random effect term, U li , is included in the model for the interaction 
between intervention and study (Equation 2.29). 
(2.29) 
Turner and colleagues have investigated the differences between 
using summary and IPO methods to analyse the log odds ratio in a 
random effects model (Turner et aJ. 2000). They found that using 
individual patient data method yielded larger estimates for the 
heterogeneity, and hence impacted on the estimates for the 
intervention effect and its standard error. These difference maybe 
also due to the summary data method performing poorly for the 
particular data set, possibly due to the corrections made for trials with 
no events in the intervention groups (Turner et al. 2000). 
2.6.2.1.2 Continuous outcome variables 
The model used for analysing continuous outcome measures is an 
extension to the fixed effect model described (Equation 2.28) where a 
random effect term, UJj' is included in the model for the interaction 
between intervention and study (Equation 2.30). A common variance 
is assumed within each study so that the variances are not allowed to 
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vary across the study, and the Eij and uJj are assumed to be 
uncorrelated. 
UJj - N(O, Z'2 ) 
Eij - N(O,0'2) 
(2.30) 
,,2 needs to be estimated from the random effect models; ML and 
REML techniques have been proposed. The former has been found 
to yield estimates which are downwardly biased; therefore the 
restricted maximum likelihood method is preferred (Whitehead 2002) 
and used within the examples in this thesis. The approaches used in 
estimating the heterogeneity are similar to those presented in Section 
2.4.2 however; the full likelihood for the individual patient data is used 
instead of calculating the likelihood based on summary data. 
For the continuous outcome models, the Kenward and Roger 
approximation may be used to artificially inflate the standard errors of 
the variance components to allow for extra variation since this model 
assumes that the heterogeneity and variance for the error terms are 
known and not estimated from the data. 
2.7 More than two treatment groups 
This chapter has described the classical methodologies for combining 
data from trials with two treatment groups. However, trials may be 
conducted where there are multiple treatment groups, such as a new 
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treatment may be compared to not only a placebo, but also a 
standard treatment. 
Conventionally when summary data methodologies have been used, 
meta-analyses which include more than two treatment groups have 
either been collapsed into two treatment arms, or separate meta-
analyses have been performed for each pair wise comparison. 
However, the former approach is questionable since it may be 
clinically inappropriate to combine, for example, a standard treatment 
with a placebo; and the latter approach also raises questions about 
independence and multiple testing since the active treatment will be 
used in the analyses more than once. It would be more efficient to 
use a method which simultaneously estimates the pair wise 
comparisons using either a factorial design or contrast statements: 
individual patient data methods allow for this. 
An advantage of using the traditional mixed effects model as 
compared to the multilevel models is that they provide a useful 
framework to analyse data were there are multiple treatment groups 
(Whitehead 2002). 
Using the IPD models to analyse trials with more than two groups in a 
meta-analysis is advantageous over using the simple summary data 
methods, since they are not subject to the problems associated with 
independence and multiple testing (Whitehead 2002). Additionally, 
only a selection of the studies need contain more than two 
intervention groups. 
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2.8 Bayesian approaches to meta-analysis 
A Bayesian framework may be applied to meta-analysis. Unlike the 
classical analysis, the Bayesian approach allows for statements and 
predictions to be made based on external knowledge concerning the 
efficacy of the intervention of interest. This information is introduced 
into the model in the form of a prior distribution. Bayes theorem is 
used to update the prior by combining it mathematically with the data 
from the individual studies, known as the likelihood, to form a 
posterior distribution. The posterior distribution may be summarised 
by its mean, which is the pooled estimate for the intervention effect; 
its standard error, and 95% credibility intervals. 
2.8.1 Prior distributions 
Prior external knowledge is an important aspect of the Bayesian 
framework. The information for the prior distribution may be sought 
from many sources. Data may be generated from previous relevant 
reviews, observational studies, or from expert opinion. Data from 
these sources can yield a variety of prior distributions and since the 
choice may considerably affect the results generated from the meta-
analysis under investigation; caution needs to be taken when 
deciding on the prior distribution; however, there is no such thing as a 
'correct' prior and consequently this has led to the methodology being 
heavily criticised. Therefore, the choice of subjective prior should be 
investigated in a sensitivity analysis. In the case where the reliability 
of the prior distribution is poor, or if prior distribution dominates the 
likelihood, then an inaccurate posterior distribution may be generated. 
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Alternatively, if the prior information is too specific, the prior may 
dominate the likelihood function from the individual trials data and 
overly influence the results of the meta-analysis. 
Where there does not appear to be a consensus on the prior 
distribution, it may be advantageous to use what is known as a 'non-
informative' or 'reference' prior distribution (Spiegelhalter et al. 2003). 
These prior distributions are usually uniform distributions over a wide 
range of values. This allows for the posterior distribution to have the 
same form as the likelihood function thereby allowing the likelihood 
function to dominate the prior distribution and hence the posterior 
distribution (Spiegelhalter et al. 2003). However, these 'non-
informative' prior distributions need to be used with caution since they 
imply that all of the values within their bounds are equally as likely as 
each other (Fisher 1996). Therefore, whichever prior distribution is 
used, a thorough sensitivity analysis of the conclusions to the choice 
of prior distribution should be employed (Sutton et al. 1998). 
2.9 Bayesian approaches to meta-analysis using 
summary data 
In a fixed effect analysis, the Bayesian framework will yield estimates 
for the overall intervention effect and its associated standard errors, 
which are comparable to the results yielded from a classical analysis 
when non-informative prior distributions are specified in the model 
(Carlin 1992). Therefore, the Bayesian analyses performed in this 
thesis were only based on random effect models with non-informative 
prior distributions. Two methods were considered based on Bayesian 
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methodology to estimate the between study heterogeneity; these 
were Empirical Bayes (EB) and a full Bayesian (FB) framework. 
2.9.1 Empirical Bayesian methodology 
The EB methodology can be thought of as part Bayesian part 
classical; it was originally used to perform Bayesian analyses before 
there was software available which was capable of performing 
computationally intensive iteration and integrations that are required 
for a full Bayesian framework. However, empirical Bayes does not 
make use of subjective a priori beliefs to derive numerical values for 
the prior distributions (Sutton et al. 1998); instead it uses the data 
from the individual studies to generate prior beliefs about the overall 
intervention effect estimate and the between study heterogeneity 
estimate (Carlin 1992). However, the same limitations apply to this 
method as to the previous classical summary data methodologies for 
ML and REML since this method does not take into account that the 
heterogeneity estimate is calculated from the data from the individual 
studies. 
A formula for estimating the heterogeneity based on an EB approach 
has been developed (Morris 1983; Berkey et al. 1995). The method is 
based on an iterative scheme similar to the REML method used in the 
classical approaches. The cycle begins where an initial value for e is 
estimated using a weighted least squares regression model. This 
value is used to calculate an initial estimate for the heterogeneity 
(Equation 2.31 ). 
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(2.31) 
The weights for a weighted least squares regression are then re-
calculated (Equation 2.23) and a second estimate of iJ is yielded. The 
process is continued until convergence of the estimate for 
heterogeneity is achieved. 
2.9.2 Full Bayesian framework 
In a full Bayesian framework, the posterior distributions for the 
intervention effect and the between study variability are estimated 
using a series of complicated integrations (Smith et al. 1993). Since 
the integrations can not be computed in closed form due to their 
relative complexities and lack of exact analytical solution, statistical 
methodology has been developed to perform the integrations using 
iterations based on simulations. The most common method used is a 
particular form of the Markov chain Monte Carlo (MCMC) method 
called Gibbs sampling (Geman et al. 1984). Gibbs sampling 
generates samples from the conditional posterior densities, which 
should converge to the desired marginal posterior densities (Smith et 
al. 1993). 
The Gibbs Sampling method may be performed in a freely available 
package called WinBUGS (Spiegel halter et al. 2003). Within 
WinBUGS, the model and prior distributions are specified together 
with the data and initial starting values for the simulations; sampling 
distributions are formed from using the model and data, which are 
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then used to perform Gibbs sampling. An attractive feature of the 
method is that it can handle missing values in the data since the 
model consists of a joint distribution over all the observed and 
missing data (Spiegel halter et al. 2003). The data is conditioned on to 
obtain a posterior distribution for the unknown parameters of interest; 
and marginalising over this posterior distribution is carried out using 
Gibbs sampling where algorithms are used to simulate values for the 
parameter so that inferences about them can be made (Spiegel halter 
et al. 2003). 
2.9.2.1 Continuous outcome measures 
Assuming the intervention effect from each study is represented as 
OJ I conventionally OJ follows a Normal distribution with mean OJ and 
variance ~ r r where i = l, .... ,k (Sutton et al. 1998) Equation (2.32). 
(2.32) 
Where the prior distribution are specified for parameters as follows: 
And vague prior distributions are used for: 
1"2 - IG(O.OOl,O.QOl) 
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2.9.2.2 Alternative methods for dichotomous outcome measures 
The Bayesian framework allows for the dichotomous data from a 2x2 
contingency table to be modelled directly (Table 2.1 in Section 
2.3.1.1). The observed number of events in each intervention group 
of the study is assumed to follow a binomial distribution, where r.; is 
the number of observed events and n. is the total number of patients, 
·1 
and the unknown risk parameters are tr., within each intervention 
·1 
group (Equation 2.33), where subscript t and subscript c refer to the 
active intervention and the control groups, respectively, for study 
i = 1, ....... ,k. 
(2.33) 
The odds for each group may be calculated (Smith et al. 1995) using 
Equation (2.34) where 0; is the log odds ratio for trial i. 
(2.34) 
IOg( trc, J = A. 
I-tr 1 
c, 
The log odds ratio, OJ' is the difference between the logarithms of the 
odds for each group as shown in Equation (2.35). 
1 0 9 ( ~ ) ) -lOg( tre, ) = OJ 
I-tr I-tr I, e, 
(2.35) 
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Heterogeneity is incorporated into the model so that the log odds ratio 
from each study is allowed to vary around the overall log odds ratio 
for the intervention effect (Equation 2.36). 
(2.36) 
Where vague prior distributions are specified for the parameters as 
follows: 
1'2 - IG(O.OOl,O.OOl) 
The distribution is conventionally specified as a Normal distribution 
and the estimation procedure follows the same format as used for 
continuous outcome measures in Equation (2.32). 
It has been suggested that there is SUbstantial gain from modelling 
the data directly using a binomial distribution since it avoids the need 
for simplifying approximations and the assumption of linearity of the 
log odds ratio (Warn et a/. 2002). Also, this method uses binomial 
distributions for the underlying distributions of the data and so is not 
subject to the requirement of a continuity correction being applied in 
the case of any sparse data cells. 
2.10 Bayesian approaches to meta-analysis using 
individual patient data 
A Bayesian framework may be used to model the data from a meta-
analysis based on individual patient data, however additional prior 
distributions need to be specified for the parameters. Dichotomous 
and continuous outcome measures are described below for random 
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effect models only, since the Bayesian framework would yield 
estimates from a fixed effect model which are comparable to those 
yielded from a classical fixed effect IPO model. The models which 
may be used for dichotomous and continuous outcome variables are 
described below. 
2.10.1 Dichotomous outcome measures 
Assuming that the outcome for a patient is denoted as Yij which is 
from a random variable Yij (Equation 2.25); and assuming Yij has a 
binomial distribution with parameter 1tij and a denominator of 1. Then 
1tij is the probability of an event for patient j in study i where 
i = 1, ...... ,k: and Yij =1 if the event occur and 0 if they are event-free. 
Comparing this model to Equation (2.29), a = 0, so that POi is the 
intervention effect in the control group for study i, and PI is the 
pooled intervention effect of an event on intervention as compared to 
control and UJj is the intervention effect in study i (Equation 2.37). 
( 
1t .. J log 1- ~ i j j = floi + ulizij (2.37) 
Where vague prior distributions are specified for parameters as 
follows: 
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1"2 - IG(O.OOl,O.OOl) 
Whitehead has compared the results from Bayesian random effect 
models of IPO and summary data (Whitehead 2002). Similar 
estimates for the log odds ratio of the intervention effect were found 
between the two methods. The standard error for the intervention 
effect was larger from the IPO model as compared to the summary 
data model which could be attributed to a larger estimate for the 
between trial heterogeneity being estimated from the IPO model. 
Whitehead has also compared the results between Bayesian and 
classical individual patient data random effect models, and has found 
that similar estimates for the treatment effect were seen between the 
models. Since the models specified for the Bayesian and classical 
[PO models are identical then the parameters estimated from the 
models should also be identical. However, difference may arise due 
to not being able to specify a truly non-informative prior for each 
parameter in the Bayesian model. The estimation process used in the 
Bayesian models are based on using simulations (Monte Carlo 
methods) and so may be subject to error in its final estimation of the 
parameters. Additionally. unlike the classical models which assume 
that the between trial heterogeneity and individual study variances 
are known, the Bayesian model allows for extra variation in its 
estimates to account for the uncertainty associated with estimating 
these components from the data. 
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2.10.2 Continuous outcome measures 
The random effect IPO model used for analysing continuous outcome 
measures in a Bayesian framework is analogous to that from a 
classical setting (see Equation 2.30); however, a. = ° so that POi is 
the intervention effect in the control group for study i. A common 
variance, (T2, is assumed for the error terms so that it is the same 
across trials. PI is the pooled intervention effect and uti is the 
intervention effect in study i. 
(2.38) 
Where vague prior distributions are specified for parameters as 
follows: 
POi - N(O,10 4 ) 
PI - N(O,104) 
(T2 - IG(O.OOl,O.OOl) 
1"2 - IG(O.OOl,O.OOl) 
Whitehead has compared the results from Bayesian random effect 
models based on summary and IPO (Whitehead 2002). Similar 
estimates for the intervention effect were seen between the models 
since both of the data sets are assumed to follow a normal 
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distribution; however, a slightly larger standard error was seen from 
the IPD model which could be attributed to a larger estimate for the 
heterogeneity due to a common within trial variance, (]"2, being 
estimated. 
Higgins and colleagues have compared the results from IPD meta-
analyses based on Bayesian and classical frameworks (Higgins et al. 
2001). They found that estimate for the intervention effect from the 
Bayesian analysis was noticeably smaller and its associated standard 
error was larger in magnitude than compared to the classical 
analysis, additionally the estimate for the heterogeneity was 
considerably smaller from the Bayesian analysis. The difference in 
the intervention effect was thought due to the Bayesian model being 
drawn towards the estimate for the largest trial and was specific to the 
example used and not generalisable (Higgins et al. 2001). 
Although the standard errors for the intervention effect estimated from 
the classical IPD random effect model can be artificially inflated using 
the Kenward and Roger approximation, this method is an 
approximation where as in the Bayesian model the parameters are 
specified as random variables and hence the Bayesian method 
estimates more variation for the between study heterogeneity then its 
classical counterpart. 
2.11 Methods for Assessing Convergence in 
Bayesian models 
Iterative simulation methodology used in the analysis of Bayesian 
statistics is a valuable method for summarising posterior distributions; 
74 
however, there are disadvantages associated with the methodology, 
particularly related to the assessment of convergence of the chains. 
Many tools have been developed to assess whether convergence has 
been achieved, these include methodology developed by Geweke 
(Geweke 1992), Gelman and Rubin (Gelman et al. 1992), Rafertyand 
Lewis (Raferty et al. 1992). These tools should be used in parallel 
with each other since no one method is superior for assessing 
convergence. 
2.11.1 Gelman and Rubin diagnostic 
Gelman and Rubin have developed a method for assessing 
convergence where multiple chains or sequences are run 
simultaneously with different starting values for the parameter of 
interest (Gelman et al. 1992). The simulations are run for a particular 
length of chain where the first q iterations represent the burn-in period 
and hence discarded, the remaining n iterations are focussed on for 
evaluation of convergence for each of the m chains. For each 
parameter of interest a between-sequence and within-sequence 
variance are calculated. The between-sequence variance is the 
variance between the m sequence means for the parameter of 
interest, and the average of the m within-sequence variances for each 
chain is calculated and represented by W. A scale factor,R, is then 
estimated from the ratio of the current variance estimate and the 
average of the within-sequence variances. The scale factor is the 
scale by which the current distribution for the parameter of interest 
might be reduced by if the simulations sequences were allowed to run 
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to infinity. When the value of R approaches one then the chain is 
thought to have converged for that particular parameter of interest. 
Potential problems with this method, which are mainly related to 
conditions where the parameter of interest has a multimodal 
distribution (Gelman et 81. 1992). This is thought to be a problem 
since the tool will assess convergence of the whole chain and if the 
modes for the distribution are wide apart then the simulations will tend 
towards one of the modes and the tool will assess convergence at 
this one mode only. Even though this method can not correct for 
multimodal distributions, it should draw attention to this problem by 
repeatedly bouncing from one mode to another. 
2.11.2 Raferty and Lewis diagnostic 
Raftery and Lewis have proposed a method for assessing 
convergence of a single chain (Raferty et 81. 1992). This method first 
assesses the length of burn-in required for the chain of iterations, 
values are specified by the user for the percentile that is to be 
assessed, degree of accuracy for the estimate in this percentile, and 
the required probability for attaining the degree of accuracy specified. 
The tool then calculates the total number of iterations that would need 
to be performed to reach convergence. The method reports an 
independence factor, I, which is a measurement of the dependence 
between the iterations in the single chain. I is the ratio of the total 
number of iterations that the model should be run for to achieve 
convergence, divided by the number of iterations calculated for the 
burn-in. Raferty and Lewis suggest that if I has a value greater than 5 
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then there are some high within-chains correlation and convergence 
has probably failed (Raferty et al. 1992). 
2.11.3 Geweke diagnostic 
A standard time series method called 'Geweke's diagnostic' may be 
used to assess if the mean of the variable of interest has converged 
(Geweke 1992). The diagnostic splits the chain generated into two 
segments, usually the first ten percent and the last fifty percent. If the 
chain has converged, then the figures in the two segments should be 
similar. A statistical calculation is performed that checks the similarity 
of the two figures, where the difference of the two figures is divided by 
the asymptotic standard error of their difference is the convergence 
diagnostic, z. It is assumed that if the chain has converged, then as 
the length of the chain tends to infinity, the sampling distribution 
should tend to a standard normal distribution. Hence, if any of the 
values for z fall in the extreme ends of the tails of a standard normal 
distribution then the chain has not converged. 
There are problems associated with this method; the first being 
related to the segments used to check convergence. It has been 
recommended by Geweke that the first 10% and last 50% of 
segments should be used and compared; assuming that convergence 
has been achieved within the last 50% of the chain, then values from 
these two segments will only be similar if the chain has already 
converged within the first 10% of the iterations (Naylor 1992), which is 
unlikely. Additionally, the interpretation of the convergence diagnostic, 
z, is unusual. The null hypothesis set up is that there is no difference 
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between the mean of the estimates in the two segments. However, 
convergence is achieved when there is sufficient evidence to not 
reject the null hypothesis (Naylor 1992). 
2.12 Random trial effects in meta-analysis using 
individual patient data 
In the previous classical and Bayesian individual patient data models 
we have assumed that the trial effects are fixed. A random effect for 
the trial effect could be specified in addition to the random effect for 
the interaction between intervention and trial effects, or as an 
alternative to having fixed interaction term between intervention and 
trial effects. Incorporating studies as random effects has been 
controversial. 
In a meta-analysis which consists of trials with various numbers of 
centres, it may be advantageous to model the trial effects as random. 
It has been argued that missing data relating to intervention 
differences may be recovered by having the trials as random effects 
when the sizes of the intervention groups within the trials vary (Brown 
et a/. 1994). 
Conversely, it has suggested that it may be inappropriate to model 
study effects as random since this would imply that the results yielded 
from a particular set of studies are drawn at random from an 
underlying population of studies (Turner et a/. 2000; Higgins et a/. 
2001 ). 
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2. 13 Assessing publication bias 
The results yielded from a meta-analysis are reflective of the data 
included in the analysis; therefore it is essential that the data are at 
least representative of the whole population of studies that have been 
conducted in the particular medical area. Publication bias may still be 
present in a meta-analysis even if a thorough search of the literature 
is performed; therefore it is necessary to visually and statistically 
inspect the data to assess if publication bias is present. 
Techniques have been devised to assess this, including the funnel 
plot (Light et al. 1984; 8egg et al. 1994), 8egg and Mazumdar's rank 
correlation test (8egg et al. 1994), an asymmetry test by Egger and 
colleagues (Egger et al. 1997) and more recently the 'Trim and Fill' 
method (Duval et al. 2000). 
2.13.1 Begg's funnel plot 
The funnel plot is the most commonly used procedure due to its 
relative simplicity to use and interpret. The funnel plot is created 
usually by plotting the standard error for the effect size against the 
effect size of the intervention for each trial (Figure 2.1). Trials that 
have smaller sample sizes will be located towards the bottom of the 
plot where the standard errors are greater. If asymmetries between 
the left and right sides of the funnel plot are seen, this may indicate 
that there is publication bias present. Figure 2.1 shows asymmetry 
where there is an absence of smaller sized trials towards the left-
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hand side of the plot indicating that smaller size trials which show a 
detrimental intervention effect could have been missed. 
Pseudo confidence intervals can be generated for the estimate and 
plotted on the figure ; these interval lines may aid the investigator to 
determine whether appears to be evidence of asymmetry in the plot 
(Figure 2.1). 
Standard error for the effect size 
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Figure 2.1 Example of Begg's Funnel Plot showing publication bias using 
hypothetical data 
2.13.2 8egg and Mazumdar's rank correlation test 
This test has been developed to statistically test for the presence of 
publication bias and is a direct statistical analogue to the funnel plot. 
The test examines whether there is a correlation between the effect 
estimates and their variances, since it has been found that publication 
bias tends to produce such an effect (8egg et a/. 1994); and produces 
a p value. However, the test has variable power being dependent on 
the number of studies included in the meta-analysis. The test was 
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found to be powerful for meta-analyses containing 75 studies; but had 
a marked reduction in power when only 25 studies were considered. 
Since it is relatively common for meta-analyses to have much less 
than 25 studies, this test may be inadequate at finding evidence of 
publication bias in many meta-analyses, therefore caution is needed 
in interpreting the results in these circumstances. 
2.13.3 Egger's asymmetry test 
This test is statistically based on estimating a regression line for 
relationship between the effect size (odds ratio or standardised 
difference) and the precision of the study (usually defined as the 
reciprocal of the study variance). The results are often presented 
visually as shown in Figure 2.2. Evidence of publication bias is 
detected if the intercept of the regression line deviates significantly 
from zero. In the example shown there does not appear to be 
evidence of publication bias since the intercept of the regression line 
is close to zero . 
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Figure 2.2 Example of Egger's Asymmetry Plot using hypothetical data 
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2.13.4 "Trim and Fill" methods 
A relatively new statistical procedure called the "Trim and Fill" method 
is a statistical and visual procedure to assess publication bias. The 
method was developed by Duval and Tweedie and is based on a non-
parametric ranking technique (Duval et al. 2000). This method 
essentially assesses the effect of adjusting for potential publication 
bias by including the missing data in the meta-analysis. 
Initially, a funnel plot is used to visually detect if asymmetry is 
present. If asymmetry is seen, an estimate of how many studies 
would be required to make the points on the plot symmetrical is 
performed. Next, the data from the asymmetrical part of the plot is 
'trimmed' and the underlying effect estimate for the remaining trials is 
calculated. Then the trimmed studies and their missing counterparts 
are included in a further analysis to calculate a new 'filled' estimate 
for the overall intervention and confidence intervals. The adjusted 
result may be presented in the form of a sensitivity analysis rather 
than as a 'better' estimate since the adjusted result could be 
misleading if the asymmetry in the plot is due to factors other than 
publication bias (Song et a/. 2000). 
2.13.5 Summary to publication bias 
Publication bias may be assessed using various visual and statistical 
methods. However, when performing these statistical tests it is wise 
to remember that these tests generally have low power in detecting 
publication bias since the power of the test depends on the number of 
studies included in the meta-analysis. 
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The test by Duval and Tweedie (Duval et al. 2000) is more 
sophisticated than the two previous methods since it allows for the 
investigator to not only assess publication bias in the studies 
identified but to also allow for adjustment in the treatment estimates 
to see the effect of including hypothetical data (Sutton et a/. 2000). 
However, it must be noted that asymmetry may be detected from the 
funnel plot which it is unrelated to publication bias, since the 
asymmetry may be related to poor methodological quality of the 
studies included in the meta·analysis (Petticrew et al. 1999). 
2.14 Summary of chapter 
This chapter has highlighted the models that can be used in meta-
analyses using summary and individual patient data methodologies, 
both in classical and Bayesian frameworks. The issues surrounding 
the whether fixed or random effects models should be used and the 
estimators for the between trial heterogeneity have been described 
and compared. Statistical methods for assessing publication bias 
have also been described. However, assessments of heterogeneity 
need to be made to aid with determining whether the fixed effect 
models are valid for use or whether it would be more appropriate to 
use a random effect model. 
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CHAPTER 3 
HETEROGENEITY IN META-ANALYSES USING 
SUMMARY AND INDIVIDUAL PATIENT DATA 
METHODOLOGIES 
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3. 1 Introduction 
The previous chapter outlined two models, the fixed effect model and 
the random effect model. The fixed effect model assumed that the 
studies are identical in design and patient population, and ignored 
any differences between the studies with regards to the intervention 
efficacies. In contrast, the random effect model accounted for any 
variation (heterogeneity) between the studies through incorporating it 
into the model and estimating its magnitude. However, neither of 
these methods explored why the studies gave varying results. It has 
been suggested that in a meta-analysis, it is important to perform a 
full investigation into exploring why these differences exist 
(Thompson 1994). 
This chapter concentrates on how the differences between the 
studies can be explored using graphical and more formal statistical 
tests, and then describes two statistical methods called subgroup 
analysis and meta-regression, which allow for covariates to be 
included in both a fixed effect model and a random effect model, 
using summary study and individual patient data. Within the random 
effect model, a variety of estimation methods are described which 
quantify any residual variation between the studies using classical 
and Bayesian methodologies. 
3.2 Types of heterogeneity in meta-analyses 
Even if a perfect replication of studies were performed to reduce 
variation of the internal faqtors, the intervention effect estimates from 
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the studies will vary due to random fluctuation. However, if these 
differences appear to vary considerably more than random fluctuation 
then it may be necessary to explore this variation. 
Heterogeneity can be categorised into four major areas relating to 
variations and difference between patient, intervention, co-
intervention, and outcome (Glasziou et al. 2002). These are factors 
which may produce a true variation in the effectiveness of the 
intervention. Patient level factors such as age or severity of disease 
could influence the effectiveness of the intervention. Also, differences 
in the intensity or dose of the intervention or the effect of co-
interventions may alter the effectiveness of the intervention under 
study. Differences in the outcome such as when it is measured or 
indeed what outcome measure is chosen could have dramatic effects 
on the efficacy of the intervention. 
However improper randomisation procedures and non-adherence 
with interventions may also be causes of heterogeneity (Glasziou et 
al. 2002). Since these may produce apparent differences in the 
intervention effect estimates which lead the investigators to assume 
that some other factor is causing the variation, whereas these 
differences may be due to the quality of the study. Indeed it has been 
shown that improper concealment of allocation for the intervention 
can produce inflated intervention effect estimates (Schulz et al. 1995). 
3.3 Assessments of heterogeneity 
Although it has been generally agreed that heterogeneity should be 
accounted for in the model, at present there is no consensus on how 
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it should be performed (Thompson 1994; Lau et al. 1998). Various 
methods exist for assessing and quantifying these differences 
between the study estimates. These range from simple graphical 
assessments to complicated formal statistical tests and estimation 
methods. The simplest method to use is the forest plot. 
3.3.1 Graphical Assessment of Heterogeneity 
In a forest plot the study estimates are plotted with their 
corresponding confidence interval limits (Figure 3.1). The size of the 
point estimate symbol on the graph · relates to the precision of the 
estimate. If high precision is present, the standard error for the point 
estimate will be small, hence the symbol is large; and vice versa. 
From Figure 3.1 there appears to be some heterogeneity between the 
study estimates, since the results are varied and the overall estimate 
is not included in the 95% CI for study F. 
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Example for assessing heterogeneity using a forest plot 
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3.3.2 Classical approaches for assessing heterogeneity 
for summary data 
A variety of statistical tests can be performed to identify if there is 
evidence of statistical heterogeneity between the study point 
estimates, including Cochran's homogeneity test (Cochran 1954) and 
Higgins and Thompson 12 statistic (Higgins et al. 2003). 
3.3.2.1 Cochran's homogeneity test 
Cochran first proposed a test for homogeneity in 1954 and this has 
been used conventionally to statistically test for between study 
heterogeneity (Cochran 1954). If we assume k studies are included 
in the meta-analysis, then under the null hypothesis, H 0' the 
underlying intervention effect, denoted by OJ for each study, are the 
same, e. 
(3.1) 
The alternative to the null hypothesis is that at least one of the 
intervention effects from the studies differs from the others. Under the 
null hypothesis the statistic Q follows a X2 distribution with its 
degrees of freedom dependent up on the number of studies included 
in the meta-analysis. 
(3.2) 
Where Wj is the weight associated with the i'th study, and OJ is 
estimate for the intervention effect from each study and 0 is the 
estimate for the pooled intervention effect. The conventional weight 
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given to each study is the reciprocal of the variance for each trial 
(Cochran 1937) (see Equation 2.11). 
The main disadvantage associated with this test is related to the 
power the test has to be able to detect heterogeneity between the 
studies (Fleiss 1986; Whitehead et al. 1991; Thompson 1994). 
Insufficient power may be seen when a sma" number of studies are 
being combined in the meta-analysis. When small numbers of stUdies 
are being combined, Fleiss recommends using a 10% significance 
level to improve detection (Fleiss 1986). It should also be noted that 
there is the potential to detect heterogeneity if large sample sized 
stUdies are used in the meta-analysis, even if the intervention 
estimates for each study appear homogeneous (Hardy et al. 1998). 
Also, this test is based on the assumption that the variances for each 
study in the meta-analysis are known, when in fact they have been 
estimated from the data and therefore has been criticised as being of 
limited value (Hardy et al. 1998). 
Therefore due to the disadvantages associated with this test it has 
been recommended that the Q statistic should not be used as the 
only tool for identifying heterogeneity (Hardy et al. 1998); but used in 
conjunction with other techniques such as the forest plot. 
3.3.2.2 Higgins and Thompson, P 
A recent method has been devised which quantifies heterogeneity as 
a proportion of the total variability in the model. This method appears 
not to be subject to the problems of Cochran's homogeneity test 
(Higgins et al. 2003). In the below equation (3.3), H is the estimate of 
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the heterogeneity from the "l test statistic as devised by Cochran and 
k is the number of studies in the meta-analysis. 
H= {Q ~ N N (3.3) 
Higgins and Thompson propose that a measure called P, which is the 
'proportion of total variability explained by heterogeneity' to determine 
if heterogeneity is present (Equation 3.4). 
2 • (H2 -1 J I =mtn H2 ,0 (3.4) 
In the case of negative values of /2 being calculated, values of /2 are 
set to zero so that the value will lie between 0% and 100%. Values of 
25%, 50% and 75% have been suggested as categorisations for low, 
moderate, and high measures of heterogeneity, respectively (Higgins 
et al. 2003). This method has the added advantage that the values 
generated may be compared across meta-analyses. However, since 
the nature of systematic reviews is to bring together studies which are 
naturally diverse in their design protocols and patient populations, 
many meta-analyses will find quantifiable levels of heterogeneity. It is 
also important to identify the reasons behind the existence of 
heterogeneity in addition to quantifying it. Even though this method is 
simple to calculate and does not appear to be subject to the 
disadvantages of Cochran's method, it is still dependent on the 
assumption that the within study variances are known for each study 
and are equal between the intervention and control groups within 
each study; additionally, the test does not produce a pooled point 
estimate adjusted for the heterogeneity. 
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3.4 Adjusting for covariates using summary data 
Conventional meta-analyses have tended to focus their methodology 
on presenting results based solely on the averaged outcomes of the 
available studies. When there is a large quantity of unexplained 
variation between the study estimates a full exploration of 
heterogeneity needs to be performed (Thompson 1994). 
Covariates could be included in the model which were thought to 
either explain the variability between estimates or influence the 
efficacy of the intervention (Rubin 1990). These could be based on 
either patient characteristics such as age, gender or study 
characteristics such as sample size, and the quality of randomisation 
procedure (Berkey et al. 1995). Subgroup analysis and meta-
regression are two such methods that allows for the covariates to be 
assessed in a model. 
3.4.1 Subgroup analysis using summary data 
If the covariate of interest may be categorised, then subgroup 
analysis may be performed to assess its effect on the overall effect 
estimate. Subgroup analyses investigate the patients' characteristic 
by considering a subset of studies from the pooled studies, therefore 
one needs to be cautious of the problems associated with' 
misclassification (Gelber et al. 1987). 
Similar methodologies are used for each subset of studies for fixed 
and random effect models as described previously. Forest plots are 
commonly used for each subset to assess visually whether there are 
any differences between the estimates for subset. Additionally, Deeks 
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and colleagues have described how Cochran's homogeneity statistic, 
Q may be used to assess whether using the subgroups has 
explained any residual heterogeneity (Deeks et at. 2001). This 
method involves calculating the Q statistic for all of the studies (Qal/ ), 
and subtracting the sum of the Q values from the m subset of 
studies (Qm)' For example, if two subsets were considered then the 
new value of Q called Qnew' would be as shown in equation (3.5). 
(3.5) 
Q is then compared to a 0/ 2 distribution with m -1 degrees of new A, 
freedom to test for a difference amongst the subgroups considered. 
3.4.2 Meta-regression analysis using summary data 
Meta-regression is a more flexible method which can be used to test 
for differences, continuous and categorical covariates may be 
included in the model. Meta-regression is based on using simple 
regression models to assess the relationship between the outcome 
and the explanatory variables; however, weightings are used in the 
model to allow for the size of the trial to be taken into account. 
In a meta-analysis of summary data, the number of included trials 
represents how many observations are modelled in the regression, 
therefore it has been recommended that meta-regressions are not 
performed with less than 10 studies in the meta-analysis (The 
Cochrane Collaboration 2003). Also, the number of covariates that 
are included in the model needs to be decided with caution since if 
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only a relatively small number of studies are included in the meta-
analysis, only a limited number of covariates may be incorporated into 
the regression analysis to prevent the residual degrees of freedom 
being exhausted. 
Two types of meta-regression exist, the fixed effect extension and the 
random effect extension. The covariates are introduced as fixed 
effects in both cases. It is thought to be appropriate to use the fixed 
effect extension when the additional variation between the 
intervention estimates can be explained by the covariates introduced 
in the model (Whitehead et al. 1991) however, in practice they may 
be rarely achieved and so it has been recommended that random 
effect models are used to allow for the covariates only explaining part 
of the heterogeneity (Sutton et al. 1998). 
This remainder of this chapter will concentrate on incorporating only 
one additional predictor in the model however the models can be 
extended to allow for multiple covariates. 
3.4.2.1 Random effects meta-regression using Classical and 
Bayesian methodologies 
The model described in Equation (2.14) may be extended so that a 
trial level covariate, Xli is now included in the model where i = 1, .... ,k 
(Equation 3.6), where U j is the random effect term, and the terms U j 
and &, are assumed to be independently distributed. e is now 
replaced by Po and represents the pooled intervention effect when 
Xli = O. The covariates are assumed fixed and known without error. 
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(3.6) 
Estimation of the parameters is achieved using a weighted least 
squares regression model, where the weights, Wi' used are given by 
the inverse of the study's variance making the assumption that: 
(3.7) 
In addition to the individual study variance being estimated from the 
data (see section 2.3): heterogeneity and the unknown regression 
parameters need to be estimated too, but to estimate the unknown 
regression parameters first need to be estimated; and vice versa. 
Similar methodologies to as described in sections 2.4.2 have been 
extended to allow for covariates to be included in the model so that 
the above parameters may be estimated. These include the weighted 
and approximate MM, ML, and REML. 
3.4.2.1.1 Approximate and weighted method of moments 
An approximate MM estimator can be used to estimate r2 from a 
meta-regression model which incorporates one covariate 
(Raudenbush 1994). An ordinary least squares meta-regression is 
performed to estimate the residual sum of squares (RSS), then an 
initial value is sought for ;2 using Equation (3.8). 
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(3.8) 
A weighted least squares regression model is then used to estimate 
the intervention effect and the covariate effect using optimal weights 
(Equation 3.7). This method is relatively simple to calculate but 
requires the use of an approximation to replace the sampling 
variance, since this method is an extension of a method that assumes 
the sampling variances from each study are the same across all of 
the studies (Raudenbush 1994; Sutton ef al. 1998). 
As an alternative to the above method, a more complex method may 
be used which estimates the heterogeneity using MM (Thompson ef 
al. 1999). Firstly, a weighted least squares regression is performed to 
obtain the heterogeneity statistic, Q, and initial estimates for the 
intervention and covariate effects. Next, the method of moments 
estimator is used to estimate the between study heterogeneity 
{Equation 3.9} where F(w,x) is a function of the weight and covariate 
for each study (Thompson ef al. 1999). 
f2 = Q - (k - ) if Q > k _ 2 or 0 otherwise (3.9) 
F w,x 
Finally, a weighted least squares regression is performed using the 
optimal weights to obtain final estimates for the intervention and the 
covariate effect. This method is more complex than both the 
approximate method and weighted method of moments without a 
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covariate, since it requires the use of matrices to estimate the 
between study heterogeneity (Thompson et al. 1999). 
A similar method has been proposed by Raudenbush however this 
method assumes that the variances within each study are balanced 
(Raudenbush 1994), so that they are same across the studies. This 
assumption cannot be met in most cases (Sutton et al. 1998) and so 
is not described in details in this thesis. 
3.4.2.1.2 Maximum likelihood 
The ML methodology used in Section 2.4.2.2 may be used where a 
fixed effect weighted least squares meta-regression is performed to 
obtain the initial values for Po and PI: where PO j is the estimate for 
the intervention effect in study i. The iterative model used in section 
2.4.2.2 may be extended to include a covariate (Equation 3.10) 
(Hardy et al. 1996). 
A2 twi[(oOj-Po-filXliJ-var(Oi)] (3.10) 
T = k 
LW; 
j=1 
The cycle is repeated using new weights as described in Equation 
(3.10) until convergence of f2 is achieved. 
3.4.2.1.3 Restricted maximum likelihood 
The REML iterative cycle described in section (2.4.2.3) may be used 
to obtain initial estimates of the unknown regression coefficients 
(Thompson et al. 1999). Then an initial estimate of the between study 
heterogeneity may be obtained using Equation (3.11). 
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This estimate may then be used to calculate optimal weights. The 
cycle is repeated until convergence of f2 is achieved. 
3.4.2.3.1 Empirical Bayes 
EB methodology may be used to obtain estimates for the between 
study heterogeneity. Initial estimates of the intervention effect and the 
covariate may be yielded and an initial estimate of the heterogeneity 
may be calculated using Equation (3.12) (Berkey et al. 1995). 
New weights are then estimated using optimal weights and the cycle 
is repeated until convergence of f2 is achieved. 
3.4.2.1.5 Full Bayesian framework 
A FB framework can be used which is similar to the methods 
described in Section (2.9.2) for continuous outcome data and for 
binary outcome data. Both of these methods require the use of priors 
for the unknown parameters; which may be non-informative (Smith et 
al. 1995), and an assessment of convergence for all of the estimate 
parameters (see Section 2.11). 
For continuous summary outcome data, the methodology used to 
perform a FB meta-regression analysis is an extension to the method 
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used in Equation (2.32) where the pooled intervention effect e is 
replaced by Po and represents the pooled effect when the covariate, 
Xii = O. The prior distribution for POi is shown as in Equation (3.13). 
(3.13) 
For dichotomous outcome data, the Bayesian framework allows for 
the data used in a 2x2 contingency table to be modelled directly (see 
Equation 2.32); Xli may be included in the model as shown in 
Equation (3.14) (Smith et al. 1995). 
(3.14) 
Po and PI may be estimated as the difference between the 
logarithms of the odds for each group (Equation 3.15). 
IOg(3!LJ -10g( 7rel J = POi + PI Xli (3.15) 
1-7r 1-7r 
'I CI 
For the above models additional vague prior distributions are 
specified. 
1'2 - IG(O.OOI,O.OOI) 
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3.5 Heterogeneity in meta-analysis using individual 
patient data 
A statistical test for heterogeneity between the k trial estimates, 
where i = 1, .... ,k may be estimated by including a fixed effect 
interaction term between intervention effects and study effects 
(Whitehead 2002). The model used for the main effects is 
comparable to the models described in Section 2.6.2 where fixed 
effects are specified for the intervention and study effects, where flo k 
is constrained to zero. The interaction term allows for the intervention 
effects to vary across the trials. 
For dichotomous outcomes the model presented in Equation (2.26) 
may be extended to Equation (3.16). A test for the interaction may be 
performed by assessing the change in deviance between this model 
and the model presented in Equation (2.26) may be compared to a 
x 2 distribution with k -1 degrees of freedom. 
( 
1£ .. ) log _IJ_ = a + flo i + fllizij 
I-1£y 
(3.16) 
For continuous outcomes the model presented in Equation (2.28) 
may be extended to Equation (3.17). The estimate for the interaction 
term may be compared to a F distribution with k -1, n - 2k degrees 
of freedom n is the total number of patients in the meta-analysis. 
(3.17) 
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However, there is usually a lack of power to test the interaction terms 
in the above two models and so in practice the variability associated 
with the intervention effect across the trials is often ignored (Brown et 
al. 1994). 
If the final model chosen for the analysis includes the interaction term, 
then caution must be observed in interpreting the estimates for the 
parameters since the estimates for the intervention effect have been 
estimated assuming that equal weight is given to the results from 
each study regardless of the size (Brown et al. 1994). Also, if the 
sizes of the studies vary greatly within the meta-analysis then the 
results yielded from this model may differ considerably from a model 
where the interaction term is omitted. Additionally, since the 
interaction term is fitted as a fixed effect then if small studies were 
seen to give spurious results, the results from this model may be 
misleading since it would be assumed that the variation in the results 
across the trials would be due to random variation only. 
3.5.1 Adjusting for covariates using individual patient 
data 
A covariate may be included in the individual patient data random 
effect model. The covariate can either relate to a patient predictor, 
such as age of the patient; or to a study level predictor, such as 
method of administration for the intervention. However, care needs to 
be used in the interpretation of the covariate since they may describe 
both within-study and between-study relationships (Higgins et al. 
2001). Additionally, if the patient level covariates included in the 
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model are the same for each patient within a study then they are 
essentially interpreted as a study level covariate. 
Random effect models are presented below where a covariate is 
included in the model using individual patient data methods either to 
allow for an imbalance between the intervention groups or to assess 
potential sources of heterogeneity. The models are described in a 
classical setting however; the same models may also be used within 
a Bayesian framework using IPD. If a Bayesian framework is 
considered then it would be necessary for prior distributions to be 
specified for all of the parameters associated with the covariate. 
3.5.1.1 Meta-regression 
A random effect meta-regression model may be used based on 
individual patient data to assess the impact of a trial level covariate 
on the outcome measure (Whitehead 2002). The models described in 
Equations (2.29) and (2.30) may be extended to include a fixed effect 
trial level covariate X2i (Equation 3.18 shown for continuous outcome 
measure). 
U li - N(O, ,,2 ) 
Cij -N(O,a2 ) 
(3.18) 
However POi and P2X2i are not separately identifiable (Whitehead 
2002). therefore a single fixed effect trial term can be written as 
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shown in Equation (3.19) (shown for continuous outcome measure); 
where Eij and U li are assumed uncorrelated. 
(3.19) 
3.5.1.2 Imbalance in prognostic factors 
An imbalance in prognostic factors between the intervention and 
control groups may arise in a particular study; therefore it may be 
advantageous to model the imbalance in an individual patient data 
random effect mode\. The models presented below are for continuous 
outcome measures, however, the models can be easily adapted to 
use for dichotomous outcome measures. 
The random effect IPO model described in Equation (2.30) (shown for 
continuous outcome measures) may be extended to include a fixed 
effect term for the patient level covariate, x2ij to assess the effect on 
an imbalance between the intervention groups (Equation 3.20) where 
E .. and u·· are assumed uncorrelated. 
lJ IJ 
(3.20) 
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3.5.1.3 Potential sources of heterogeneity 
Potential sources of heterogeneity may be investigated to determine 
whether there are patient level factors which affect the size of the 
intervention effect. This may be achieved through modelling an 
interaction term between the intervention and patient level covariate 
using a random effect IPD model. The models presented below are 
for continuous outcome measures, however, the models can be 
easily adapted to use for dichotomous outcome measures. 
Extending the model presented in Equation (3.20), the effect for the 
interaction term between the patient level covariate and the 
intervention is included as fixed effect and represented as x 2ij zij 
(Equation 3.21). The Eij and U li terms are assumed to be 
u ncorrelated. 
U li - N(O, '(2 ) 
Eij -N(O,u2 ) 
(3.21) 
Thompson and Sharp have investigated the effects of including a 
study level covariate in a random effect meta-analysis based on 
classical summary and IPD using the log odds ratio (Thompson et al. 
1999); for the summary data methods they used MM, ML and REML 
to estimate the heterogeneity. They found the methods were 
comparable in the interpretations of the results however, they also 
found that the estimates for the intervention and covariate parameters 
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and their associated standard errors depended upon the estimate 
yielded for the heterogeneity. Slightly smaller estimates for 
heterogeneity were seen from the ML and REML methods as 
compared to modelling the IPD; conversely the MM gave a larger 
estimate. 
3.5.2 Problems with exploring heterogeneity 
Subgroup analysis is an attractive assessment to use since it allows 
for the studies to be grouped in subsets, however, problems may 
arise where there are insufficient numbers of studies in each subset, 
or where studies are misclassified into the subset. 
Meta-regression analysis should be only treated as exploratory since 
distinct disadvantages are recognised; there is the potential for an 
association to be found between a covariate and the outcome event 
purely by chance or due to other confounding factors (Sutton et al. 
1998). Also, this type of analysis is prone to aggregation bias if the 
covariate is measured at individual level but summarised and 
included in the meta-analysis at trial level (Greenland 1987). 
Aggregation bias occurs where the relationship between the covariate 
means for the summary data and the summary events do not directly 
reflect the relationships between covariate means for the patients and 
the patients events (Sutton et al. 1998). Additionally all of "the 
estimation procedures used above for meta-regression suffer from 
the same inherent problems as detailed for each method in Sections 
(2.4.2) and (2.9.2). 
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Additionally, the classical methods for estimating point estimates for 
the between trial heterogeneity described in this section do not take 
into account variation in the estimate. Further methods have been 
proposed to calculate approximate confidence intervals for these 
heterogeneity estimates based on either moment estimates (Larholt 
et a/. Unpublished) or maximum likelihood methods; however, both 
methods have been found to be restrictive in either requiring the 
individual sampling variances from each trial to be less than the 
estimate for heterogeneity, or are based on asymptotic 
methodologies (Biggerstaff et a/. 1997). Unlike the classical method 
which assume that the between trial heterogeneity is known rather 
than estimated from the data, full Bayesian approach allows for the 
variation associated with the estimating heterogeneity from the data 
to be incorporated into the analysis. Additionally, credibility intervals 
for the between trial heterogeneity may be estimated from the model. 
Thompson and Sharp have recently compared the methods 
described here to explain heterogeneity in two meta-analyses where 
one trial level covariate was included and the outcome measure was 
the log odds ratio (Thompson et al. 1999). They found it was 
important to take into account residual heterogeneity not explained by 
the inclusion of a trial level covariate, and ignoring the residual 
heterogeneity was found to under-estimate the standard errors of the 
regression coefficients, and thereby overstating the importance of the 
covariate. The choice over which estimator for the between trial 
heterogeneity was less clear; for the classical methods they found the 
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maximum likelihood estimator were more asymptotically efficient but 
tended to under-estimate the between trial heterogeneity as 
compared to the REML method. Also, the weighted method of 
moment's technique which included the covariate was found to be 
relatively more complex to use to estimate heterogeneity than the 
simple method of moments technique without the covariate. 
Both the empirical Bayes and a full Bayesian framework were 
considered in the Bayesian analyses; empirical Bayes was found to 
yield very large estimates for the between trial heterogeneity as 
compared to the classical methods and indeed the full Bayesian 
framework. The full Bayesian framework was found to take into 
account the imprecision of estimating the between trial heterogeneity 
from the data; however, this advantage of the method was found to 
have little impact on the results in practice. Therefore the authors 
concluded than they recommend using REML for most practical 
applications in practice (Thompson et al. 1999). 
An obvious advantage of using individual patient data in a meta-
analysis is that differences between the studies may be investigated 
in more depth than would be achieved from using summary data. 
However, this relies on all of the studies measuring the same patient 
level covariates. Also, this type of information can not usually be 
extracted from a publication and so the data needs to have been kept 
preferably in an electronic format. 
Where data is missing at study level, it has been proposed that 
values of zero are assigned to the patients within the particular study 
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so that the difference in the characteristic between the intervention 
and control group is zero (Higgins et al. 2001); however, this 
assumes that the characteristic was balanced between the groups. 
Due to the nature of the methodologies used in a Bayesian 
framework, the Bayesian software allows for missing data at study 
and/or patient level to be included in the analyses by assuming a 
specific distribution for the variable, and is therefore advantageous 
over the classical methods. 
Within the random effect IPD model, the effect for the covariate is 
included in the model as a fixed effect however; there is a choice over 
how the interaction between the covariate and the intervention effect 
is specified. A logical choice would be to specify a random effect term 
since the intervention has been specified as a random effect too 
however; problems arise if there are an insufficient number of studies 
being included in the meta-analysis due to deficient data being 
available to model the extra variance components. 
3.6 Summary to chapter 
This chapter has described the types of methodologies that can be 
used to visually and statistically assess the presence of heterogeneity 
in meta-analyses of summary data and IPD. Also, methods for 
including covariates in summary and IPO models have been 
presented and discussed using classical and Bayesian 
methodologies. 
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Three meta-analyses in the area of stroke medicine will be used in 
this thesis to describe and exemplify the models used in this and the 
previous chapters. The next chapter gives an overview to the area of 
stroke medicine, including the incidence, aetiology, risk factors and 
outcome measures that are associated with stroke. 
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CHAPTER 4 
AN INTRODUCTION TO STROKE 
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4.1 Introduction 
The World Health Organisation has defined stroke as 'a syndrome of 
rapidly developing clinical signs of focal (or global) disturbance of 
cerebral function, with symptoms lasting 24 hours or longer or leading 
to death. with no apparent cause other than that of vascular origin' 
(Hatona 1976). Stroke is the fourth most common cause of death and 
the primary cause of adult disability in the UK (Department of Health 
2003). Despite this only a small proportion of funding is spent on 
stroke research compared with the quantity spent on cancer research 
(Rothwell 2001). However, recently the Government have considered 
stroke to be an important public health issue and stroke is now a core 
part of the National Service Framework for the elderly (Department of 
Health 2001). 
4.2 Incidence and cost of stroke 
Each year 1,825,000 strokes occur in the UK, USA and European 
Union (Sudlow et al. 1997), with approximately 100,000 first strokes 
occurring in Britain alone (King's Fund Consensus Statement 1988). It 
has been estimated that about 25% of men and 20% of women can 
expect to suffer a stroke if they live to be 85 years of age (Bonita 
1992). However, two thirds of strokes are not fatal therefore the cost 
of stroke care is great when the lengths of hospital stays, possibly 
followed by community support or nursing home care are considered. 
About a third of stroke survivors are functionally dependent one-year 
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post stroke, and in the UK alone it has been estimated that there are 
about 250,000 disabled stroke survivors (Stroke Care 1998). 
In terms of overall cost, stroke care consumes between 4-5% of 
health service expenditure. Although this proportion may remain the 
same, actual expenditure on stroke care is likely to rise in real terms 
over the next 20 years because of the effects of the ageing population 
(The Stroke Association 1996). 
4.3 Aetiology and symptoms of stroke 
A stroke follows when part of the brain becomes damaged as a result 
of a problem with the blood supply. The location of the stroke is seen 
in the lack of blood supply around a certain area in the brain and this 
determines which symptoms or complications are seen. The clinical 
diagnosis of stroke may be confirmed through a computed 
tomography (CT) scan, magnetic resonance imaging (MRI) scan, or 
autopsy. CT and MRI techniques allow for similar presenting 
conditions, such as tumour or infection, to be differentiated from 
stroke. 
Around 80 per cent of strokes occur where there is a blockage (or 
occlusion) to an artery from a blood clot; this is known as an 
ischaemic stroke (Rudd et al. 2000). The remaining 20 per cent of 
strokes are due to either a bleed in the brain; an intracerebral 
haemorrhage, or a bleed onto the surface of the brain; a 
subarachnoid haemorrhage (Rudd et a/. 2000). Patients may suffer a 
mini-stroke or transient ischaemic attack (TIA). The main difference 
between a mini-stroke and a full stroke is that the deficits or 
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symptoms seen following a mini-stroke are resolved within 24 hours 
of onset, with no lasting complications. 
Most strokes present suddenly and without warning. The most 
common symptom is weakness to one side of the body, which may 
involve the face or limbs (Dennis 1988). Symptoms arise mainly from 
the stroke itself or through swelling (oedema). A variety of 
neurological symptoms may be present after stroke onset (Warlow et 
al. 1996), these include cortical symptoms such as difficulty 
swallowing, balance problems, difficulty understanding or expressing 
spoken language, dyslexia, or difficulty writing; sensory symptoms 
such as loss of vision in one side of the vision field, or total visual 
loss; and behavioural or cognitive symptoms such as confusion and 
forgetfulness. Other presentations include incontinence and loss of 
consciousness 0Narlow et al. 1996). 
The symptoms a patient has after stroke onset, such as weakness or 
speech problems, can help to determine which area of the brain has 
been damaged. Several classification methods exist, the most 
commonly used was developed by Bamford and colleagues (Bamford 
et al. 1991). This contains four subtypes of stroke; lacunar syndromes 
(LACS); posterior circulation syndromes (POCS); total anterior 
circulation syndrome (TACS); and partial anterior circulation 
syndrome (PACS). 
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Table 4.1 shows how the subtype of stroke may be determined, 
where the numbers represent the following deficits: 
1 a. One side of weakness and/or sensory deficit affecting face 
1 b. One side of weakness and/or sensory deficit affecting arm 
1 c. One side of weakness and/or sensory deficit affecting leg 
2. Cortical symptoms/signs such as dysphagia, neglect 
3. Loss of vision in one side of the vision field 
4. Signs such as ataxia, discontugated eye movements 
Table 4.1 
classification 
Subtype 
LACS 
TACS 
POCS 
PACS 
Combination 
Any two of 1 
1 and 2 and 3 
3 and/or 4 
Any two of 1 , 2, 3 
Or anyone of 1 
Determining the subtype of stroke using the Bamford 
The subtypes of stroke are associated with the degree of damage to 
the brain and hence may be used to predict outcome. Patients 
diagnosed with a lacunar stroke (LACS) will generally have a milder 
stroke since only weakness or sensory deficits are seen. In contrast 
patients with a total anterior circulation syndrome (TACS) will have a 
more severe stroke because in addition to those seen for LACS, other 
symptoms relating to loss of vision and cortical symptoms are seen, 
and hence more of the brain is affected. This rating is also reflected in 
the outcome for these patients, where approximately 2 % of LACS 
patients die within 30 days of stroke as compared to 39% of TACS 
patients (Samford et al. 1990). Patients diagnosed with partial 
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anterior circulation syndromes (PACS) and posterior circulation 
syndromes (POCS) have been found to have mortality rates of 4% 
and 7%, respectively, at 30 days post stroke (Bamford et al. 1990). 
4.4 Risk factors for stroke 
The main risk factors for stroke are increasing age, high blood 
pressure, exercise inactivity, cigarette smoking, high cholesterol 
levels, cardiovascular problems (such as angina or heart attack), 
atrial fibrillation (irregular heart rhythm) and diabetes (Warlow et al. 
1996). A higher risk of stroke is also associated with genetic 
inheritance, especially if the relative had a stroke whilst they were 
relatively young «50 years). This is thought to be related to not only 
genetic factors predisposing an individual, but may be also attributed 
to a family history of high cholesterol level and diabetes. Lower social 
class and ethnicity have been found to increase the risk of stoke 
where people from an African-Caribbean, African or southern Asian 
ancestry are at a higher risk of stroke than people with White 
ethnicity. 
The British Hypertension Society has suggested that optimal levels 
for blood pressure, irrespective of age, should be <140mm Hg for 
systolic blood pressure and <85mm Hg for diastolic blood pressure 
(Williams et at. 2004). Blood pressure is modified by many factors 
such as obesity, salt intake, and lack of exercise (Rudd et al. 2000). 
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4.5 Prognostic factors for outcome 
About a third of the patients which have a stroke will die shortly after 
stroke onset. Another third of patients will make a complete or near-
complete recovery given time. The remaining third of patients will 
remain functionally dependent following a stroke. A patients' outcome 
following stroke has been linked with factors such as smoking, old 
age, high blood pressure, cardiovascular problems and diabetes. In 
addition to these, other factors which are related to a poor outcome 
following stroke include urinary incontinence, history of a previous 
stroke, pre-morbid disability, impaired level of consciousness after 
stroke onset, total anterior circulation syndrome (TACS), large stroke 
lesion, presence of cognitive impairment, severe motor deficit, and 
visuospatial dysfunction (Hier et a/. 1991). 
4.6 Treatments following stroke 
Various drug treatments have been developed for treating stroke 
patients, these include anti platelet drugs and anticoagulant drugs, 
which make blood less sticky and reduce clotting; and 
antihypertensive drugs to lower blood pressure. Rehabilitation is used 
as a treatment towards improving outcome after stroke, and utilises 
the expertise of the multidisciplinary team, comprising of an 
occupational therapist, physiotherapist, speech and language 
therapist and psychologist. They help to aid physical recovery and 
encourage independence by managing physical, emotional and social 
effects of stroke. 
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4.7 Stroke outcome measures 
Many outcome measures are important in the area of stroke 
medicine. Since one third of patients will require help with functional 
abilities following a stroke, mortality is not the only important measure 
of effectiveness of an intervention for stroke patients. Disability 
measures were introduced into stroke trials in the 1960's and the use 
of the measures has gradually increased. Any measure that is used 
to assess outcome should be shown to be valid and reliable; 
however, many stroke trials have used non-validated outcome 
measures (Roberts et al. 1998). 
Recently, the World Health Organisation (WHO) has updated the 
classification for the International Classification of Functioning, 
Disability and Health, or the ICF 
(http://www.who.intlclassificationlicf/intros/icf-Eng-Intro.pdf). The ICF 
is now separated into 2 sections, each containing two components. 
Section 1 deals with the broad area of functioning and disability, and 
is subdivided into two components; body functions and structures, 
and activities and participation. The body functions and structures 
component assesses the changes in physiological functions and 
anatomical structures. In contrast, the activities and participation 
component assess the capacity and performance of executing tasks 
in the standard and current environment. The second section to the 
rCF concentrates on aspects of contextual factors of an individual's 
life and living. This section is subdivided into two components; 
environmental factors, and personal factors, which deal with the 
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external and internal influences on functioning and disability, 
respectively. 
Other outcome measures which fulfil the areas the ICF identifies 
include rating scales for handicap levels, quality of life, mood levels, 
satisfaction levels, health care costs and disability, the length of stay 
in hospital, and the discharge destination after hospital. These 
measures are widely acknowledged outcome assessments for stroke 
patients (Gompertz et al. 1993). Wade and colleagues have collated 
stroke scales and comment that the scales used to investigate the 
efficacy of a particular intervention should be valid, reliable and 
sensitive to clinically relevant changes. In addition to this, they should 
also be simple to administer, and easily communicated to non-
specialists and consumers, including patients and relatives (Wade 
1986). 
A variety of stroke outcome measures will be used in the examples in 
this thesis which include the activities of daily living, instrumental 
activities of daily living, leisure participation and activity, minor 
psychiatric measures, recurrent stroke, and death and dependency 
outcome measures. 
4.7.1 Activities of daily living 
Self-care tasks such as continence, dressing, personal hygiene and 
basic mobility, are referred to as personal activities of daily living 
(ADL). The Barthel Index was developed in 1965 by Mahoney and 
Barthel (Mahoney et a/. 1965) and later modified by Granger 
(Granger et al. 1979). The scale measures the patients' performance 
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in 10 activities of daily living items. The items are divided into two 
components; the first component is related to activities of self-care 
and includes assessing dependence in feeding, grooming, bathing, 
dressing, bowel and bladder continence and toilet use. The second 
component relates to mobility levels and assesses ambulation, 
transferring, and stair climbing. The maximum score is 100 if the 5-
point increment is used, indicating that the patient is fully independent 
in physical functioning; the lowest score is zero and relates to a totally 
dependent bed-ridden state. Due to the ordinal nature of the outcome 
measure, conventionally cut-off scores have been used to define 
different categories. A cut-off of 60 on the Barthel Index corresponds 
to a shift from dependence to assisted dependence (Granger et a/. 
1979). The Barthel Index has been shown to be a valid and reliable 
measure to use for stroke patients as a postal self-reported 
questionnaire (Gompertz et a/. 1994) and for use over the telephone 
(Wade 1992). Other values have been used to dichotomise the data 
from the Barthel Index, including a cut of 80 has been recommended 
in accordance with the European Stroke Database 
(http://www.ncl.ac.uklstroke-research-unit/posters/bsrcsmx.htm). 
Another ADL measure is the self-care section of the Rivermead Index 
(Whiting et al. 1980). The Rivermead ADL is very similar to the 
Barthel Index and is directed specifically towards the stroke 
population although it does not assess continence of bowels or 
bladder. The Rivermead ADL scale is based on the patient's 
performance and is scored on a 3-point scale; dependent, 
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independent but requires verbal supervision; or independent. These 
ADL measures concentrate upon actual observed behaviour and not 
potential abilities (Wade 1992), and do not measure why patients fail 
to achieve certain tasks or achieve independence. 
4.7.2 Instrumental activities of daily living 
Activities of daily living scales such as the Barthel Index have some 
weaknesses which are mainly related to ceiling and flooring effects, 
where patients either make a complete recovery or remain severely 
disabled. Therefore, measures are needed which assess the higher 
levels of activity (Duncan et al. 2000). 
Instrumental activities of daily living tasks include more complex 
activities required to live in the community such as walking outside, 
cooking, household management, and the ability to engage in social 
activities (Gladman et al. 1993). The Extended Activities of Daily 
Living scale is an example of an instrumental ADL scale and was 
developed for use in stroke patients. The extended ADL scale is a 22-
item questionnaire and consists of four uni-dimensional sub-scales 
assessing mobility (6 items), kitchen (5 items), domestic (5 items) and 
leisure abilities (6 items). The questions were designed to place 
emphasis on whether the patient did the activity, and not on if they 
could do it, and therefore looks at activity rather than capability (Nouri 
et al. 1987). The scale was designed to be used as a postal 
questionnaire, and has been shown to be reliable and valid and 
therefore it is attractive as an outcome measure. 
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4.7.3 Leisure participation and activity 
Leisure interests and hobbies used to be viewed as a way that the 
patients fill in their time and not thought to be of interest as an 
outcome measure. However, literature has suggested that leisure 
participation is related to life satisfaction (Allen et al. 1984), and forms 
a positive aspect of life. Leisure participation has been shown to 
decline with age, and after disabling conditions, such as stroke 
(Drummond 1990). The Nottingham Leisure Questionnaire (NLQ) was 
developed to measure leisure participation in stroke patients, and to 
monitor effects of interventions (Drummond et al. 1994). The NLQ is a 
37-item questionnaire where each item represents an activity, the 
frequency that the activity is performed is also recorded using five 
possible categories (very regularly, regularly, occasionally, 
infrequently, never). It has been shown to be reliable and valid when 
administered by a therapist (Drummond et al. 1994) but has not been 
tested for use as a postal questionnaire. However, recently the 37-
item questionnaire has been shortened to a more compact 30-item 
questionnaire (Drummond et a/. 2001), by removing some questions 
which had either a low prevalence or did not represent positive 
activities, such as 'day-dreaming' or 'just sitting'. Also, the response 
categories that represented the frequency of activity were collapsed 
down to three (regularly, occasionally, never). The shortened version 
was found to be valid for use as a postal questionnaire and had good 
reliability rates when administered in this manner (Drummond 'et al. 
2001). 
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4.7.4 Common mental disorders 
Many patients will suffer depression after stroke and therefore this 
should clearly feature in any outcome assessment. The General 
Health Questionnaire (Goldberg 1972) is a self-administered 
screening questionnaire. The questionnaire measures depression as 
well as somatic symptoms, anxiety and insomnia, and social 
dysfunction by determining a critical number of key symptoms rather 
than a particular symptom. This questionnaire has been modified and 
validated for use in stroke patients (Ebrahim 1985). 
4.7.5 Recurrent stroke 
The estimate risk of a recurrent stroke within 5 years of the initial 
stroke is 17% (Hillen et al. 2003), and was found to be related to 
stroke patients having ischaemic heart disease, atrial fibrillation, or 
diabetes. Increased risks of recurrence were associated with older 
patients. Similar rates of recurrence were seen across subtypes of 
stroke (Hillen et al. 2003). Also, stroke patients which are admitted to 
hospital with high blood pressure were found to have an increased 
risk of recurrence within 14 days of the initial stroke (Leonardi-Bee et 
al.2002). 
4.7.6 Combined death and functional scales 
A common outcome measure for stroke trials is the combined 
outcome of death or dependency, or death or disability. This is 
thought to reflect a 'poor outcome' where not only mortality is 
considered, but also the level of dependency or disability of the stroke 
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survivors. Dependency is usually measured using a validated 
outcome measure of activities of daily living, such as the Barthel 
Index; and disability is commonly measured using a scale such as the 
modified Rankin scale (van Swieten et al. 1988). The Rankin scale is 
a validated outcome measure which is based on a six point scale 
which ranges from no disability, through increasing levels of disability, 
and finally death; and measures independence rather than 
performance of specific tasks (van Swieten et al. 1988). 
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An introduction to the data sets 
The thesis will focus on analysing data from three meta-analyses of 
randomised controlled clinical trials. Each meta-analysis has been 
designed to answer a specific key question in the area of stroke 
management and hence all of the patients included in each of the 
meta-analyses have had at least one cerebrovascular event, such as 
a stroke or transient ischaemic attack. 
The first meta-analysis (Chapter 5) is concerned with patients who 
have very recently had a stroke. The healthcare question the meta-
analysis addresses is whether altering a patients' blood pressure in 
the acute phase of stroke, using medication, is beneficial in 
increasing the patients' chance of survival at long term follow-up. 
The second meta-analysis (Chapter 6) concentrates on patients who 
have been discharged from hospital following a stroke. The 
healthcare question this meta-analysis is targeting is whether 
occupational therapy in the community setting is effective in 
increasing the patients' abilities at performing everyday household 
and leisure tasks in stroke patients. 
The last meta-analysis (Chapter 7) involves patients who have 
previously suffered a stroke or transient ischaemic attack. The 
healthcare question this meta-analysis investigates is whether a 
combination of antiplatelet agents, dipyridamole and aspirin, will 
reduce the risk of subsequent stroke. 
123 
CHAPTERS 
ALTERING BLOOD PRESSURE IN A C U T ~ ~
STROKE: A SYSTEMATIC REVIEW AND META .. 
ANALYSIS OF RANDOMISED CONTROLLED 
TRIALS 
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5.1 Introduction 
High blood pressure (BP), defined by the World Health Organisation 
as a BP>140/85 mmHg, is present in 75-80% of patients with acute 
ischaemic and haemorrhagic stroke (Wallace et al. 1981; Britton et al. 
1986; Leonardi-Bee et al. 2002). The mechanisms underlying 
hypertension in stroke remain unclear but include pre-existing 
hypertension, activation of neuroendocrine systems (sympathetic, 
glucocorticoid, mineralocorticoid), increased cardiac output, the stress 
of hospitalisation, and the Cushing reflex (reactive increases in 
systemic blood pressure in response to a raised intracranial pressure) 
(Carlberg et al. 1991; Harper et al. 1994; Boreas et al. 2001). 
Many studies, and a meta-analysis of them, have found that high BP, 
whether measured casually or using 24 hour ambulatory readings, is 
associated with a poor outcome, judged as an increase in death or 
combined death and disability or dependency (Carlberg et al. 1993; 
Dandapani et al. 1995; Robinson et al. 1997; Leonardi-Bee et al. 
2002; Will mot et al. 2004). High BP is also associated with a greater 
risk of recurrence, and possibly of developing fatal cerebral oedema, 
after ischaemic stroke (Leonardi-Bee et al. 2002). 
The frequency of high BP in acute stroke and its independent 
association with a poor outcome, suggest that BP should be lowered. 
However, impaired cerebral autoregulation is present during the acute 
phase of stroke (Meyer et al. 1973), such that regional cerebral blood 
flow becomes passively dependent on arterial blood pressure. Hence, 
it has been hypothesised that lowering BP might further reduce 
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perfusion and worsen outcome leading to considerable debate as to 
whether BP should be lowered acutely (Spence et al. 1985; Yatsu et 
al. 1985; International Society of Hypertension Writing Group 2003). 
Other factors also need to be considered, including drug class, and 
timing of administration (Bath et al. 1997). Although no large and 
definitive randomised controlled trials assessing the management of 
BP in acute stroke have been completed, many studies have 
investigated the effect of vasoactive drugs in acute stroke and an 
integrated analysis of these might further elucidate the relationship 
between altering BP and outcome. Therefore the 'Blood pressure in 
Acute Stroke Collaboration' (BASe) project was initiated to 
investigate relationships of vasoactive drugs in acute stroke using a 
series of systematic reviews (Bath et a/. 1997). 
5.1.1 Blood pressure in Acute Stroke Collaboration 
The objective of BASC was to determine whether altering blood 
pressure in patients with acute stroke is safe and effective in reducing 
the risk of death, and death or dependency. To determine the effects 
of vasoactive drugs on blood pressure three phases were 
undertaken. 
The first phase was to identify and assessed the relationships 
between vasoactive drugs and outcome where the primary aim of the 
individual trials was to alter blood pressure in patients with acute 
stroke (Blood pressure in Acute Stroke Collaboration (BASC) 
2001 (b». Five small randomised control/ed trials were identified which 
contained six drug classes. Of these only calcium channel blockers 
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were found to significantly impact on lowering blood pressure; 
however no significant effect on outcome was seen in any of the 
trials. 
The second phase of BASe was to identify and assess the effects of 
vasoactive drugs in the acute treatment of stroke where the primary 
aim of the trial was not necessarily to assess the drug's effect on 
blood pressure (The Blood pressure in Acute Stroke Collaboration 
(BASe) 2001 (a». Sixty five completed randomised controlled trials 
were identified and data were obtained from 32 of these. Calcium 
channel blockers, ACE-inhibitors, beta blockers, glyceryl trinitrate and 
prostacyclin were found to reduce blood pressure within 2 days as 
compared to control. However, magnesium, naftidrofuryl and 
piracetam did not appear to alter early blood pressure. Death was 
found to be increased in trials which assessed either streptokinase, 
beta blockers or piracetam. However, no noticeable effects were seen 
for any of the drug classes for death or dependency. 
5.2 Design of study 
The third phase of BASC is to perform a systematic review and meta-
analysis of data from randomised controlled trials of vasoactive drugs 
in patients with acute stroke, where measurements of systolic blood 
pressure were recorded. It was decided to use systolic blood 
pressure rather than diastolic or mean arterial blood pressure 
because systolic is thought to be more precise in measuring blood 
pressure. This is because some automated measurements of blood 
pressure, such as the OMRON, use the systolic blood pressure 
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measurement to calculate the diastolic measurement, and hence its 
derivatives, such as mean arterial blood pressure and pulse pressure. 
5.2.1 Measures of interest 
The primary outcome measure is death at the end of trial. Secondary 
outcome measures include death or dependency/disability at the end 
of trial. 
5.3 Study selection and search strategy 
For a trial to be eligible for inclusion in this systematic review it has to 
fulfil the following criteria: (i) randomisation, (ii) controlled, (iii) 
vasoactive drug which would be expected, on pharmacological 
grounds, to lower blood pressure, (iv) patients with ischaemic or 
haemorrhagic stroke within two weeks of onset, (v) baseline systolic 
blood pressure measurements. Vasoactive drugs with hypotenstive 
properties included alpha-receptor antagonists, angiotensin 
converting enzymes (ACE) inhibitors, angiotensin II receptor 
antagonists, beta-receptor antagonists calcium channel blockers 
(eGB), dipyridamole, diuretics, magnesium, naftidrofuryl, nitrates, 
papaverine, pentoxifylline, prostacyclin, serotonin receptor 
antagonists, sympathomimetics, theophylline, thromboxane 
antagonists, vinpocetine, and their derivatives. 
Trials were excluded from the review if they were controlled but 
confounded trials where active treatments were compared (without a 
control group), or if they included patients with subarachnoid 
haemorrhage. 
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A comprehensive literature search, using a strategy developed by the 
Cochrane Stroke Group (Sandercock et al. 2003) was performed to 
identify trials using The Cochrane Library (2003 Issue 1), MEDLINE 
(1966-March 2003), EMBASE (1980-March 2003) and Web of 
Knowledge (1981-March 2003). Searches were also made of the 
reference list of identified trials, reviews of hypertension in acute 
stroke and the UK National Research Register. The project was also 
advertised at meetings and in journals (Blood pressure in Acute 
Stroke Collaboration 2003). No restrictions on the language of the 
publication were made. 
5.4 Data collection and management 
Identified trials were assessed independently by the secretariat of the 
collaboration. Contact authors were approached about joining BASC 
and sharing their individual patient data. If contact with collaborators 
was not made, repeat invitations were sent out; strenuous efforts 
were made to find trialists who had moved or to identify another 
senior author. 
Thirty-six eligible trials were identified involving in 8,058 acute stroke 
patients (Figure 5.1). Outcome data from all of these trials were either 
abstracted from the original publication (Martin et al. 1985; Gelmers 
1988; Herrschaft 1988; Paci et al. 1989; Bogousslavsky et al. 1990; 
Martinez-Villa et al. 1990; Murphy et al. 1990; Mohr et al. 1992; 
Kramer et al. 1994; Wimalaratna et a/. 1994; De Deyn et al. 1997; 
Lamsudin et al. 1997; Bogousslavsky et al. 2002; Lees et al. Personal 
communication) or through the sharing of individual patient data 
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(Wester et al. 1984; Huczynski et al. 1985; Uzuner et al. 1985; 
Pokrupa et al. 1986; Steiner et al. 1986; Barer et al. 1988; Azcona et 
al. 1990; Gray et al. 1990; Limburg et al. 1990; Autret et al. 1992; 
Kaste et al. 1994; Norris et al. 1994; Wahlgren et al. 1994; Muir et al. 
1995; Squire et a/. 1996; Steiner et al. 1996; Dyker et al. 1997; Muir 
et al. 1998; Bath et al. 2001; Rashid et al. 2003; Barer et a/. 
Unpublished; Lowe et al. Unpublished). 
Trials of vasoactive 
drugs 
N=59 
Outcome data not Blood pressure not 
recorded - recorded 
N=4 N=14 
Potential trials for 
inclusion N=41 
Planned/ongoing 
I-trials N=5 
Eligible trials for 
inclusion N=36 
Data extracted Individual patient 
from publication data shared 
N=14 N=22 
Figure 5.1 Flow chart for trial identification and selection 
However, data on blood pressure were only available for 34 of the 
trials; the data from the other two trials had been previously lost 
(Martin et al. 1985) or the authors could not be contacted (Gelmers 
1988). 
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Trial, year of Subjects Vasoactive treatment Individual data 
publication 
ASCLEPIOS, 1990 230 Isradipine 0/ 
Autret, 1992 312 Naftidrofuryl 0/ 
Bath,2001 37 Glyceryl trinitrate 0/ 
BEST pilot, 1988 55 Atenolol/propananol 0/ 
BEST,1988 302 Atenolol/propananol ./ 
Bogousslavsky, 1990 52 Nimodipine JC 
Bogousslavsky, 2002 293 Fibroblast JC 
Dyker, 1997 28 Perindopril ./ 
Gelmers, 1988 186 Nimodipine JC 
Gray, 1990 100 Naftidrofuryl 0/ 
Herrschaft, 1988 40 Piracetam JC 
Huczynski, 1985 30 Prostacyclin ./ 
IMAGES. pilot 1998 51 Magnesium sulphate JC 
INWEST,1994 281 Nimodipine ./ 
Kaste.1994 355 Nimodipine ./ 
Kramer, 1994 482 Nimodipine JC 
Lamsudin, 1997 150 Nimodipine JC 
Lees, 1995 60 Magnesium sulphate ./ 
Limburg, 1990 26 Flunarizine ./ 
Lowe, 1992 112 Nimodipine ./ 
Martin, 1985 32 Prostacylin JC 
Martinez-Vila, 1990 164 Nimodipine JC 
Mohr, 1992 1064 Nimodipine JC 
Muir, 1995 25 Magnesium sulphate 0/ 
Norris, 1994 189 Nimodipine ./ 
Paci,1989 41 Nimodipine JC 
PASS, 1997 927 Piracetam JC 
Pokrupa, 1986 23 Prostacyclin .; 
PRISTINE. 1996 620 Naftidrofuryl .; 
Rashid. 2003 90 Glyceryl trinitrate .; 
Squire, 1996 147 Lifarizine .; 
Steiner. 1986 100 Naftidrofuryl .; 
Strand. 1984 26 Magnesium sulphate .; 
TRUST. 1990 1215 Nimodipine JC 
Uzuner, 1995 88 Nimodipine .; 
Wimalaratna, 1994 125 Nimodipine JC 
Table 5.1 .. Trial characteristics for the Identified trials 
Five further other trials were excluded because they were ongoing at 
the time of analysis (8ath 2001; Lees ef a/. 2001; COSSACS 2003; 
Robinson ef al. 2003; Willmot ef al. Unpublished). 
Shared individual patient data and abstracted data were checked for 
consistency, re-coded to ensure uniformity and merged into a single 
database using SAS version 8.02 (SAS Institute Inc). Combined death 
and disability/dependency were defined a priori as: 8arthel Index<60 or 
adapted 7 point Rankin Scale>3 (Steiner ef al. 1986). Some trials used 
their own scale and a dichotomous variable was created according to 
the grand median score for that trial. 
5.5 Assessment of publication bias and quality 
8egg's funnel plot was used to assess visually if there was evidence of 
publication bias within the meta-analysis. The plot suggested that there 
was a lack of smaller sized stUdies which showed detrimental effects. 
Additionally, two of the point estimates were located outside the pseudo 
95% confidence interval lines; hence there may be a suggestion of 
publication bias in this review (Figure 5.2). 
8egg and Mazumdar rank correlation test found no evidence of 
publication bias (p=0.307, 36 trials), similarly the trim and fill method 
found that no trimming needed to be performed; however, Egger's 
asymmetry test found evidence of publication bias (p=0.026, 36 trials). 
Methodological quality for each trial was assessed on the basis of the 
method of randomisation employed, whether the allocation to treatment 
was concealed, the completeness of follow-up achieved, and whether 
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the outcome assessment was blinded to the allocation of treatment 
using recognised criteria (The Cochrane Collaboration 2003). 
Thirty-one of the 36 trials were deemed to be of high quality, the 
remaining five were found to be of a moderate quality due to either 
inadequate allocation of concealment for treatment assignment or 
unclear methods of randomisation (Table 5.2). 
Standard error of log odds ratio 
o 
0.5 
• 
• 
• 
1.5 
• 
2 ~ - - - - - ' - - - - - T - - - - - r - - - - - , ,• 
-4 -2 a 2 4 
Log odds ratio 
Figure 5.2 Begg's funnel plot for death at the end of trial 
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Trial, year of Allocation to Adequate Placebo 
publication concealment randomisation controlled 
ASCLEPIOS, 1990 A Yes Yes 
Autret, 1992 B Yes Yes 
Bath,2001 A Yes Yes 
BEST pilot, 1988 B Yes No 
BEST,1988 A Yes Yes 
Bogousslavsky, 1990 A Yes Yes 
Bogousslavsky, 2002 A Yes Yes 
Dyker, 1997 A Yes Yes 
Gelmers, 1988 A Yes Yes 
Gray, 1990 A Yes Yes 
Herrschaft, 1988 A Yes Yes 
Huczynski, 1985 A Unclear Yes 
IMAGES, pilot 1998 A Yes Yes 
INWEST,1994 A Yes Yes 
Kaste, 1994 A Yes Yes 
Kramer, 1994 A Yes Yes 
lam sud in, 1997 A Yes Yes 
Lees, 1995 A Yes Yes 
Limburg, 1990 A Yes Yes 
Lowe, 1992 A Yes No 
Martin, 1985 A Yes Yes 
Martinez-Vila, 1990 A Yes Yes 
Mohr, 1992 A Yes Yes 
Muir, 1995 A Yes Yes 
Norris, 1994 A Yes Yes 
Paci,1989 A Yes Yes 
PASS, 1997 A Yes Yes 
Pokrupa, 1986 A Yes Yes 
PRISTINE, 1996 A Yes Yes 
Rashid, 2003 B Yes No 
Squire, 1996 A Yes Yes 
Steiner, 1986 A Yes Yes 
Strand, 1984 A Yes Yes 
TRUST,1990 A Yes Yes 
Uzuner, 1995 B Yes No 
Wimalartna, 1994 A Yes Yes 
A Low risk of bIas, B Moderate rrsk of bias, C HIgh rrsk of bias 
Table 5.2 Assessment of quality for the 36 trials 
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5.6 Trial level demographics 
Trials were assessed to determine whether patients were similar 
between the trials. The demographics of the patients across the trials 
appeared to be relatively well balanced (Table 5.3). The trial by 
Herrschaft and colleagues (Herrschaft 1988) recruited slightly younger 
patients (mean 57 years) than the other trials whereas the IMAGES 
pilot trial recruited slightly older patients (mean 75 years) (Lees et a/. 
Personal communication). The majority of the trials recruited more 
males than female patients. The two extremes for the percentages of 
males ranged from 35% males (Limburg et al. 1990) to 73% males 
(Bogousslavsky et a/. 1990). The mean baseline systolic blood 
pressures from the trials were above 140 mm Hg indicating that the 
patients generally had higher than optimal blood pressures. 
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Trial, year of Age (years) Gender, male (%) SBP (mmHg) 
publication [mean, (SO)] [mean (SO)] 
ASCLEPIOS, 1990 69 (10) 146 (62) 159 (27) 
Autret, 1992 68 (8) 189(61) 162 (28) 
Bath,2001 74 (9) 18 (49) 161 (22) 
BEST pilot, 1988 71 (10) 28 (51) 149 (27) 
BEST,1988 69 (11) 159 (52) 156 (27) 
Bogousslavsky, 1990 65 (-) 38 (73) 147 (-) 
Bogousslavsky, 2002 70 (12) 175 (61) 157 (-) 
Dyker, 1997 70 (10) 17 (61) 172 (22) 
Gelmers, 1988 70 (-) 111 (60) -(-) 
Gray, 1990 67 (9) 46 (46) 154 (25) 
Herrschaft, 1988 57 (-) 27 (61) 165{-) 
Huczynski, 1985 61 (12) 16 (53) 159 (31) 
IMAGES, pilot 1998 75 (9) 19 (37) 160 (-) 
INWEST,1994 72 (10) 136 (46) 160 (28) 
Kaste, 1994 58 (9) 236 (66) 156 (26) 
Kramer, 1994 63 (-) 258 (54) 154 (-) 
Lamsudin, 1997 -(-) 96 (64) 168 (-) 
Lees, 1995 68 (13) 30 (50) 155 (27) 
Limburg, 1990 67 (14) 9 (35) 160 (32) 
Lowe, 1992 68 (9) 66 (59) 157 (27) 
Martin, 1985 68 (-) -(-) -(-) 
Martinez-Vila, 1990 72 (-) 70 (57) 152 (-) 
Mohr, 1992 66 (-) 617 (58) 151 (-) 
Muir, 1995 70 (10) 16 (64) 160 (26) 
Norris, 1994 72 (10) 104 (55) 147 (25) 
Paci,1989 63 (-) 28 (69) 153 (-) 
PASS, 1997 71 (-) 479 (52) 160 (-) 
Pokrupa, 1986 63 (13) 11 (48) 150 (20) 
PRISTINE,1996 72 (9) 321 (52) 161 (26) 
Rashid,2003 72 (12) 41 (46) 152 (20) 
Squire, 1996 69 (13) 82 (56) 157 (24) 
Steiner, 1986 69 (7) 54 (54) 147 (25) 
Strand, 1984 74(11) 14 (54) 162 (32) 
TRUST,1990 73 (-) 555 (46) 157 (-) 
Uzuner, 1995 63 (12) 44 (50) 145 (24) 
Wimalaratna, 1994 70 (-) -(-) 159 (-) 
- Data not available from publication 
Table 5.3 Patient demographics at baseline by trial 
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5.7 Outcome assessments and measures 
All of the trials recorded death at the end of trial; however for the 
secondary outcome measure death or dependency at the end of trial, 
this was only available for 21 of the trials (Huczynski et al. 1985; Uzuner 
et a/. 1985; Steiner et a/. 1986; Barer et a/. 1988; Herrschaft 1988; 
Azcona et a/. 1990; Limburg et al. 1990; Murphy et al. 1990; Norris et 
al. 1994; Wahlgren et al. 1994; Muir et al. 1995; Squire et al. 1996; 
Steiner et al. 1996; De Deyn et al. 1997; Muir et al. 1998; Bath et al. 
2001; Bogousslavsky et al. 2002; Rashid et a/. 2003; Lees et a/. 
Personal communication; Barer et a/. Unpublished; Lowe et al. 
Unpublished). 
5.7.1 Type of intervention 
The drugs given in the trials may be categorised by class based on 
mechanism of action. Nine classes of vasoactive drugs were involved in 
the 26 trials; these were calcium channel blockers, beta blockers, 
naftidrofuryl, nitric oxide donor, magnesium, prostacyclin, piracetam, 
tiblast growth factor, and perindopril (Table 5.4). The majority of trials 
involved assessing the efficacy of a calcium channel blocker. The 
vasoactive drugs were either given orally, intravenously or 
transdermally using patches. 
5.7.2 Timing of assessments 
The timings for the outcome assessments varied between the trials. 
The median time to the end of trial was 12 weeks (range 2 weeks to 52 
weeks) (Table 5.4). 
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Trial, year of Drug Class Recruitment Timing of assessment 
publication window (hours) (weeks) 
ASCLEPIOS, 1990 CCB 12 12 
Autret, 1992 Naftidrofuryl 72 24 
Bath,2001 Nitric oxide donor 120 12 
BEST pilot, 1988 Beta blocker 48 24 
BEST,1988 Beta blocker 48 24 
Bogousslavsky, 1990 CCB 48 4 
Bogousslavsky, 2002 Fiblast 6 12 
Dyker, 1997 Perindopril 168 2 
Gelmers, 1988 CCB 24 4 
Gray, 1990 Naftidrofuryl 48 24 
Herrschaft, 1988 Piracetam 120 4 
Huczynski, 1985 Prostacyclin 72 4 
IMAGES, pilot 1998 Magnesium 12 4 
INWEST,1994 CCB 24 24 
Kaste, 1994 CCB 48 52 
Kramer, 1994 CCB 48 4 
Lamsudin, 1997 CCB 24 2 
Lees, 1995 Magnesium 12 12 
Limburg, 1990 CCB 24 24 
Lowe, 1992 CCB 48 24 
Martin, 1985 Prostacyclin 36 2 
Martinez-Vila, 1990 CCB 48 4 
Mohr, 1992 CCB 48 24 
Muir, 1995 Magnesium 24 12 
Norris, 1994 CCB 42 52 
Paci,1989 CCB 12 4 
PASS, 1997 Piracetam 12 12 
Pokrupa, 1986 Prostacyclin 48 4 
PRISTINE, 1996 Naftidrofuryl 48 52 
Rashid, 2003 Nitric oxide donor 72 12 
Squire, 1996 CCB 12 13 
Steiner, 1986 Naftidrofuryl 168 52 
Strand, 1984 Magnesium 36 24 
TRUST,1990 CCB 24 24 
Uzuner, 1995 CCB 24 2 
Wimalaratna, 1994 CCB 24 24 
Table 5.4 Trial characteristics for the 36 trials 
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5.7.3 Time between stroke onset and recruitment into 
study 
All trials recruited patients within a pre-specified time limit from the 
onset of stroke. The median maximum time from stroke onset to 
recruitment was 45 hours (range 6-168 hours) (Table 5.4). 
5.8 Analysis of the merged data set using summary 
data methods 
The combined data set contained individual patient information from 36 
trials and comprised of 8,058 stroke patients. Patients received either a 
vasoactive drug (n=4,494), or placebo/control (n=3,564). 
5.8.1 Data analysis for death at the end of trial 
The proportions of patients which died at the end of trial in each 
treatment group within each trial were used as the primary outcome 
measure. The odds ratios and variances for each trial were calculated 
as detailed in section 2.3.1.1. 
5.8.2 Results for death at the end of trial 
In a conventional fixed effect analysis as described in section 2.4.1, 
patients randomised to a vasoactive drug had non-significantly 
increased risk of death as compared to patients which received 
control/placebo (OR 1.10, 95% CI 0.98, 1.23). 
5.8.3 Results for secondary outcomes 
From a conventional fixed effect analysis as described in section 2.4.1, 
patients randomised to a vasoactive drug had a non-significant increase 
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in the risk of death and dependency at the end of trial (OR 1.11, 95% CI 
0.98, 1.24). 
5.9 Assessment of heterogeneity using summary 
data 
The conventional methods presented above assume that each of the 
trials is estimating a single underlying treatment effect. An assessment 
of heterogeneity needs to be performed to evaluate whether this 
assumption is justified. Visual and statistical assessments used for 
death at the end of trial. 
5.9.1 Graphical assessment of heterogeneity 
The forest plot indicates that there is some heterogeneity between the 
trial estimates when compared overall (Figure 5.3). Therefore, to 
formally assess the presence of heterogeneity between the estimates, 
statistical testing of heterogeneity was performed. 
5.9.2 Statistical assessments of heterogeneity using 
classical methods 
To formally assess whether there was evidence of heterogeneity 
between the trials the Cochran's homogeneity Q test and Higgins and 
Thompson /2 were performed. Also, other analyses were used to 
quantify the heterogeneity between the trial estimates using un-
weighted and weighted MM, ML, REML, EB and FB (Table 5.5). For the 
FB model, assessments of convergence were adequate using a burn-in 
of 10,000 and a sample chain of 40,000 iterations. 
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Figure 5.3 Forest plot for death at the end of trial 
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Heterogeneity Test -l P value /2 
Cochran's Q test 28.05 0.62 
[2 0 
Estimation methods Odds Ratio 95%CI f2 
MM, un-weighted 1.102 0.983, 1.236 0 
MM, weighted 1.102 0.983, 1.236 0 
ML 1.102 0.983, 1.236 0 
REML 1.102 0.983, 1.236 0 
EB 1.102 0.983, 1.236 0 
FB 1.072 0.923, 1.229+ 0.139 
Odds ratio IS the odds ratio of mortality on vasoactive drug relative to control. + 95% 
credibility interval 
Table 5.5 Heterogeneity test and analYSis results for death at the end of 
trial based on summary data 
Cochran's homogeneity test did not find evidence of heterogeneity 
between the trial estimates (p =0.62). /2 was estimated as zero for the 
overall comparison (Table 5.5) indicating that none of the variability 
between the trial estimates could be attributed to heterogeneity. 
From Table 5.5, the estimates for heterogeneity from the classical and 
EB methods were all zero, and hence the estimates for the treatment 
effect were identical as to those from the fixed effect models; indicating 
that there was a small but non-significant 10% increase in the risk of 
death at the end of trial associated with vasoactive drug use. 
The FB approach found a small quantity of heterogeneity, hence the 
standard errors were slightly larger in magnitude as compared to the 
other models; however, the treatment effect remained non-significant at 
the 5% level. 
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5.10 Exploring heterogeneity 
It appears that the difference in the estimates for the treatment effects 
between the trials may be due to sampling variation only and not due to 
heterogeneity. Although these tests did not find evidence of 
heterogeneity, it may still be advantageous to determine whether any 
prognostic factors either relating to patient characteristics, such as 
baseline blood pressure, or trials factors, such as drug class, can 
explain some of the residual variation between the trials. Subgroup 
analyses were used to assess the influence of trial factors, and meta-
regression analyses were used to assess the influence of patient 
characteristics. 
5.10.1 Subgroup analyses 
Subgroup analyses were performed to assess the relationship between 
death at the end of trial and two trial characteristics: class of the 
vasoactive drug used, and the time from stroke onset to recruitment. 
5.10.1.1 Class of vasoactive drugs 
Trends towards increases in the risk of death were seen for all of the 
drug classes (Figure 5.3), except magnesium where a non-significant 
41 % decrease in the risk of death was associated with a vasoactive 
drug as compared to control/placebo (OR 0.59,95% CI 0.26, 1.34). 
The Q value for the change in heterogeneity was 0.751: indicating that 
there does not appear to be any evidence of a difference between the 
drug classes for death at the end of trial. 
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Figure 5.4 Subgroup analyses for death by the time limit for stroke onset 
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5.10.1.2 Time from stroke onset to recruitment 
The inclusion criteria for each trial involved recruiting patients within a 
time limit, and this limit varied between the trials. Trials were grouped 
into either ~ 4 8 8 hours or >48 hours (Figure 5.4). The estimates for death 
at the end of trial were very similar between the two groups ( ~ 4 8 8 hours 
OR 1.10,95% CI 0.98, 1.24; >48 hours OR 1.11, 95% CI 0.74,1.65). 
The p value for the change in heterogeneity was 1.00; also indicating 
no differences in the risk of death between the two time limit to 
recruitment groups. 
5.10.2 Meta-regression analyses 
The patient characteristics of interest were systolic BP at baseline and 
the early change in systolic BP. Early change in BP was defined as 
either the difference between 24 hours BP and baseline BP, or the 
difference between 48 hour BP and baseline BP (in the cases where 24 
hour BP was not recorded in the trials). Baseline BP and early change 
in BP were assessed using the absolute values for each of the factors, 
additionally the difference in the absolute values between the 
vasoactive and control/placebo groups for each trial were used for 
baseline BP to assess the effect of mismatched baseline BP's between 
the treatment groups. 
For the analyses, baseline BP was centred at 160 mm Hg, the 
difference in BP was centred at 0 mm Hg, and the percentage change 
in early BP was centred at 0%. 
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Method Odds ratioS 95%CI SBPOo 95%CI ;2 
MM, approx 1.267 1.089,1.473 1.035 1.007, 1.065 0 
MM, weighted 1.267 1.089, 1.473 1.035 1.007, 1.065 0 
ML 1.267 1.089, 1.473 1.035 1.007, 1.065 0 
REML 1.267 1.089, 1.473 1.035 1.007, 1.065 0 
EB 1.267 1.089,1.473 1.035 1.007, 1.065 0 
FB 1.265 1.047, 1.514 1.038 1.005, 1.072 0.131 
Method Odds RatioS 95%CI tSBPOo 95%CI f2 
MM, approx 1.129 1.005, 1.268 1.01B 0.987, 1.050 0 
MM, weighted 1.129 1.005, 1.268 1.018 0.987,1.050 0 
ML 1.129 1.005, 1.268 1.018 0.987, 1.050 0 
REML 1.129 1.005, 1.268 1.018 0.987,1.050 0 
EB 1.129 1.005, 1.268 1.018 0.987, 1.050 0 
FB 1.107 0.954, 1.276 1.019 0.984, 1.055 0.144 
Method Odds RatioS 95%CI ASBP%o 95%CI f2 
MM, approx 0.863 0.582, 1.279 0.967 0.920, 1.017 0 
MM, weighted 0.863 0.582, 1.279 0.967 0.920, 1.017 0 
ML 0.863 0.582, 1.279 0.967 0.920, 1.017 0 
REML 0.863 0.582, 1.279 0.967 0.920, 1.017 0 
EB 0.863 0.582, 1.279 0.967 0.920, 1.017 0 
FB 0.843 0.513, 1.368 0.968 0.911, 1.029 0.193 
-- - ------- -- ---- ------- -- - --
§ Odds of death on vasoactive drug relative to control at the centred covariate value, n Multiplicative increase in mortality OR when covariate is increased by 
1 unit, SBPO baseline systolic BP, tSBPO difference in SBP between treatment groups, ASBP% early percentage change in SBP, + 95% credibility intervals 
Table 5.6 Death at the end of trial using summary data meta-regression methods 
Although heterogeneity was only found in the FB model, a series of 
random effect meta-regression models were used to explore the 
relationships between death at the end of trial and the covariates (see 
section 3.4). The methods used to estimate heterogeneity were the 
weighted and approximate MM, ML, REML, EB and FB. For the FB 
model, assessments of convergence of were found adequate when 
using a burn-in of 10,000 and a sample chain of 40,000 iterations. 
Similar estimates for the treatment and covariates effects were seen 
from all of the models for each of the covariates. Slight differences 
between the magnitudes of the treatment and covariate effects between 
the classical and Bayesian models are related to the Bayesian models 
estimating heterogeneity where slightly smaller odds ratios for the 
treatment effect were seen from these models as compared to the 
classical models (Table 5.6). 
In the baseline systolic BP adjusted model, the covariate was centred to 
160mm Hg. A significant relationship was seen between baseline 
systolic BP and the treatment effect which implied that there was a 4% 
increase in the estimated odds ratio per every 10 mm Hg increase in 
systolic BP (95% CI 1 %, 7%) (Table 5.6). However, it did not appear 
that the difference in SBP between the treatment groups or the early 
percentage change in the vasoactive group was related to the treatment 
effect at the end of trial (Table 5.6). 
5.11 Individual patient data methods 
In a classical fixed effect IPD model, patients randomised to a 
vasoactive drug were found to have a trend towards a higher risk of 
death at the end of trial as compared to those randomised to control 
(OR 1.10, 95% CI 0.98, 1.24) (Table 5.7). 
Odds ratio (OR) 95%CI i 2 
Fixed effect model 
Classical approach 1.103 0.983, 1.237 -
Random effect model 
Classical approach 1.096 0.972, 1.237 0.002 
Bayesian approach 1.097 0.922,1.256+ 0.032 
. .. OR IS the odds of mortality on vasoactive drug relative to control, :t credibility Intervals . 
Table 5.7 Death at the end of trial using individual patient data 
methodologies 
5.12 Assessment of heterogeneity using individual 
patient data methods 
Assessments of heterogeneity between the trials were explored using 
an interaction term between trial and treatment group in the above fixed 
effect model. From this interaction term model, it appeared that there 
was no significant difference between the trials (p =0.643). For 
consistency of analyses, heterogeneity was estimated using both 
classical and Bayesian methodologies based on random effect IPD 
models. For the FB models, assessments of convergence were made 
using criteria as described in section 2.5.3, and adequate assessments 
were achieved when a burn-in of 5,000 iterations and a sample chain of 
50,000 iterations were used. 
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Similar results were seen from the classical and Bayesian IPO random 
effect models for the treatment effect which implied that vasoactive 
drugs were non-significantly associated with a 10% increase in the risk 
of death at the end of trial as compared to control/placebo. 
Heterogeneity was estimated from both the classical and Bayesian 
models, however, the magnitude of the heterogeneity did not impact 
greatly on the results since they were similar to the fixed effect classical 
IPO model (Table 5.7). 
5.13 Exploring heterogeneity using individual 
patient data methods 
Both classical and Bayesian methods found quantifiable amounts of 
heterogeneity between the trials. Therefore trial level covariates, such 
as drug class and time to recruitment; and patient level covariates, such 
as baseline systolic BP and the early change in systolic BP, were 
included in the random effect models to assess their influence on death 
at the end of trial. For the FB models, assessments of convergence 
were made using criteria as described in section 2.5.3, and adequate 
assessments were achieved when a burn-in of 5,000 iterations and a 
sample chain of 50,000 iterations were used. 
5.13.1 Trial level covariates using individual patient 
data 
Drug class was modelled using a classical random effect IPD meta-
regression model as described in section 3.5.1.3 to assess its impact on 
death at the end of trial. No differences in death at the end of trial were 
seen between the classes of drug considered in this review (p =0.916). 
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5.13.2 Patient level covariates using individual 
patient data 
Classical and Bayesian models were performed to assess the impact of 
time from stroke onset to recruitment, baseline systolic BP and early 
change in systolic BP on death at the end of trial using random effect 
IPD models. For the FB models, adequate assessments of 
convergence were seen when a burn-in of 10,000 iterations and sample 
chains of 50,000 iterations were used. 
Initially, an interaction term between the covariate and treatment effect 
terms was included in the models to ascertain whether the treatment 
effect varied across the range of covariates. Two of the models found 
no evidence on an interaction therefore the interaction was 
subsequently dropped from these models (baseline SBP interaction 
p =0.249, SBP early change interaction p =0.940). However, some 
evidence of a possible interaction was seen with time from stroke onset 
to recruitment and hence these two separate models were used where 
time from stroke onset to recruitment was split into ~ 8 8 hours and >48 
hours (p =0.060). 
In the covariate adjusted models presented in Table 5.8, the results for 
the treatment effect and covariate effects between the classical and 
Bayesian models were very similar. 
In the baseline systolic BP adjusted model, patient randomised to a 
vasoactive drug had a significantly higher risk of death at the end of trial 
by 14% as compared to those randomised to control/placebo. 
Additionally. the results indicated that there was a 4% increase in the 
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risk of death at the end of trial for every 10mm Hg increase in baseline 
SSP (Table 5.8). 
In the early change in systolic BP model, the covariate didn't appear to 
be influential in the risk of death at the end of trial. 
The random effect models were then adjusted for time from stroke 
onset to recruitment into the trial as a continuous measure, however the 
models were split into ~ 4 8 8 hours and >48 hours from stroke onset. 
Patients that were recruited within 48 hours were 2% significantly less 
likely to have a poor outcome as the time to recruitment increased for 
every hour (95% CI 1 %, 3%). However, this effect was not observed in 
patients that were recruited after 48 hours since stroke onset (Table 
5.8). 
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IPO Models Odds rati09 95%CI Estimate!} 95%CI ;2 
Vasoactive drug vs. control SBPO 
REML 1.138 1.012, 1.279 1.004 1.001, 1.007 0 
FB 1.139 1.006, 1.289t, 1.004 1.001, 1.007t 0.085 
Vasoactive drug vs. control ASBP% 
REML 1.125 0.922, 1.372 1.004 0.997,1.010 0.014 
FB 1.093 0.876,1.361t 1.004 0.997,1.010t 0.059 
Vasoactive drug vs. control Time to recruitment ($48 hours) , 
REML 1.053 0.916, 1.209 0.981 0.970, 0.992 0.005 
FB 1.020 0.856, 1.1 95t 0.976 0.965, 0.987t 0.034 
Vasoactive drug vs. control Time to recruitment (>48 hours) 
REML 0.574 0.050, 7.110 0.979 0.917, 1.045 1.994 
FB 0.782 0.052, 10.67t 0.974 0.913,1.051t 2.654 
--
_ .. _----- -
§ Odds of death on vasoactive drug relative to control at the centred covariate value, 0 the estimate is the multiplicative increase in the odds of mortality for 
each 1 unit increase in the covariate, for those receiving a vasoactive drug or for those receiving control, the covariates are SBPO baseline systolic SP, 
ASBP% early change in systolic BP, t 95% credibility intervals 
Table 5.8 Death the end of trial using individual patient data adjusted for patient level covariates 
5.14 Discussion of findings 
The discussion of the findings from this systematic review are 
presented in six sections which relate to a summary of the overall 
findings, limitations of the data used in the review, comparison of the 
statistical methods, discussion of the results, practical implications of 
the results and suggestions for future research. 
5.14.1 Summary of overall findings 
The management of blood pressure during the acute phase of stroke 
remains an enigma and will continue to be widely debated. In the 
absence of completed large and definitive randomised controlled 
trials assessing this question, we have performed a systematic review 
of existing randomised controlled trials. 
Thirty-six randomised controlled trials of vasoactive drugs in acute 
stroke where blood pressure assessments had been made were 
identified from a comprehensive search strategy which was 
performed up to March 2003. Individual patient data were available 
from 24 of these trials; data from the other 12 trials had been 
previously discarded or we were unable to contact the authors of the 
trial. However. tabulated data from these 12 trials were extracted from 
the publications and merged with the individual patient data from the 
other trials. 
The data base comprised of data from 8,058 stroke patients, and the 
patients from these trials were randomised to either a vasoactive drug 
or control/placebo. Baseline characteristics of the patients appeared 
to be well balanced between the treatment groups from the individual 
trials. 
At the end of trial, patients randomised to a vasoactive drug had 
slightly higher risk of death and death or dependency as compared to 
patients randomised to control/placebo; however these effects were 
not statistically significant at the 5% level. 
5.14.2 
5.14.2.1 
Limitations of the data used 
Number of studies included in the meta-analysis 
The search strategy used in this systematic review identified thirty-six 
randomised controlled trials of a vasoactive drug given to stroke 
patients in the acute phase of stroke where blood pressure 
measurements had been assessed. Outcome data for these trials 
were available from all of the trials either through sharing individual 
patient data or extracted from publications. However, systolic blood 
pressure measurements at baseline were available from only 34 of 
the 36 trials; the data from the other two trials could not be extracted 
from the publications and the authors from the original articles could 
not be contacted. 
We decided to assess the impact of vasoactive drugs which were had 
potential blood pressure lowering effects; therefore, studies which 
involved drugs which increase blood pressure, such as diaspirin 
cross-linked haemoglobin (DCLHb), where excluded. This was 
because they are thought to increase the risk of death and death or 
dependency in acute stroke patients (Saxena et al. 1997; Saxena et 
al. 1999; The Blood pressure in Acute Stroke Collaboration (BASC) 
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2001 (a» due to them actively increasing systolic blood pressure, 
which increases the risk of recurrence, possibly cerebral oedema 
(Leonardi-Bee et al. 2002) or haemorrhage to the infarct (Rordorf et 
a/. 1997). 
5.14.2.2 Timings of the outcomes 
It was decided a priori to use the end of trial as the primary outcome 
assessment time. This was to allow for a consistent end point to be 
used across the trials and thought preferable to using an arbitrary end 
point, such as 12 weeks, since there was a lack of data at a 
consistent time point across the trials. 
5.14.2.3 Extent of the shared individual patient data 
Although the original trials collected considerable amounts of data on 
prognostic factors and outcome during the baseline and at the end of 
trial, the data shared with the collaboration were not consistent across 
the trials. All of the trials had data for death at the end of trial and time 
from stroke onset to recruitment, therefore the unadjusted analyses 
and the analyses adjusted for time from stroke onset to recruitment 
should have yielded results which have minimal bias. However, bias 
could be present in the results involving BP measurements. Although 
baseline systolic BP was not available from two of the trials, the data 
from these trials only comprised of 3% of the total data, hence would 
probably have little effect on the overall results. Conversely, early 
change in blood pressure could only be calculated for 24 of the trials, 
therefore this could have had a major impact on the results when 
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assessing the relationship between early change in BP and death at 
the end of trial. 
Finally, we were unable to adjust for other potential prognostic 
factors, such as diabetes or atrial fibrillation (see section 4.4); since 
these data were not available for most of the identified studies. 
Hence, some sources of heterogeneity will have not been explored in 
the analyses. 
5.14.2.4 Outcome assessments 
The primary and secondary outcome assessments used in this 
systematic review were selected a priori before the first two initial 
phases of the review were implemented following discussions with 
the collaborators of the Blood pressure in Acute Stroke Collaboration 
(BAS C). 
A trial was deemed eligible for inclusion into the systematic review if it 
recruited stroke patients within 2 weeks of stroke onset. This criterion 
was used to ensure that the vasoactive treatments would be given in 
the acute phase of stroke. Death at the end of trial was chosen as the 
primary outcome measure because it was the primary end point for 
the majority of the trials and thought to be the best measure of 
efficacy for an acute stroke treatment. Death or dependency at the 
end of trial was included in this review as the secondary outcome 
measure. This was to allow for a more detailed analysis of functional 
ability on the patients which had survived till the end of trial. However, 
due to the lack of data for this outcome where data were available 
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from only 21 of the 36 trials; further in-depth analyses could not be 
performed. Also, data on early death (within 30 days of treatment), 
intermediate events, such as recurrence, or time to an event, could 
not be assessed in this review due to a lack of data from the trials. 
5.14.2.5 Publication bias 
Systematic reviews are susceptible to several biases, including 
publication bias. In this review evidence of publication bias was found 
from using Egger's Asymmetry test (Egger et al. 1997). From Egger's 
Asymmetry plot, there appeared to be some evidence of a lack of 
smaller trials which found detrimental effects, however; it was not 
apparent from either 8egg and Mazumdar's rank correlation test 
(8egg et al. 1994) or the non-parametric trim and fill method (Duval et 
al.2000). 
Publication bias relating to an absence of the smaller trials which 
showed a detrimental effect through not being published is a common 
finding. This is because the earlier trials are more likely to be smaller 
in size, hence more likely to be published if they showed a beneficial 
effect. Also it is acknowledged that subsequent larger trials are more 
likely to have been conducted if the earlier smaller trials showed 
beneficial effects. Although there may be a lack of these smaller 
trials, the overall pooled estimate for the treatment effect from the 36 
trials showed a trend towards an increase in the risk of death and 
hence the absent smaller trials would endorse the overall results and 
possibly make the detrimental effect statistically significant at the 5% 
level. 
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Evidence of publication bias may be related to other reasons, such as 
poor methodological quality of the included trials (Petticrew et 81. 
1999; Sutton et 81. 2000). Further analysis from using a sensitivity 
analysis indicated that excluding trials with poor methodological 
quality appeared to reduce some of the publication bias, however 
some publication bias remained which still indicated a lack of small 
studies which found detrimental effects associated with using a 
vasoactive drug in acute stroke patients (Egger's test for Asymmetry 
p =0.04). Additionally, excluding these poor methodological trials 
resulted in a borderline significant increase in the risk of death at the 
end of trial in patients randomised to a vasoactive treatment as 
compare to those randomised to control (OR 1.11, 95% CI 0.99, 1.26; 
31 trials). 
5.14.3 
5.14.3.1 
Comparison of the statistical methods 
Assessments of heterogeneity 
The assessment of heterogeneity on the results was initially 
investigated using a forest plot, which revealed that there appeared to 
be little heterogeneity between the trials. Statistical assessments of 
heterogeneity were performed based on summary data methods, 
which consistently found no heterogeneity between the results, from 
using Cochran'S homogeneity test and /2. No evidence of 
heterogeneity was seen from using an individual patient data model 
by including a fixed effect interaction term between the trial and 
treatment. This systematic review contained data from 36 trials and 
hence all of these methods should have had sufficient power, hence it 
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appears that the differences between the trials may be due to 
sampling variation alone. 
This was a surprising finding due to the assortment of drug classes 
that were included in the review which are known to have varying 
mechanisms for action in lowering blood pressure. Therefore, it was 
interesting to find that biological heterogeneity does not preclude 
statistical heterogeneity in this meta-analysis (Glasziou et al. 2002). 
5.14.3.2 Impact of quantifying heterogeneity 
A range of estimation methods were used in a series of random effect 
models based on summary data to assess whether there were any 
differences between the results from the models. All of the classical 
and EB models estimated no heterogeneity between the trials. The 
FB model estimated a small amount of heterogeneity however the 
magnitude had little impact on the results of the treatment effect. 
hence all of the models performed adequately in this meta-analysis. 
Fixed and random effect IPD models were then used to assess the 
impact of vasoactive drugs on death at the end of trial. In a fixed 
effect model, patients randomised to a vasoactive drug had a 10% 
non-significant increase in the risk of death as compared to patients 
which received control/placebo. Due to the random effect models 
estimating very small quantities of heterogeneity the results from 
these models were very similar as to the fixed effect model. 
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5.14.3.3 Impact of exploring heterogeneity 
Various estimations models were used in a series of meta-regression 
models to assess whether there were any treatment effect modifiers, 
and whether there were any differences between the results from the 
estimation methods. 
All of the methods yielded similar results for the treatment and 
covariate effects for each covariate separately. A significant effect 
was seen which implied that baseline systolic BP had an effect on the 
treatment effect, where there was a 4% increase in the estimated 
odds ratio per 10 mm Hg increase in baseline systolic BP. No 
significant effects were seen on treatment for early change in systolic 
BP or the difference in baseline systolic BP between the groups. The 
clinical implications for the effect of baseline systolic BP on the 
treatment effect estimate will be discussed in section 5.14.4.2. 
From the adjusted IPO models, although no evidence of effect 
modifiers were seen for baseline systolic BP or early change in 
systolic BP; there appeared to be some evidence of an effect with the 
time to recruitment from stroke onset. This finding appeared to be 
contrary to the results from the subgroup analysis using summary 
data methodologies. Therefore, subsequent analyses of time to 
recruitment were split into two groups for the IPO analyses; ~ 4 8 8 hours 
and >48 hours. In patients randomised within 48 hours of stroke 
onset, patients appeared to be at a lower risk of death at the end of 
trial for each additional hour from their stroke onset. The clinical 
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implications for the effect of time to recruitment will be discussed in 
section 5.14.4.3. 
Additionally, although baseline systolic blood pressure did not appear 
to be an effect modifier, it appeared to be related to death at the end 
of trial; where a 4% increase in the risk of death was seen per 10 mm 
Hg increase in systolic BP irrespective of intervention assignment. 
Also, in this model patients randomised to a vasoactive drug were 
significantly at a 14% higher risk of death at the end of trial as 
compared to patients randomised to control/placebo. 
5.14.4 Discussion of the results 
This systematic review provides substantial evidence for the 
management of acute stroke with regards to the efficacy of 
vasoactive drugs given to stroke patients in the acute phase of stroke. 
The aim of this review was to estimate the extent that vasoactive 
drugs impact on death at the end of trial and to assess its relationship 
with systolic BP. 
5.14.4.1 Impact of vasoactive drug on death, and death or 
dependency 
The principal finding from this systematic review was that vasoactive 
drugs given in the acute phase of stroke was non-significantly 
associated with a 10% increase in the risk of death and 11 % increase 
in the risk of death or dependency at the end of trial. When the 
models were adjusted for baseline systolic blood pressure, treatment 
with a vasoactive drug was found to be significantly associated with a 
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14% increase in the risk of death at the end of trial. This suggests that 
patients may be at a higher risk of a poor outcome if they are treated 
in lowering blood pressure acutely after stroke onset. 
Cerebral autoregulation is a concept that implies that cerebral blood 
flow is maintained a constant levels even when there are changes in 
systemic perfusion, such as those caused by a stroke (Feldmann et 
al. 1999). Autoregulation also ensures that there is a constant supply 
of oxygen, glucose, and other essential nutrients and that capillary 
pressure is kept at an optimal level (Feldmann et al. 1999). However, 
cerebral autoregulation is lost during stroke and therefore lowering 
blood pressure in hypertensive patients could reduce vital penumbral 
blood flow, thus leading to poor outcome from neurological 
deterioration secondary to reduced cerebral perfusion (Rashid 2003). 
The British Hypertension Society recommends that antihypertensive 
treatment should be initiated in people with sustained systolic blood 
pressure ~ ~ 160 mm Hg (Williams et al. 2004); which was also the 
mean systolic blood pressure of the patients included in this review. 
However, the results from this review would suggest that these 
patients may be at a higher risk of mortality and morbidity if blood 
pressure lowering treatments are initiated too acutely after stroke 
onset. 
Two other systematic reviews have assessed the effect of lowering 
blood pressure and outcome. The first systematic review of 
randomised controlled trials assessed the impact of blood pressure 
lowering or treatment of hypertension in patients with non-acute 
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stroke (>14 days post-ictus). We found that lowering blood pressure 
was associated with significant reductions in stroke, non-fatal stroke, 
myocardial infarction and total vascular events; whilst overall mortality 
was not altered (Rashid et al. 2003). 
The second systematic review of published reviews found that 
antihypertensive treatments showed efficacy in reducing the risk of 
morbidity and mortality from first ever stroke (Lawes et al. 2004). 
Bearing in mind the results from this review, the findings from these 
reviews can't be extrapolated to assume that similar benefits would 
be seen in acute stroke patients and therefore it is suggested that 
long term benefit of secondary stroke prevention by treating 
hypertension acutely may be inappropriate and detrimental to 
mortality and morbidity. 
There appeared to be little variation in the risk of a poor outcome 
between the trials included in this review, and the findings from this 
review compare well to those of previous meta-analyses using 
aggregate data (The Blood pressure in Acute Stroke Collaboration 
(BASC) 2001 (a); Blood pressure in Acute Stroke Collaboration 
(BASe) 2001 (b». 
5.14.4.2 Impact of baseline systolic blood pressure 
From the meta-regression analyses based on summary data, 
increasing baseline systolic blood pressure was significantly related 
to an increase in the relative odds ratio for the treatment effect. This 
effect appears to be contrary to popular belief that a patient with a 
163 
higher blood pressure receiving a vasoactive drug will have a higher 
risk of a poor outcome; and does not appear to be replicated in the 
individual patient data analyses since no interaction between systolic 
blood pressure and treatment was seen. 
However, potential explanations for the finding from the meta-
regression analysis exist; the result may be related to the fact that 
high blood pressure is associated with an increased risk of fatal 
cerebral oedema and recurrent stroke (Leonardi-Bee et al. 2002) and 
so the effect seen is really a reflection of these intermediate effects; 
however these effects could not be assessed in this review because 
few trials recorded them. 
Alternatively, previous research has indicated that there is the 
possibility with meta-regression analyses of finding false-positive 
results which are not replicated from analyses based on individual 
patient data (Sutton et al. 1998; Lambert et al. 2002; Higgins et al. 
2004). Sutton and colleagues suggest that meta-regression analyses 
should only be treated as exploratory since there are distinct 
disadvantages (Sutton et a/. 1998). These are due to the potential for 
an association to be found between the summary level covariate and 
treatment effect purely by chance or due to other confounding factors 
or due to aggregation bias (Greenland 1987), where the relationship 
between the covariate means for the summary data and the treatment 
effect do not directly reflect the relationships within an individual 
(Sutton et al. 1998). 
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This review also highlighted that baseline systolic blood pressure was 
an important predictor of outcome when an individual patient data 
model was considered; where a 4% increase in the risk of death was 
seen for every 10mm Hg increase in systolic blood pressure 
irrespective of treatment assignment. 
High blood pressure is commonly seen in patients presenting with a 
stroke (Wallace et al. 1981; Britton et al. 1986; Leonardi-Bee et al. 
2002) and is thought to be the direct result of the cerebrovascular 
events itself, either relating to a severe neuroendocrine stress 
response or due to hypoperfusion of the brain tissue (Carlberg et al. 
1991). However, is has also been postulated that the increase in 
blood pressure may be due a transient phenomenon due to acute 
mental stress associated with being admitted to hospital or accident 
and emergency (Carlberg et al. 1991). Raised blood pressures 
usually fall spontaneously within a few days (Wallace et al. 1981; 
Mortis et al. 1997); and within 10 days post stroke two thirds of 
patients will be normotensive (Carlberg et al. 1991). 
The relationship and magnitude of this effect has also been found in a 
large randomised controlled trial involving 17,398 acute stroke 
patients (Leonardi-Bee et al. 2002). This large trial was able to look at 
the relationships between blood pressure and intermediate events, 
and found that recurrent ischaemic stroke within 14 days post ictus 
and presumed cerebral oedema were independently associated with 
high systolic blood pressure. Therefore, one could extrapolate these 
findings from this randomised controlled trial to our review and 
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suggest that the relationship between high systolic blood pressure 
and mortality may be due to an increase in intermediate events such 
as recurrence or cerebral oedema. 
Increased blood pressure at baseline does not appear to be subject 
to a previous hypertension, since only a third of patients presenting 
with stroke have a history of hypertension (Oppenheimer et al. 1992), 
and other studies have found no relationship between previous 
hypertension and either early death, or death and dependency 
(O'Connell et al. 1994). 
5.14.4.3 Impact of time from stroke onset to recruitment 
Patients randomised to a vasoactive drug early and within 48 hours 
post-ictus were more likely to have a poor outcome. This finding is 
probably confounded by severity, where more severe patients are 
admitted to hospital earlier and hence recruited into a trial earlier. 
Data on prognostic factors such as severity were not available from 
enough trials to allow this issue to be further examined. Similarly, the 
effect of timing may have been confounded by drug class since 
patients in calcium channel blocker trials were always treated early. 
This finding was seen only in the individual patient data and not 
present in the summary data model where it was assessed as a 
dichotomous cut at 48 hours. Therefore, it appears that the individual 
patient data model may have been more sensitive in assessing the 
relationship between time to recruitment and outcome since the 
actual time of the event was used where individual patient data 
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allowed and the analyses did not solely rely on the time limit for 
recruitment for an individual trial. 
5.14.4.4 Generalisability of the findings 
Research spanning several decades has been performed to help 
identify factors which influence outcomes, and reach conclusions 
about the optimal management of acute stroke patients. Blood 
pressure management in the acute phase of stroke is one of the 
areas where there has been a lot of interest and research. 
This systematic review and meta-analysis conducted an extensive 
search strategy to identify all eligible randomised controlled trials 
which have monitored blood pressure levels and assessed the 
efficacy of vasoactive drugs. Although it is likely that all of the 
available data has been identified, one of the assessments for 
publication bias indicated asymmetry where small trials which showed 
a detrimental effect of vasoactive drugs were under-represented in 
this review. The inclusion of such trials would have not significantly 
altered the overall finding that vasoactive drug given in the acute 
phase of stroke worsened outcome at the end of trial, but instead 
endorse these results. There are currently five ongoing randomised 
controlled trials that need to be included in any future analyses. 
However, the results from this review should be generalisable since 
they form a collective body of evidence from thirty-six randomised 
controlled trials involving blood pressure monitoring and assessing 
vasoactive drugs in stroke patients. 
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The findings from this meta-analysis provide a balanced interpretation 
of the available evidence and support the results from earlier studies 
that high systolic blood pressure at baseline is associated with a poor 
outcome after stroke (Dandapani et al. 1995; Robinson et al. 1997; 
Leonardi-Bee et al. 2002). However, our research provides more 
information about the relationship between a variety of vasoactive 
drugs and outcome and shows the first results between patient 
characteristics and outcomes. 
5.14.5 Practical implications 
This review has demonstrated that vasoactive drugs given to patients 
in the acute phase of stroke can be detrimental to their outcome, 
especially when baseline systolic blood pressure . is taken into 
consideration. Therefore this review suggests that caution is used 
when administering blood pressure lowering agents to acute stroke 
patients. 
Actively lowering blood pressure too acutely after stroke onset may 
be harmful in ischaemic stroke patients because they may decrease 
blood perfusion in the ischaemic border zone (Wood 1984). However, 
there is evidence that there is an increased risk of brain oedema if an 
elevated blood pressure is not treated (Wallace et al. 1981). 
Therefore, it is important to identify those patients which require 
urgent treatment of their hypertension and it has been recommended 
that stroke patients should only be treated with vasoactive drugs 
when very high blood pressures are seen acutely (systolic blood 
pressure >200 mm Hg) (Lavin 1986) or where the raised blood 
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pressure (S8P ~ 1 6 0 0 mm Hg) is persistent over the two week since 
stroke onset (Williams et al. 2004). 
In depth analyses were performed in this review which highlighted 
that certain subgroups of patients may be at the greatest risk of a 
poor outcome from receiving a vasoactive drug. Analyses indicated 
that increased risks in mortality were associated with increasing 
systolic blood pressure at baseline, and a shorter time from stroke 
onset within 48 hours post ictus. Surprisingly, the early change in 
systolic blood pressure did not appear to mediate the treatment effect 
or outcome at the end of trial. However, these factors were identified 
through post hoc analyses and the findings need to be validated from 
other data of a randomised controlled trial to truly assess whether 
these patients are at increased risks of mortality. 
Also, since baseline blood pressure appears to be influential on the 
efficacy of the vasoactive drug, this highlights the importance of using 
adequate randomisation techniques such as minimisation or 
stratification on baseline S8P to ensure that the estimates from the 
trial are not overly influenced by mismatching of baseline blood 
pressure. Many of the trials within this review had a mismatch of 
baseline blood pressure between the treatment groups. 
5.14.6 Future research 
In spite of the negative finding of this study, namely that active 
lowering of BP appears to be associated with a worse outcome, data 
from large and definitive trials of lowering BP are underway (Bath 
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2001; Lees et al. 2001; COSSACS 2003; Robinson et al. 2003; 
Willmot et al. Unpublished). 
It is unclear whether the relationship between systolic blood pressure 
and death at the end of trial identified from this review, is a causal 
association; and it must be remembered that the results from this 
review relating to blood pressure measurements could be biased and 
imprecise since most trials were not intending to alter blood pressure 
so its measurement was often poor and incomplete. This is because 
most of the studies included in this review were not aiming to alter BP 
and assess its effect on outcome, and therefore were probably under-
powered, and not able to adequately assess important issues such as 
timing and dosing of treatment, efficacy in different types of stroke 
(ischaemic, haemorrhagic, cortical, lacunar), continuation of previous 
antihypertensive drugs, and baseline blood pressure. Future trials will 
need to study these issues as well as effects on cerebral perfusion, 
recurrence and cerebral oedema. Most of the existing studies in this 
review have data from drug classes which are now known to have no 
beneficial effects in acute stroke, such as calcium channel blockers 
(Horn et al. 2001), and naftidrofuryl (Stenier et al. 1996). In contrast, 
little data exist for other drug classes where a stronger rationale 
exists for their potential efficacy, such as nitrates (Willmot et al. 2003) 
and angiotensin receptor antagonists. 
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CHAPTER 6 
COMMUNITY OCCUPATIONAL THERAPY FOR 
STROKE PATIENTS: A SYSTEMATIC REVIEW 
AND META-ANALYSIS OF RANDOMISED 
CONTROLLED TRIALS 
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6.1 Introduction 
Rehabilitation is defined by the WHO (Aho et al. 1980) as 'the 
combined and co-ordinated use of medical, social, educational and 
vocational measures for training or retaining the individual to the 
highest level of functional ability'. Occupational therapy is an essential 
component of the rehabilitation package, and offers a wide range of 
interventions designed to promote recovery through purposeful 
activity by focusing on disability (Walker et al. 1999). Occupational 
therapists encourage patients to practise all forms of activities of daily 
living (ADL) such as dressing and feeding. However, occupational 
therapists also promote independence in extended activities of daily 
living (EADL), such as household management and leisure pursuits. 
After a stroke, patients often lose the abilities to perform ADL and 
EADL tasks. Occupational therapists are one of the multidisciplinary 
team which may provide practice to regain these abilities in the 
hospital and community after discharge from hospital. However, at 
present it is unclear whether community based rehabilitation services 
such as those offered by occupational therapists are beneficial to the 
patient. There is an increase in emphasis for these services to 
enhance early discharge from hospital therefore it has become more 
important for these community based services to grow. Therefore, an 
evaluation of these community based services is of fundamental 
importance to the delivery of efficient evidence based stroke care. 
Several clinical trials have been performed to assess the efficacy of 
occupational therapy in stroke patients after discharge from hospital. 
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A meta-analysis of occupational therapy using data from the literature 
has already been published (Steuljens et al. 2003). This large review 
which aimed to determine whether occupational therapy interventions 
improve outcome of stroke patients, identified a small but significant 
effect size for the efficacy of comprehensive occupational therapy on 
self-care, EADL, and social participation. However, trials of 
occupational therapy have disparate findings with regards to whether 
occupational therapy was effective in increasing ADL and EADL 
abilities. The variation in findings may be due to the type and intensity 
of intervention. Internal trial factors relating to the design and 
protocol, such as length of follow up; or patient's factors, such as age, 
may have an influence on the effect of intervention by making a 
patient more or less receptive to the therapy. Therefore it is important 
for the review to take into account these factors. 
6.2 Design of study 
A systematic review based on a meta-analysis of individual patient 
data from randomised controlled trials of community occupational 
therapy in stroke patients discharged from hospital. 
6.2.1 Measures of interest 
The primary outcome measure is the EADL scale at the end of 
intervention. This was chosen because EADL are the aim focus of 
community intervention. It is thought that self care ADL will have been 
attended to during the patients hospital stay in the first few weeks 
after stroke. Other secondary outcome measures included the leisure 
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questionnaire, general health questionnaire, activities of daily living, 
both at the end of intervention and end of trial; and the extended 
activities of daily living scale, and death, at the end of trial. 
6.3 Study selection and search strategy 
For a trial to be included in the meta-analysis it had to fulfil the 
requirements of randomisation, at least single blinding, and either 
have follow-up assessments completed using a postal questionnaire, 
or using a blinded independent assessor. The intervention had to be 
based in the community and not in hospital. 
A comprehensive search strategy was performed using search 
engines using the keywords 'occupational therapy', 'stroke', 
community rehabilitation', rehabilitation', 'activities of daily living', and 
'leisure therapy'. These databases included the Cochrane Library 
(Issue 4. 2003). MEDLINE (1966-Nov 2003). EMBASE (1980-Nov 
2003), CINAHL (1982-Nov 2003), PsyclNFO (1967-Nov 2003), AMED 
(1985-Nov 2003). Wilson Social Sciences Abstracts (1984-Nov 2003). 
Science Citation Index and Social Sciences Citation Index (1981-Nov 
2003). The Cochrane Stroke Group Trials Register (last searched 
November 2003) was also searched. Reference lists were searched 
from publications and thorough contact with other known researchers. 
Abstracts from national and international occupational therapy 
conferences were also hand searched. No restrictions on language 
were made. The library at the College of Occupational Therapy was 
also searched for relevant theses and dissertations. 
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Nine trials were identified which fulfilled the inclusion criteria (Turton 
et al. 1990; Jongbloed et al. 1991; Corr et al. 1995; Drummond et al. 
1995; Walker et a/. 1996; Logan et al. 1997; Walker et al. 1999; 
Gilbertson et al. 2000; Parker et al. 2001) (Figure 6.1). Disparate 
findings were seen between the published trial results, where even 
though all of the trials have shown beneficial effects of community 
occupational therapy, only half of the trials found results which 
reached statistical significance at the 5% level. The largest trial to 
date (TOTAL) found that occupational therapy provided little benefit in 
stroke patients (Table 6.1). 
Trial, year of Number Primary outcome Result of 
publication of scale primary 
patients outcome 
Turton,1990 22 Peg test Positive 
Walker, 1996 30 NSDA Positive 
Jongbloed, 1991 40 KAI Neutral 
Drummond,1996 65 NLQ Positive 
Carr, 1995 110 Barthel, NEADL Neutral 
Logan, 1997 111 NEADL Positive 
Gilbertson, 1999 138 NEADL Neutral 
Walker, 1999 185 NEADL Positive 
TOTAL,2001 466 GHQ, NEADL, NLQ Neutral 
Ordered by size of trial (ascending). KAI IS the Katz Adjustment Index, NLQ is the 
Nottingham Leisure Questionnaire, NSDA is the Nottingham Stroke Dressing 
Assessment, GHQ is the General Health Questionnaire, and NEADL is the 
Nottingham Extended Activities of Daily Living 
Table 6.1 Published results for the effect of community occupational 
therapy on stroke patients 
175 
Therapy basedintelVention 
in stroke patients 
n=27 
Excruded r-
n=10 
Clinical trial (ReT) 
n=17 
Excluded 
-n=6 
Occupational therapy specific 
n=11 
Ongoing/planned 
,-
n=2 
Completed 
n=9 
Data unavailable·· 
r-
n=1 
Data available 
n=8 
Figure 6.1 Flow chart for trial identification and selection 
These disparate findings need to be statistically combined to identify 
firstly, whether community occupational therapy improves functioning, 
and if so which components of occupational therapy are beneficial, 
and in which patients they provide the most benefit. 
6.4 Data collection and management 
The trialists were contacted and asked if they would share their data 
with the collaboration. Data received from the tria lists were either sent 
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via email or were collected by the collaboration in the form of 
questionnaires. All of the trialists contacted were willing to share the 
data; however, one data set had been discarded a few years 
previously (Turton et a/. 1990). 
The data from the questionnaires were entered into SAS version 8.02 
(SAS Institute Inc) and double-checked to ensure minimal errors. 
Data from computer disks or emails were formatted into a SAS 8.02 
format. The analyses used in the publications were repeated to 
ensure consistency of results. Where inconsistencies were found the 
trialists were contacted and the issues were resolved. The 
discrepancies were mostly attributed to the typographical errors in the 
publications. 
Before the data were merged into a single data set, re-coding of 
variables, including outcome measures, was performed to achieve 
consistency across trials. In the case of the Nottingham Extended 
Activities of Daily Living (EADL) scale, the assessment may be based 
on the 66-point version where a scoring of (0,1,2,3) is used or on the 
22-point version where a scoring of (0,0,1,1) is used. Since the 
(0,1,2,3) scale can be converted easily into the (0,0,1,1) scale, this 
latter format was used across all trials. 
Similarly, with the General Health Questionnaire the scoring may be 
performed in a similar manner. A common scoring of (0,0,1,1) was 
used across the trials for comparability. However, another 
complication of this questionnaire is that various versions exist. Two 
versions of the general health questionnaire were identified in this 
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meta-analysis; the 12-point scale and the 28-point scale. A priori cut 
offs were used to make these two scales comparable. For the 12-
point scale a cut of >2 indicates a case, which is comparable to a cut 
off of >4 on the 28-point scale (Wade 1992). 
For the Nottingham Leisure Questionnaire, a 3-point (0,1,2) or a 5-
point (0,1,2,3,4) scoring method may be used. The five-point scoring 
method was collapsed to the three-point scoring method by 
combining the 0 and 1 scores, and the scores 3 and 4. 
The self care section of the Rivermead Activities of Daily Living scale 
was used in two of the trials to assess functional performance 
(Drummond et al. 1995; Walker et al. 1996). The Barthel Index was 
used to assess functional performance in the majority of the other 
trials and therefore a comparable functional performance measure 
needed to be specified to ensure that these two measures 
represented similar scores. An a priori cut off of ~ 1 1 0 was used for the 
Rivermead scale which has been shown empirically to be comparable 
to the a priori cut off of ::;;16 for the Barthel Index (::;;80 on the 100 
point-scale indicates dependency). 
6.5 Assessment of publication bias and quality 
Begg's funnel plot was used to assess visually if there was evidence 
of publication bias within the meta-analysis. The plot was symmetrical 
in appearance and the point estimates were all located within the 
pseudo 95% confidence interval lines; hence the test concluded there 
was no substantial evidence of publication bias (Figure 6.2). 
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However, due to the subjective nature of interpreting this figure, 
formal tests for publication bias were also performed. 
The 8egg and Mazumdar rank correlation test (p=0.624), Egger's 
asymmetry test (p=O.728) and the trim and fill method did not find 
evidence of publication bias. 
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Figure 6.2 Begg's funnel plot for EADL at the end of the intervention 
phase 
Seven of the eight trials with individual patient data were deemed to 
be of high methodological quality, with evidence of blinded 
randomisation procedures, concealment of allocation, and masked 
outcome assessments (Table 6.2) (The Cochrane Collaboration 
2003). The trialists involved in the Jonglboed trial were asked to 
provide more information about the design of the trial; unfortunately 
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they could not clarify the method of randomisation used in the trial. 
The ninth trial which had discarded the raw data, also had a lower 
level of quality due to the randomisation process being based on date 
of birth of the patients, and doubts over whether the outcome 
assessor was blinded (Table 6.2). 
Trial, year of Type of Blinding Method of Blinded outcome 
publication study randomisation assessment! 
assessor 
Turton, 1990 RCT B Quasi, block Unclear 
randomisation 
Jongbloed, RCT B Unclear Yes 
1991 
Carr, 1995 RCT A Opaque, sealed Yes 
envelopes 
Drummond, ReT A Numbered opaque, Yes 
1995 sealed envelopes 
Walker, 1996 Cross- A Numbered opaque, Yes 
over sealed envelopes 
Logan. 1997 RCT A Numbered opaque, Yes 
sealed envelopes 
Walker. 1999 RCT A Numbered opaque, Yes 
sealed envelopes 
Gilbertson, RCT A Numbered opaque, Yes 
2000 sealed envelopes 
Parker, 2001 RCT A Central Yes 
randomisation by 
telephone 
A= Low risk of bias, B= Moderate risk of bias, C- High risk of bias 
Table 6.2 Assessment of quality for the nine identified trials 
6.6 Trial level demographics 
Trials were assessed to determine whether patients were similar 
~ e t w e e n n the trials (Table 6.3). High percentages of dependent stroke 
patients were found in the Drummond and Walker trials (95.4% and 
73.3%, respectively). Both of these trials utilised the Rivermead self 
care section scale as the assessment of dependency. The average 
ages were relatively similar across the trials. The sex of the patients 
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in each trial were mostly balanced except for slight imbalances in two 
of the trials (Jongbloed et al. 1991; Corr et al. 1995). 
Trial, year of Number of Gender, Dependent Age, mean 
publication patients male (%) patients (%) (SD) 
Jongbloed, 1991 40 27 (71.1) 5 (13.5) 68.8 (10.6) 
Corr, 1995 110 41 (37.3) 51 (52.6) 75.5 (9.0) 
Drummond, 1995 65 37 (56.9) 62 (95.4) 66.0 (11.2) 
Walker, 1996 30 16 (53.3) 22 (73.3) 68.1 (9.4) 
Logan, 1997 111 56 (50.5) - 72.4 (11.0) 
Walker, 1999 185 94 (50.8) 51 (27.6) 68.1 (9.4) 
Gilbertson, 2000 138 62 (44.9) 36 (26.1) 69.0 (12.0) 
TOTAL,2001 466 269 (57.7) 105 (22.6) 71.0 (10.3) 
Table 6.3 Patient demographics at baseline by tnal 
6.7 Outcome assessments 
The Extended Activities of Daily Living (EADL) scale was used at the 
end of intervention in five of the eight trials (Drummond et al. 1995; 
Logan et a/. 1997; Walker et al. 1999; Gilbertson et al. 2000; Parker 
et al. 2001). In addition to the above trials, the trial by Corr and Bayer 
(Corr et al. 1995) used the assessment at the end of trial. 
The Nottingham Leisure Questionnaire was used in four trials 
(Drummond et al. 1995; Walker et al. 1999; Gilbertson et al. 2000; 
Parker et al. 2001) however, one of the trials only used the 
assessment at the end of the intervention phase (Walker et al. 1999) 
and another trial only used it at the end of the trial phase (Gilbertson 
et a/. 2000). 
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End of intervention and end of trial dependency scores were 
assessed using either the Barthel Index (Carr et al. 1995; Logan et al. 
1997; Walker et al. 1999; Gilbertson et al. 2000; Parker et a/. 2001) or 
the Rivermead self care section scale (Walker et al. 1996). The trial 
by Jongbloed and colleagues did not assess dependency at either 
follow-up time (Jongb/oed et al. 1991). 
Data from the General Health Questionnaire was available for 
patients from three trials (Logan et al. 1997; Walker et al. 1999; 
Parker et al. 2001) and for carers from two trials (Walker et al. 1999; 
P ~ r k e r r et a/. 2001). All of the trials had data on death at the end of 
trial. 
6.7.1 Mode of assessments 
Outcome assessments were either postal or completed with the aid of 
an assessor which visited the patients in their home. Three trials used 
a postal end of treatment follow-up procedure and the other trials 
used an assessor. At the end of the trial assessments, four used a 
postal follow-up questionnaire and the remaining four used an 
assessor (Table 6.4). The trial by Gilbertson and colleagues used an 
independent assessor at the end of intervention and a postal 
questionnaire at the end of trial. 
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Trial. year of Method of follow-up Method of follow-up 
publication End of intervention End of trial 
Jongbloed. 1991 Independent assessor Independent assessor 
Carr. 1995 Postal questionnaire Postal questionnaire 
Drummond. 1995 Independent assessor Independent assessor 
Walker. 1996 Independent assessor Independent assessor 
Logan. 1997 Postal questionnaire Postal questionnaire 
Walker. 1999 Independent assessor Independent assessor 
Gilbertson. 2000 Independent assessor Postal questionnaire 
TOTAL. 2001 Postal questionnaire Postal questionnaire 
Table 6.4 
trial 
Method of follow-up used at the end of intervention and end of 
6.7.2 Type of intervention 
As mentioned earlier in the introduction. occupational therapy is a 
package of treatment which can be aimed at promoting independence 
through leisure pursuits and activity. or through activities of daily 
living. One trial solely used therapy aimed leisure pursuits (Jongbloed 
et a/. 1991). 4 trials used therapies aimed at activities of daily living. 
one trial assess the usefulness of a component of activities of daily 
living; dressing practice. and the remaining two trials assessed 
activities of daily living and leisure therapy in a parallel design (Table 
6.5). 
6.7.3 Timing of assessments 
All of the trials used different end of intervention and end of trial 
assessment times. Therefore it was decided that the first assessment 
after the final session of the intervention would be known as the 'end 
183 
of intervention' phase. The last follow-up assessment would be 
known as the 'end of trial' phase. 
The end of intervention assessment ranged in times from as short as 
5 weeks (Jongbloed et al. 1991; Gilbertson et al. 2000) to 6 months 
(Walker et al. 1999; Parker et al. 2001), with the most frequently used 
follow-up period was 3 months (Table 6.5). The end of trial 
assessments ranged from 18 weeks (Jongbloed et al. 1991) to one 
year (Corr et al. 1995; Walker et al. 1999; Parker et al. 2001; Walker 
et al. 2001), with the most commonly used time point of six months. 
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Trial, year of Number of Intervention Intervention length End of intervention End of trial 
publication patients assessment (months) assessment (months) 
Jongbloed, 1991 40 Leisure 5 sessions 1.25 4.5 
Corr, 1995 110 ADL Up to 6 months 12 
Drummond, 1995 65 ADL or Leisure Min 10 sessions 3 6 
Walker, 1996 30 ADL 12 weeks 3 6 
Logan, 1997 111 ADL 6 weeks 3 6 ! 
Walker, 1999 185 ADL Up to 5 months 6 12 
Gilbertson, 2000 138 ADL 6 weeks 2 6 
TOTAL, 2001 466 ADL or Leisure Min 10 sessions 6 12 
Table 6.5 Timings for intervention and assessments by trial 
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6.8 Analysis of the merged data set using summary 
data methods 
The data from the eight individual trials were merged into a single data 
set. Data from the ninth trial were not available for inclusion. The 
combined data set contained patient information on 1,143 stroke 
patients. Table 6.6 shows the demographics of the stroke patients by 
intervention group (dressing practice, conventional ADL or leisure 
therapy) and the control group (usual or no intervention). 
The overall demographic characteristics were typical of an ageing 
stroke population, mean age 71 years (range 28-96), 53% male and 
33% were dependent prior to stroke. The data set was balanced 
between the intervention groups for age, gender, baseline dependency, 
whether the patient lived alone (Table 6.6), and for side of stroke (left 
48.0%, right 50.7%, bilateral 1.3%). 
Variable ADL based Leisure based Control I Overall 
therapy therapy Usual care results 
N 481 174 488 1143 
Age yrs, 71.1 (10.4) 69.5 (11.5) 72.4 (10.2) 71.4 (10.5) 
mean (SO) 
Gender 253 (53) 102 (59) 247 (51) 602 (53) 
male, n (%) 
Dependent, n 140 (33) 60 (34) 132(31) 332 (33) 
(%) 
Lives alone, 182 (41) 44 (29) 189 (42) 415 (40) 
n(%) 
. .. . . . . ADL ActiVities of Dally LIVing. SO Standard DeViation . 
Table 6.6 Demographics for the combined data set by intervention group 
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6.8.1 Data analysis for EADL at the end of the 
intervention phase 
The mean score on the EADL scale (22 point scare) for each 
intervention group within each trial was used as the primary outcome for 
the summary measures analysis. The interventions were coded by the 
type of therapy assigned (control/usual therapy, and a global 
occupational therapy group which included leisure based therapy and 
activities of daily living based therapy) in each model. Leisure based 
therapy and activities of daily living based therapy were combined for 
the main analyses since the primary hypothesis under investigation 
related to the efficacy of all types of occupational therapy. Comparisons 
were made to compare efficacy between the intervention groups. 
The difference between the means and pooled variances for each trial 
were calculated as detailed in section 2.3.2.1. All of the trials used the 
Nottingham EADL scale, therefore the data were analysed using the 
weighted mean difference approach with the weights proportional to the 
reciprocal of the pooled variance for each study (see section 2.4). 
Trial, year Active Control group Difference Pooled 
group in means variance 
Nl Meanl (801) N2 Mean2 (802) 
Drummond 41 8.6 (4.8) 21 8.2 (4.2) 0.42 1.539 
1995 
Logan 43 8.7 (5.4) 43 5.1 (4.8) 3.53 1.207 
1997 
Walker 84 13.5 (5.0) 79 11.2 (5.9) 2.26 0.725 
1999 
Gilbertson 64 9.5 (5.1) 69 7.9 (5.4) 1.64 0.830 
2000 
TOTAL 233 10.8 (6.4) 119 10.3 (6.4) 0.53 0.521 
2001 
Table 6.7 Summary measures for the five trials that measured the EADL 
scale at the end of the intervention phase 
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6.8.2 Results for the EADL at the end of the intervention 
phase 
In a conventional fixed effect model, as described in section 2.4.1; 
patients receiving community occupational therapy had, on average, an 
EADL score 1.55 points higher (on a 22-point scale) at the end of 
intervention as compared to those randomised to receive usual care 
(Weighted mean difference, WMD 1.55, 95% confidence intervals, CI 
0.75,2.34). 
6.8.3 Results for secondary outcomes 
Using a conventional fixed effect model as described in section 2.4.1, 
patients receiving community occupational therapy had an EADL score 
which was higher by 0.94 points (on a 22 point scale) at the end-of-trial, 
as compared with those randomised to receive usual care (95% CI 
0.10,1.78). 
Subjects receiving community occupational therapy also had a higher 
Nottingham Leisure Questionnaire score, by 1.21 points (on a 37 
item174 point scale) (95% CI -0.17, 2.41) at end of intervention and 1.45 
points at end-of-trial (95% CI 0.05, 2.85), as compared with usual care. 
A significant odds reduction of 29% in disability (assessed using the 
Barthel Index or Rivermead Scale) was present at end of intervention 
(odds ratio, OR 0.71, 95% CI 0.52, 0.99) (Table 6.8). No effects were 
detected on common mental disorders (GHQ) in either patients or 
carers at end of intervention or end of trial, or on death by end of trial 
(Table 6.8). 
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Outcome Number of trials Odds Ratio (95% CI) 
End of intervention phase 
Activities of Daily Living 5 0.71 (0.52, 0.99) 
Patient GHQ 3 0.76 (0.54, 1.07) 
CarerGHQ 3 0.74 (0.49,1.13) 
End of trial phase 
Activities of Daily Living 5 0.75 (0.55, 1.03) 
Patient GHQ 2 1.09 (0.69, 1.61) 
CarerGHQ 2 1.11 (0.70,1.76) 
Death 8 1.07 (0.69, 1.65) 
Odds ratio IS the odds of the particular outcome on occupational therapy relative to 
control/usual care 
Table 6.8 Relationship between outcome measures and community 
occupational therapy at the end of intervention and end of trial, based on 
summary data 
6.9 Assessment of heterogeneity using summary 
data methods 
The above analyses have assumed that a common underlying estimate 
for the intervention effect exists for all of the trials. An assessment of 
heterogeneity needs to be performed to evaluate whether this 
assumption is valid. Visual and statistical assessments of heterogeneity 
were investigated for the primary outcome measure, EADL at the end of 
the intervention phase. 
6.9.1 Graphical assessment of heterogeneity 
Figure 6.3 shows the forest plot for the EADL at the end of the 
intervention phase. The forest plot indicates that there are some 
differences in the estimates for the intervention effect between the trials 
and hence formal tests for heterogeneity were performed. 
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6.9.2 Statistical assessment of heterogeneity using 
classical and Bayesian methods 
To formally assess whether there was evidence of heterogeneity 
between the trials estimates Cochran's homogeneity Q test, Higgins 
and Thompson's /2 were performed. Also, other analyses were also 
used to quantify the heterogeneity between the trial estimates using 
weighted and un-weighted MM, ML, REML, EB and FB (Table 6.9). 
Cochran's homogeneity test did not find evidence of heterogeneity 
between the trials estimates (p=0.145). However, /2 indicated that 
41.5% of the total variability within the meta-analysis may be attributed 
to heterogeneity between the trial estimates. 
From Table 6.9, the estimates for heterogeneity from the un-weighted 
and weighted MM, ML, REML and EB were 0.703, 0.607, 0.269, 0.559 
and 0.624 respectively. The magnitude of the heterogeneity from these 
models seemed to have little impact on the estimates and standard 
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errors for the intervention effect. The FB model found the most 
heterogeneity, 1.599, and hence the standard error and confidence 
intervals were slightly wider from this model as compared to the others, 
although the intervention effect remained highly significant. 
Heterogeneity Test X2value P value 12 
Qtest 6.830 0.145 
[2 0.410 
Estimation analyses Intervention (SE) 95%CI f2 
MM, un-weighted 1.631 (0.564) 0.526, 2.736 0.703 
MM, weighted 1.616 (0.544) 0.549, 2.682 0.607 
ML 1.589 (0.474) 0.660,2.518 0.269 
REML 1.613 (0.535) 0.564, 2.661 0.559 
EB 1.617 (0.550) 0.539, 2.696 0.624 
FB 1.674 (0.803) 0.126,3.221; 1.599 
Intervention relates to the estimate of EADL on occupational therapy relative to 
control, SE Standard Error, :t: 95% credibility intervals 
Table 6.9 Heterogeneity test and analysis results for EADL at the end of 
the intervention phase based on summary data 
6.10 Exploring heterogeneity 
There appears to be heterogeneity between the trials, this may be 
related to differences within the trials either at patients' level or trial 
level. Subgroup analyses and meta-regression methods were 
performed to assess whether trial level covariates such as method of 
follow up, or type of intervention or patient predictors such as age, 
gender or baseline dependency, may influence the results from each 
trial and hence explain some of this residual heterogeneity. 
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6.10.1 Subgroup analyses 
Subgroup analyses were performed to assess the relationship between 
EADL at the end of intervention and the mode of follow-up used to 
record the scores, and the type of intervention received. 
6.10.1.1 Mode of follow-up 
In the five trials which assessed EADL at the end of the intervention 
phase, two used postal questionnaires, the remaining three used an 
independent assessor which visited the patients' home and aided with 
their completion of the assessment. Using an independent assessor 
yielded an overall estimate of 1.63 (95% CI 0.55, 2.71), whereas using 
the postal questionnaire yielded an overall estimate of 1.44 (95% CI 
0.25, 2.63) (Figure 6.4). The p value for the change in heterogeneity 
was 0.823. Therefore, the method of follow-up does not appear to 
influence the EADL scores at the end of the intervention phase. 
6.10.1.2 Type of intervention 
Two main types of intervention exist for occupational therapy. The first 
concentrates on improving activities of daily living, and involves 
promoting independence in areas such as mobility. The second type of 
therapy concentrates on leisure activities and encourages patients to 
become more involved and independent in participation. The types of 
interventions assessed in the trials will vary from trial to trial since the 
intervention is therapy based and is tailor made to each patient. 
Therefore, the frequency and intensity of intervention will also vary from 
patient to patient. 
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Figure 6.4 Subgroup analysis plot for EADL at the end of the intervention 
phase by the mode of follow up 
Two types of active intervention were assessed in the trials, activities of 
daily living (ADL) therapy and leisure therapy. The data for the trials 
were split by the type of intervention received (ADL, leisure, 
control/usual therapy). Overall, 3 trials had used ADL based therapy, 
and 1 used leisure based therapy and two trials assessed both in a 
parallel design. 
Using ADL based therapy was associated with a significant increase in 
the EADL scale of 1.56 points (95% CI 0.72, 2.39), whereas using 
leisure based therapy resulted in a non-significant increase of 0.61 
points on the EADL scale (95% CI -0.81, 2.03) (Figure 6.5). Assuming 7 
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independent trials are evaluated, the p value for the change in 
heterogeneity was 0.262. Although this value is not statistically 
significant at the 5% level, the type of intervention used may to have 
some influence on the estimates for the intervention effect, where ADL 
based therapy may be more effective on impacting on extended 
activities of daily living (Figure 6.5). 
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Figure 6.5 Subgroup analysis plot for EADL at the end of the intervention 
phase by the type of intervention used 
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6.10.2 Meta-regression analyses 
Meta-regression methods were used to assess the relationship between 
the primary outcome and several predictors. These included differences 
in the average age of the patients between the two groups, the 
difference in the percentage of male patients between the two groups, 
and the difference in the percentage of dependent patients between the 
two groups. These covariates were created using a summary measure 
for each intervention group, in each of the trials. 
All five trials with EADL at the end of intervention had age and gender 
data, however one of these trials did not record data on baseline 
dependency (Logan et al. 1997) 
Previously, evidence of heterogeneity was found between the trial 
estimates, therefore a series of random effect models were used to 
explore the relationships between EADL and the covariates (see 
Section 3.4). The methods used to estimate heterogeneity were the 
weighted and approximate MM, ML, and REML, EB and FB. 
Assessments of convergence were adequate when a burn-in of 10,000 
iterations and a sample chain of 10,000 iterations were used. 
For each of the covariates, similar estimates for the effects were seen 
from all of the models. Slight differences between the magnitudes of the 
effects from the models were related to the differences in the estimates 
for heterogeneity. In each of the covariate adjusted models, none of the 
models found there was a relationship between any of the predictors 
and the estimates of the relative mean difference for the treatment 
effect (Table 6.10). 
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Method InterventionS (SE) 95%CI Agefl (SE) 95%CI i ~ ~
MM, approx 1.412 (1.265) -1.068, 3.892 0.123 (0.553) -0.960, 1.206 1.607 
MM, weighted 1.361 (1.064) -0.725,3.447 0.146 (0.476) -0.788, 1.079 0.927 
ML 1.207 (0.754) -0.271, 2.685 0.214 (0.363) -0.498, 0.926 0.118 
REML 1.364 (1.072) -0.737,3.464 0.145 (0.479) -0.794,1.083 0.950 
EB 1.379 (1.126) -0.828, 3.587 0.137 (0.500) -0.842, 1.117 1.124 
FB 1.532 (1.973) -2.244, 5.336+ 0.073 (0.801) -1.491,1.617+ 2.003 
Method Intervention9 (SE) 95%CI Gendefl (SE) 95%CI t' 
MM, approx 1.745 (0.586) 0.596, 2.894 0.086 (0.076) -0.064, 0.235 0.780 
MM, weighted 1.745 (0.527) 0.711,2.779 0.085 (0.069) -0.050, 0.220 0.461 
ML 1.733 (0.427) 0.896, 2.570 0.083 (0.057) -0.026, 0.194 0 
REML 1.745 (0.528) 0.710,2.780 0.085 (0.069) -0.050, 0.220 0.465 
EB 1.745 (0.527) 0.713,2.777 0.085 (0.068) -0.050,0.219 0.457 
FB 1.735 (0.834) 0.082, 3.377+ 0.088 (0.105) -0.123,O.302t 1.570 
Method InterventionS (SE) 95%CI Dependfl (SE) 95%CI t .. 
MM, approx 0.818 (0.734) -0.621, 2.258 0.150 (0.191) -0.224, 0.524 0.221 
MM, weighted 0.814 (0.686) -0.531,2.159 0.151 (0.179) -0.201,0.502 0.099 
ML 0.808 (0.643) -0.452, 2.069 0.152 (0.169) -0.180, 0.483 0 
REML 0.817 (0.709) -0.573, 2.206 0.150 (0.185) -0.212,0.512 0.155 
EB 0.814 (0.682) -0.522,2.150 0.151 (0.178) -0.199,0.500 0.089 
FB 0.805 (1.612) -1.974,3.504+ 0.149 (0.402) -0.549, 0.849t 1.534 
§ EADL estimate on OT relative to control when the difference in the percentage of the covariate between the OT and control groups equals zero. SE Standard error, n 
Multiplicative increase in EADL estimate when the covariate is increased by 1 %, Gender relates to male patients, Depend relates to dependent patients. + credibility intervals. 
Table 6.10 EADL at the end of the intervention phase using summary data meta-regression methods 
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6.11 Individual patient data methods 
In a classical fixed effect IPD model where a common variance is 
assumed across the trials, patients randomised to occupational 
therapy were found to have significantly higher EADL scores at the 
end of intervention phase by 1.4 points as compared to those 
randomised to usual care (Table 6.11 ). 
Intervention (SE) 95%CI i 2 
Fixed effect model 
Classical approach 1.437 (0.421) 0.611,2.263 
-
Random effect model 
Classical approach 1.576 (0.582) 0.435,2.717 0.522 
Bayesian approach 1.567 (0.584) 0.486,2.731+ 0.826 
Intervention is the EADL estimate for occupational therapy relative to control, SE 
standard error, + credibility intervals. 
Table 6.11 EADL at the end of intervention phase using individual patient 
data methodologies 
6.12 Assessments of heterogeneity using 
individual patient data methods 
An interaction term between trial and intervention was included in the 
above model to test whether there was heterogeneity between the 
trials; allowing for this test having low power when a small number of 
trials are combined, there may be some difference between the trial 
estimates in this meta-analysis (p =0.192). Therefore, heterogeneity 
was estimated using both classical and Bayesian methodologies. 
Classical and Bayesian random effect IPD models were used where a 
common variance was assumed across the trials. Additionally, 
assessments of convergence for the FB model were made using 
methods described in section 2.11. The assessments were 
satisfactory when a burn-in of 10,000 iterations and a sample chain of 
40,000 iterations were used. 
Similar results were seen from the classical and Bayesian IPO 
random effect models for the intervention effect which implied that 
occupational therapy was significantly associated with a higher EADL 
score of 1.6 points at the end of intervention as compared to usual 
care (Table 6.11). Slightly more heterogeneity was estimated from 
using the Bayesian model; however, this did not appear to impact 
greatly on the standard error for the intervention effect when 
compared to the classical model. 
6.13 Exploring heterogeneity using individual 
patient data methods 
Both classical and Bayesian IPD methods found that quantifiable 
estimates of heterogeneity existed between the trials. Therefore trial 
level covariates, such as method of follow up, and patient level 
covariates, such as age, gender, baseline dependency and type of 
intervention, were included in the random effect models to assess 
their influence on the EADL score at the end of intervention. 
6.13.1 Trial level covariates using individual patient 
data 
Method of follow-up was modelled using a classical random effect 
IPD meta-regression model as described in Section 3.5.1.3 to assess 
its impact on EADL at the end of intervention. No differences in the 
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pooled intervention effects for the EAOL scores were seen between 
using a postal questionnaire or an independent assessor (p =0.993) 
6.13.2 Patient level covariates using individual 
patient data 
Classical and Bayesian models were performed to assess the impact 
of age, gender, baseline dependency and type of intervention on 
EAOL at the end of intervention using random effect IPD models. For 
the FB models, assessments of convergence were performed as 
described in section 2.11 and found to be adequate using a burn-in of 
10,000 iterations and a sample chain of 40,000 iterations. 
Initial/y, an interaction term between the covariate and intervention 
terms was included in the models to ascertain whether the 
intervention effect varied across the range of the covariates (except 
for the type of intervention covariate). All of the models found no 
evidence of an interaction and therefore the interaction was 
subsequently dropped from the classical and Bayesian models (age 
interaction p =0.433, gender interaction p =0.765, and dependency 
interaction p =0.727). 
In the covariate adjusted models presented in Table 6.12, the results 
for the intervention effects and covariate effects are very similar 
between the Bayesian and classicallPO models. 
In the age adjusted models, patients randomised to occupational 
therapy had higher EADL scores of 1.4 points at the end of 
intervention phase as compared to patients receiving usual care. 
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However, the ages of the patients did not appear to be a significant 
predictor of EADL at the end of the intervention phase (Table 6.12). 
In the gender adjusted models, patients randomised to occupational 
therapy had significantly higher EADL score of 1.6 pOints at the end 
of intervention phase as compared to patients that received usual 
care. Additionally, gender was found to be a significant predictor of 
EADL which suggested that male stroke patients scored 
approximately 1.3 points higher on the EADL as compared to females 
(Table 6.12). 
In the models adjusted for baseline dependency, significant 
differences between the groups were seen which suggested that 
patients randomised to occupational therapy scored 1.4 points higher 
than patients randomised to usual care. Also, baseline dependency 
was found to be an important predictor of EADL; where dependent 
patients were found to score approximately 6 paints lower on the 
EADL scale as compared to independent stroke patients. 
Significantly higher EADL scores at the end of intervention were 
found in patients which received ADL based occupational therapy as 
compared to usual care (estimate 1.602, 95% CI 0.718, 2.487). 
However, no significant differences were seen in the EADL scores 
between the patients which received leisure based occupational 
therapy and those which received usual care (estimate 0.939, 95% CI 
-0.317,2.195). 
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IPO Models Estimate (SE) 95%CI Estimate (SE) 95%CI ;2 
Intervention§ AgeO (years) 
REML 1.422 (0.543) 0.358, 2.486 -0.087 (0.019) -0.125, -0.049 0.161 
FB 1.447 (0.613) 0.347, 2.686+ -0.026 (0.020) -0.064,0.012+ 0.866 , 
Intervention§ Gender'll (male) , 
REML 1.562 (0.609) 0.368,2.756 1.257 (0.411) 0.450, 2.065 0.337 
FB 1.476 (0.655) 0.320, 2.828:t: 1.248 (0.411) 0.437,2.255+ 1.248 
I ntervention§ O e p e n d e n c y ' ¥ ( d e ~ e n d e n t ) )
REML 1.454 (0.518) 0.439, 2.469 -6.265 (0.482) -7.212, -5.319 0.111 
FB 1.369 (0.675) 0.128, 2.598+ -6.144 (0.484) -5.195, -7.087+ 1.096 
§ Intervention is the EADL estimate on occupational therapy relative to control, n Estimate for age is the multiplicative increase in the estimate of EADL for 
each year increase in age, irrespective of intervention assignment, \f the estimates for gender or dependency is the increase in the estimate for EADL for 
males or dependent patients as compared to female or independent patients, respectively, irrespective of treatment. SE Standard error, :t 95% Credibility 
Intervals. 
Table 6.12 EADL at the end of the intervention phase using individual patient data adjusted for patient level covariates 
6.14 Discussion of findings 
The discussion of the findings from this systematic review is presented 
in six sections which relate to a summary of the overall findings, 
limitations of the data used in the review, comparison of the statistical 
methods, discussion of the results, practical implications of the results 
and suggestions for future research. 
6.14.1 Summary of the overall findings 
Nine randomised controlled trials of community occupational therapy in 
stroke patients were identified from a comprehensive search strategy 
which was performed up to November 2003. Individual patient data 
were available from eight of these trials; the data from the ninth trial had 
been discarded previously. The remaining eight trials recruited 1,143 
stroke patients, and the patients from these trials were randomised to 
either occupational therapy or usual care. Two types of occupational 
therapy were identified from the trials; activities of daily living and 
leisure therapy. Baseline characteristics of the patients appeared to be 
balanced between the intervention groups from the individual trials. 
At the end of intervention, patients randomised to occupational therapy 
had significantly higher scores for EADL and ADL measures, and a 
non-significant higher score for NLQ. Additionally, intervention effects 
for EADL and NLQ were significantly maintained to the end of trial. No 
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effects were seen between the intervention groups for death and minor 
psychiatric disorders as measured in the patients or their carers. 
6.14.2 
6.14.2.1 
Limitations of the data used 
Number of studies included in the meta-analysis 
The search strategy used in this systematic review identified nine 
randomised controlled trials of occupational therapy given to stroke 
patients in the community setting. However, only five of these trials had 
recorded EADL at the end of the intervention phase and so were used 
in the primary analyses. Although the primary outcomes from each of 
the individual trials could have been combined using standardised 
mean difference methodology to allow for data from all of the nine trials 
to be used, it was decided a priori that the results from such an analysis 
would be meaningless to clinicians. An attempt was also made to 
combined the outcomes of personal and extended ADL however; this 
would have only contributed data from the same five trials as well. 
6.14.2.2 Timings of the outcomes 
It was decided a priori to use the end of intervention and end of trial 
phases as the two assessment times. These endpoints were decided to 
allow for the different lengths of intervention treatments across the 
trials; and were thought preferable to using a particular timing, such as 
six months, since there was a lack of a consistent timing across the 
trials. Also, it was thought that defining the a priori assessment timings 
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would be less biased and meant that the reviewers did not decide the 
timings based on the results presented in the publications. Also, the fact 
that the effects seen for the outcomes appeared to be maintained at the 
end of intervention and end of trial suggest that the timings used were 
appropriate. 
6.14.2.3 Extent of the shared individual patient data 
Although the original trials generally collected considerable amounts of 
data during the baseline and follow-up assessment periods, it was 
frequently seen that the information collected was not consistent across 
the trials. For example, although the trial by Logan and colleagues 
assessed EADL at the end of intervention, it did not collect baseline 
dependency data (Logan et al. 1997) hence the trials had to be 
excluded form the analyses when this variable was considered. Also, 
the trial by Carr and colleagues only assessed EADL at the end of trial, 
and no assessments were made at the end of the intervention phase for 
any of the outcomes (Corr et al. 1995). 
Two scoring systems may be used for the EADL scale, within this meta-
analYSis a consistent scoring method had to be used to ensure the data 
from the trials could be combined. Therefore, the (0,1,2,3) scoring 
system was collapsed into the (0,0,1,1) system. A previous study only 
found significant intervention effects for occupational therapy when the 
(0,1,2,3) system was used as compared to the (0,0,1,1) scale (Walker 
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et al. 1999); this was thought due to the (0,0,1,1) scale being less 
sensitive to a change over a period of intervention. Therefore, it is 
suggested that the magnitude of the intervention effect seen from this 
meta-analysis may be an under-estimate of the true intervention effect 
that would be seen if the (0,1,2,3) system had been used since the 
magnitude seen in this meta-analysis would be related to an increase in 
the EADL scale from either (0) to (2) or (1) to (3) if the (0,1,2,3) scale 
had been implemented. 
In addition to the outcome presented in this chapter, we also wanted to 
assess the effect of community occupational therapy in stroke patients 
on reducing the levels of handicap and caregiver strain since a previous 
study had found significant improvements on these two outcomes 
(Walker et al. 1999); however a lack of data from other trials prevented 
these outcomes being assessed in this systematic review. 
6.14.2.4 Outcome assessments 
The primary and secondary outcome measures used in this review 
were selected a priori before the trials were identified and following 
discussions with the principal collaborators of the group. These scales 
were thought to be pertinent to the aims that occupational therapy 
attempts to influence. It was acknowledged that the scales have ceiling 
and flooring effect, and therefore it was decided that the primary 
outcome should account for this. Therefore, to overcome the potential 
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ceiling effects seen with the ADL scales, EADL was chosen as the 
primary outcome to assess whether occupational therapy improves 
EADL tasks in stroke patients. 
6.14.2.5 Experience of the therapists 
Within the majority of the trials, the senior occupational therapist which 
provided the interventions for the patients were also studying for a PhD. 
Therefore, it could be argued that these therapists had a specific 
interest in the results of the trials, hence were more motivated to 
provide an intervention which was found to be significantly better than 
the usual care received by the patient randomised to the control groups. 
Also, these therapists were researcher occupational therapists and 
perhaps had more experience in targeting the areas that would be 
picked up on the outcome assessments as compared to the therapists 
which provided the usual care to the control groups. Another possibility 
is that the researcher occupational therapists may be more familiar with 
the literature on targeted rehabilitation being more effective and 
therefore may have modified their practice. 
However, the EADL outcome assessments used within the trials were 
not biased since either a questionnaire was completed by the patient or 
an independent assessor was used who was blinded to the intervention 
allocation. Also, only two of the nine trials identified in this review were 
deemed to be of a slightly lower quality due to unclear reporting of 
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randomisation techniques, and since these two trials did not contribute 
data to the primary outcome analysis, it can be suggested that the 
results seen from this review are from high quality randomised 
controlled trials and are likely to be generalisable and'unbiased. 
6.14.3 
6.14.3.1 
Comparison of the statistical methods 
Assessment of heterogeneity 
The impact of heterogeneity on the results was assessed using various 
statistical models for EADL at the end of intervention. Initially, statistical 
assessments of heterogeneity were performed which produced results 
which were contrary to each other; where relatively high levels of 
heterogeneity appeared to be present in the results between the trials 
from using /2 where as Cochran's homogeneity test yielded a non-
significant p value. This difference is not surprising since the power 
associated with Cochran's homogeneity test is reduced when the meta-
analysis contains data from a small number of trials (Fleiss 1986; 
Whitehead et a/. 1991; Thompson 1994). No evidence of heterogeneity 
was also seen when assessed in an individual patient data model by 
including a fixed effect interaction term between intervention and trial. 
Again, the lack of significance is related to a lack of power from 
assessing a small number of trials included in this meta-analysis (Brown 
et al. 1994). 
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6.14.3.2 Impact of quantifying heterogeneity 
A range of estimation methods were then used in a random effect 
model to assess whether there were differences between the results 
from the summary data models. All of these models estimated 
quantifiable amounts of heterogeneity between the trials; however, the 
magnitude of the heterogeneity had little impact on the significant 
results for the intervention effect, hence all performed adequately in this 
meta-analysis. 
Fixed and random effect individual patient data models were then used 
to assess the impact of occupational therapy on EADL at the end of 
intervention. In a fixed effect model, patients randomised to 
occupational therapy had significantly higher EADL scores than those 
receiving usual care, this significant effect was maintained when a 
random intervention by trial effect was included in the model. 
6.14.3.3 Impact of exploring heterogeneity 
Various estimation methods were then used in meta-regression models 
to assess whether there were any intervention effect modifiers and 
whether there were any differences between the results from the 
estimation methods. All of the models yielded similar results for the 
intervention and covariate effects which implied that age, sex and 
baseline dependency did not modify the intervention effects. The lack of 
significance for the covariate in the models was somewhat expected 
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due to the small number of trials being assessed. The Cochrane 
Collaboration has suggested that meta-regression models should not 
be used to assess the influence of covariates on treatment effect unless 
there are at least ten studies included in the meta-analysis (The 
Cochrane Collaboration 2003). 
From the adjusted IPD models, although no evidence of effect modifiers 
were seen for the covariates under investigation; several predictors for 
EADL were found. These included gender and baseline dependency; 
however age did not appear to impact on the results. 
Male patients were found to have higher EADL scores than compared 
to females; this finding may be related to differences in the goals that 
the patients aim to achieve at the end of the intervention phase. Bearing 
in mind the ages of the patients included in this review, it is thought that 
the main aim of the men in this group is to get their independence to be 
able to drive a car again which assumes independence in personal 
tasks; where as the women are more likely to want to gain 
independence in household tasks. Therefore, since driving a car (and 
the associated tasks that go with this factor) scores highly on the EADL 
the differences seen in gender may well be a true finding. 
Dependent patients were found to score approximately 6 points lower 
on the EADL as compared to patients with independence. This is 
intuitive since the dependent patients have a lack of ability to be able to 
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perform the higher functional tasks that are required of the EADL 
assessment since they are still dependent in personal ADL tasks. 
Two of the trials in the meta-analysis had multiple intervention groups 
(Drummond et al. 1995; Parker et al. 2001) and having data at the IPD 
level enabled contrasts to be specified for the type of intervention 
received which wouldn't have been possible using the conventional 
subgroup analysis methods associated with summary data. In this 
instance, subgroup analysis was an inefficient method and also 
assumes independence for the control group, which was used more 
than once in the subgroup analyses. 
Therefore, it appears that there were little differences in the results from 
the models using summary data or IPD in this meta-analysis. However, 
the individual patient data models allowed for more in-depth analysis to 
be performed and appeared to be more efficient where multiple 
intervention groups exist. 
6.14.4 Discussion of the results 
This systematic review provides substantial evidence for the efficacy of 
occupational therapy given to stroke patients in the community setting. 
The aim of this systematic review was to estimate the extent that 
occupational therapy given in the community setting to patients 
following a stroke generally influences EADL. 
210 
6.14.4.1 Impact of occupational therapy on Extended Activities 
of Daily Living 
The principal finding from this systematic review was that occupational 
therapy for stroke patients living in the community was associated with 
a higher EADL score at the end of intervention and end of trial. This 
indicated that stroke patients were able to carry out more activities of 
daily living, such as walking outdoors, household chores or travelling on 
public transport. 
Independence in anyone of these activities would enable the patient to 
participate in the more demanding activities of daily living, thereby 
adding to their quality of life. Although a definition of the amount of 
change for EADL that would constitute a clinically meaningful 
improvement was not specified a priori, it is felt that an increment of one 
point may be clinically important. This modest benefit is in keeping with 
previously published studies, including the findings of a stroke unit trial 
(Juby et al. 1996), and is not negated by the neutral findings of TOTAL 
(Parker et al. 2001). 
6.14.4.2 Impact of occupational therapy on other outcomes 
Additionally, community based occupational therapy appeared to 
extend across a range of outcomes measures including activities of 
daily living, and leisure participation. 
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Activities of daily living were assessed using either the Barthel Index or 
the Rivermead self care Assessment. This outcome measure is known 
to have ceiling and floor effects, therefore it was reassuring that 
significant intervention effects were seen between the occupational 
therapy and control groups, since it implies that occupational therapy 
dies not just improve higher functional tasks such as those measured 
by the EADL, but also improve more basic personal tasks such as 
bathing, brushing hair, and continence. 
Leisure participation was measured using the Nottingham Leisure 
Questionnaire at the end of intervention and end of trial. Occupational 
therapy was significantly associated with higher leisure scores at the 
end of trial. This implies that occupational therapy can have long lasting 
effects on leisure participation and possibly life satisfaction (Allen et al. 
1984). 
6.14.4.3 Differences between TOTAL and the other trials 
The trial by Parker and colleagues may have demonstrated little benefit 
from community occupational therapy for several reasons (Parker et al. 
2001). The use of postal outcome may have made the findings of 
TOTAL less open to observer bias and so it is possible that the smaller 
effect seen in TOTAL is more genuine that that found in other trials 
where independent assessments were implemented. Another reason 
why the TOTAL study may have not found a large clinical benefit is that 
212 
the intervention in TOTAL was administered by clinicians, and not 
research occupational therapists, who may have been less motivated 
as their daily work was not contributing to a higher degree (see Section 
6.14.2.5). Another possible reason is that the research protocol 
imposed some restrictions on the type of interventions making their 
effectiveness less than optimal. 
6.14.4.4 Impact of the type of intervention 
Subgroup analyses indicated that the benefits of occupational therapy 
were greatest when targeted where occupational therapy aimed at 
influencing ADL appeared to improve extended activities of daily living. 
Conversely, further analyses suggested that occupational therapy 
directed at influencing leisure pursuits improved leisure activities, but 
not EADL scores (Walker et 81. 2004). This observation that the 
provision of one specific intervention does not generalise to other areas 
is contrary to the current view held by many clinicians (Walker et al. 
2003). However the findings from this systematic review and meta-
analysis are consistent with other recent stroke rehabilitation trials 
(Seitz et 81. 1987; Dean et 81. 1997). 
Although the active intervention was dichotomised based on either 
activities of daily living or leisure therapy, this may still not adequately 
describe the intervention received since the components of the 
interventions used in the trials were tailor-made for each patient. The 
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frequency and intensity of the intervention could not be assessed in this 
meta-analysis since it was found that they were highly correlated. 
Additionally, unmeasured factors, such as the number of aids and 
adaptations or the seniority of the therapist, are thought to be of 
influence too however, the data set had very incomplete data for these 
measures and further investigations could not be performed. 
6.14.4.5 Generalisability of the findings 
It is only in the last decade that a research culture has existed within the 
occupational therapy profession and existing evidence is sparse. This 
analysis of community occupational therapy trials included only 
relatively recent published work and no old unpublished studies were 
identified. An extensive search strategy was used to identify eligible 
studies, and statistical testing for missing trials was non-significant. 
Therefore probably all of the available data had been identified. The 
unavailable data for one of the identified trials (Turton et a/. 1990), 
accounted for only 2% of the total data. The inclusion of these data 
would not have significantly altered the findings. There are currently two 
ongoing trials that need to be included in any future analyses. However, 
the results from this review should be generalisable since they form the 
collective body of evidence from nine randomised controlled trials of 
community occupational therapy in stroke patients. Although the trials 
individually attempted to recruit patients which were representative of a 
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population of stroke patients, this may have not been fully achieved and 
therefore the results from this meta-analysis may be biased towards 
patients which are likely to use this service. 
The findings from this meta-analysis provide a balanced interpretation 
of the available evidence and endorse an earlier systematic review of 
published data by Steuljens and colleagues (Steuljens et al. 2003). 
However, our research provides more information about the relationship 
between specific interventions and outcome and shows the first results 
between patient characteristics and outcomes. 
6.14.5 Practical implications 
This review has demonstrated that occupational therapy offered to 
stroke patients in the community can improve their rehabilitation needs 
quickly and with lasting effects. Therefore, this review suggests that all 
stroke patients within one year of stroke onset should be offered 
occupational therapy in the community setting. In depth analyses were 
performed in this review which highlighted that certain subgroups of 
patients may benefit the most from occupational therapy. No significant 
interactions were seen between treatment and several predictors. 
However, analyses did indicate that male stroke patients and patients 
which were not dependent at baseline had higher EADL scores at the 
end of intervention. Surprisingly, age of the patients was not found to be 
an important predictor of a patients EADL score. However, these factors 
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were identified through post hoc analyses and the findings need to be 
validated from other data of a randomised controlled trial to truly assess 
whether these patients benefit the most from occupational therapy. 
The results from this systematic review has important implications to 
service providers who need to ensure that patients are offered specific 
interventions, such as community occupational therapy, to those who 
would benefit the most. 
There may well be differences between services offered in these trials 
because of the differences in interventions and settings, and in view of 
this, work now is needed to characterise the necessary conditions for 
effective and efficient services. However the provision of occupational 
therapy remains justified on evidence-based grounds and it would 
appear that the rehabilitation needs of a substantial number of stroke 
patients in the community can be met feasibly by occupational therapy 
with measurable and lasting benefits. 
The costs of such a service as specified in this review could not be 
estimated from the data, and if such a scheme was available to all 
stroke patients the costs of providing such a service needs to be 
minimised to make the scheme viable. An attempt to quantify the 
optimal frequencies and intensities of the occupational therapy 
intervention were performed; however, analysis of these factors 
appeared to be closely negatively correlated with the baseline 
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dependency of the patients and therefore could not be quantified. The 
optimal amount these factors to ensure that the costs of providing such 
a service to the community are minimised could not be assessed. 
6.14.6 Future research 
This study attempted to combine all of the available evidence and to 
estimate the benefit of an intervention of occupational therapy to stroke 
patients in the community. However, it has not been able to identify 
exactly what it is about occupational therapy that significantly improved 
the patients EADL. This was due to not only a lack of specific data 
relating to the intervention used within the trials, but also due to the 
complexities involved with tailor making these intervention packages to 
the individual patients. 
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CHAPTER 7 
DIPYRIDAMOLE IN STROKE PATIENTS: A 
SYSTEMATIC REVIEW AND META-ANALYSIS OF 
RANDOMISED CONTROLLED TRIALS 
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7.1 Introduction 
Aspirin is recommended for use in patients with prior stroke or transient 
ischaemic attack to reduce the risk of recurrence (Lees et al. 2000). In a 
meta-analysis of summary data, the Anti-Thrombotic Trialists (ATT) 
found that aspirin reduced the relative odds of further vascular events 
by 22% (Antithrombotic Trialists Collaboration 2002). However, the side 
effects of aspirin (principally gastrointestinal disturbance and bleeding) 
and its modest efficacy mean that alternative or additional antiplatelet 
agents might be useful clinically. A number of alternative antiplatelet 
agents exist for use after stroke, including dipyridamole and clopidogrel. 
These antiplatelet agents have been shown to have a similar efficacy as 
aspirin in reducing recurrence in stroke patients (CAPRIE Steering 
committee 1996; Diener et a/. 1996). However, these drugs are more 
expensive than aspirin, so their use is more limited. 
It is postulated that the combination of either one of the treatments, 
dipyridamole or clopidogrel, with aspirin may provide extra benefits than 
compared to a single treatment alone. The largest study to date, ESPS 
II, was a factorial designed study of aspirin, dipyridamole, a combination 
of the two agents, or placebo. This study found that there was added 
benefit in reducing stroke recurrence by using the combination of 
aspirin and dipyridamole as compared to either dipyridamole (relative 
risk reduction, RRR 24.7%) or aspirin (RRR 23.1 %) alone (Diener et a/. 
1996). However, the routine use of dipyridamole in secondary 
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prevention after cerebrovascular events has been controversial. This 
key trial (Diener et a/. 1996), has been criticised on a number of 
grounds based on the design and conduct of the study (Davis et a/. 
1998). First, the relatively high recurrence rate seen in the aspirin only 
group may be related to the low level of dose (50 mg daily; as 
compared with ESPS 330mg three time daily), whereas a higher dose 
may have significantly lowered this rate. Additionally, high levels of 
drop-outs were seen in the dipyridamole and dual treatment groups, 
which were related to adverse events of headache and gastrointestinal 
bleeding. Although these criticisms do not necessarily invalidate the 
results that combined aspirin and dipyridamole was superior to both 
aspirin alone and dipyridamole alone in preventing further stroke. 
Additionally, A TT did not find that the combination of aspirin and 
dipyridamole was superior to aspirin alone in reducing a composite 
vascular outcome (comprising non-fatal stroke, non-fatal myocardial 
infarction and vascular death) in patients with prior vascular disease 
(Antithrombotic Trialists Collaboration 2002). 
In addition to the ESPS II trial, several other smaller studies have been 
performed which assessed the combination of dipyridamole and aspirin 
in the secondary prevention of stroke. Therefore to fully evaluate the 
efficacy of the combination treatment, the information from these 
smaller trials needs to be taken into consideration. The trials appear to 
be disparate with regards to the efficacy of the combined treatment on 
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stroke recurrence therefore it is essential for the review to investigate 
the variations by assessing the importance of internal factors at trial 
level such as the dose of aspirin, and at patient level such as the type of 
qualifying event, age and gender of the patients. 
7.2 Design of study 
A systematic review was performed involving a meta-analysis of 
individual patient data from randomised controlled trials of dipyridamole 
in patients with prior ischaemic stroke and/or transient ischaemic attack. 
7.2.1 Measures of interest 
The primary outcome measure was subsequent fatal or non-fatal stroke 
at the end of trial. Secondary outcome measures at the end of trial were 
non-fatal stroke, fatal and non-fatal myocardial infarction, vascular 
death, and a composite outcome consisting of non-fatal stroke, non-
fatal myocardial infarction, or vascular death. 
7.3 Study selection and search strategy 
Trials were eligible if they fulfilled the requirements of randomisation, 
double blinding to allocation of treatment, recruitment of patients with 
previous stroke or transient ischaemic attack, and involved dipyridamole 
in at least one treatment arm. 
A comprehensive literature search was performed to identify all eligible 
randomised controlled trials, whether published or unpublished, of 
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dipyridamole in cerebrovascular disease. Electronic searches of the 
Cochrane Library (Issue 4, 2002), MEDLINE (1966-2001 inclusive), 
EMBASE (1980-2002), and Web of Knowledge (1981-2002) were 
performed using the keywords 'dipyridamole', 'stroke', 'prevention', and 
'cerebr*' in combination with the recommended search routine for 
identifying randomised controlled trials (Deeks et al. 1996). Reference 
lists from the identified publications and earlier reviews of dipyridamole 
in stroke (Sze et a/. 1988; Lowenthal et a/. 1994; Diener 1998; Tijssen 
1998; Wilterdink et al. 1999; Antithrombotic Trialists Collaboration 2002) 
were also searched, and the trialists and manufacturer of dipyridamole 
(Boehringer Ingelheim) were contacted. No restrictions on language of 
were made. Non-randomised or confounded trials were excluded, as 
were those which involved non-stroke patients or did not include 
dipyridamole in one of the treatment arms. 
Trial, year of Subjects Treatment Primary Result 
publication groups outcomes 
Acheson, 1969 169 DIP Stroke Neutral 
Guiraud- 440 ADI A/C t Stroke Neutral 
Chaumeil,1982 
AICLA,1983 604 AD/A/P Stroke Positive 
ACCSG,1985 890 AD/A Stroke, death Neutral 
Caneschi, 1985 50 AD/A/D Stroke Neutral 
ESPS, 1990 2,500 AD/P Stroke, death Positive 
ESPS II, 1996 6,602 AD/A/DIP Stroke Positive 
A, aspirin; C, control; 0, diPYridamole; P, placebo t All groups had dihydroergotamine. 
Table 7.1 Trial characteristics for the identified trials 
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Data from two further ongoing studies were not available; the ESPRIT 
trial is comparing combined aspirin and dipyridamole with aspirin (De 
Schryver 2000), and PRoFESS is comparing two combinations, aspirin 
and c1opidogrel versus aspirin and dipyridamole (Sacco et al. 2004). 
Seven completed trials involving 11,255 patients were identified which 
assessed dipyridamole in the secondary prevention of stroke (Acheson 
et al. 1969; Guiraud-Chaumeil et al. 1982; Sousser et al. 1983; 
Caneschi et al. 1985; The American-Canadian Co-operative Study 
Group 1985; ESPS Group 1990; Diener et al. 1996) (Figure 7.1). 
Stroke (ReT) 
n=77 
Duplicates 
f-
n=68 
Completed 
n=9 
Ongoing/planned 
-n=2 
Completed 
n=7 
Data unavailable 
f- ' 
n=2 
, 
Data avaHabJe 
n=5 
, 
Figure 7.1 Flow chart for trial identification and selection 
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All of the seven completed randomised controlled trials had been 
published and used subsequent stroke as a principal outcome. From 
the publications, three of the trials found that recurrence was reduced 
with the combination treatment of dipyridamole and aspirin as opposed 
to other treatments (Sousser et al. 1983; ESPS Group 1990; Diener et 
al. 1996). The remaining four trials found no evidence individually that 
stroke recurrence was lowered when the combination treatment was 
used (Table 7.1). 
7.4 Data collection and management 
The principal investigator from each trial was contacted and asked if 
they would share their individual patient data with the collaboration. The 
data were exchanged electronically in all cases. 
Data from two randomised controlled trials were unavailable, the first 
was published in 1969 and had been discarded previously (Acheson et 
al. 1969); the authors from the second trial could not be contacted 
(Caneschi et al. 1985). However, both of these trials were relatively 
small in size, 169 and 50 patients respectively, and contributed to only 
1.9% of the total. Tabulated data from these two trials were extracted 
from the publications and used in the unadjusted analyses. 
The shared individual patient data were checked against the results 
from the publications and any discrepancies were resolved through 
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contact with the relevant principal investigator. No major discrepancies 
were found in the data sets. Before the data were merged into a single 
data set in SAS version 8.02 (SAS Institute Inc), re-coding of the 
variables were performed to a uniform manner across all trials. 
7.5 Assessment of publication bias and quality 
Publication bias was assessed for subsequent stroke at the end of trial, 
and compared between the groups for the dual treatment against a 
combined group consisting of patients randomised to either aspirin 
alone, dipyridamole alone, or placebo. The trial by Acheson and 
colleagues was excluded from the assessment since the trial did not 
use the dual treatment of aspirin and dipyridamole. 
Using Begg's funnel plot, the plot appeared to be relatively symmetrical 
in appearance and the point estimates were all located within the 
pseudo 95% confidence interval lines; hence there did not appear to be 
any evidence of publication bias from the seven trials (Figure 7.2). 
However, due to the small number of randomised controlled trials 
included in this meta-analysis further assessments were made. 
Standard error of the log odds ratio 
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Figure 7.2 Begg's funnel plot for recurrence at the end of trial, AD vs. other 
groups 
The 8egg and Mazumdar rank correlation test found no evidence of 
publ ication bias (p=O.707, continuity corrected) , also Egger's 
asymmetry test (p=0.482) and the trim and fill method did not find any 
evidence of publication bias. 
Methodological quality for each trial was assessed on the basis of the 
method of randomisation employed, whether the allocation of treatment 
was concealed , the completeness of follow-up achieved, and on 
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whether the outcome assessment was blinded to the allocation of 
treatment using recognised criteria (The Cochrane Collaboration 2003). 
Six of the seven trials were deemed to have a high level of quality by 
satisfying at least three of the above criteria (Table 7.2). However, the 
remaining trial was found to have a lower quality due to the inadequate 
trial designs and reporting (Caneschi et al. 1985). 
Trial, year of Concealment Randomisation Blinded outcome 
publication to allocation assessor 
Acheson, 1969 A Central randomisation Yes 
Guiraud- B Pre-determined list Yes 
Chaumeil, 1982 
AICLA,1983 A Pre-determined Yes 
schedule 
ACCSG,1985 A Random allocation Yes 
Caneschi, 1985 8 Unclear Unclear 
ESPS, 1990 A Not specified Yes 
ESPS II, 1996 A Central randomisation Yes 
A= Low risk of bias, B= Moderate risk of bias, C= High risk of bias 
Table 7.2 Assessment of quality for the identified trials 
7.6 Trial level demographics 
The data were assessed to determine whether patients were similar 
between the trials (Table 7.3). The demographics of the patients across 
the trials appeared to be relatively well balanced. All of the trials 
recruited slightly more male patients than female stroke patients. The 
Guiraud-Chaumeil trial had the highest percentage of recruited male 
patients. The percentage of patients whose qualifying event was stroke 
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varied considerably between the trials, ranging between 0% and 84%. 
The American-Canadian Co-operative study group trial only recruited 
patients whose qualifying event was a transient ischaemic attack. 
Trial, publication year Subjects Age, mean (SD) Male, (%) Stroke (%) 
Acheson, 1969 169 58.1 (-) 117 (69) 106 (63) 
Guiraud-Chaumeil, 440 62.4 (9.4) 372 (85) 260 (59) 
1982 
AICLA,1983 604 63.2 (10.3) 420 (70) 510 (84) 
ACCSG,1985 890 63.3 (10.2) 594 (67) 0(0) 
Caneschi, 1985 50 -(-) 36 (72) 40 (80) 
ESPS, 1990 2500 63.5 (10.7) 1450 (58) 1302 (52) 
ESPS II, 1996 6602 66.7 (11.1) 3828 (58) 5038 (76) 
.. SD is the standard deViation. - Data not available 
Table 7.3 Patient demographics at baseline by trial 
7.7 Outcome assessments and measures 
All of the seven randomised controlled trials recorded subsequent 
stroke, non-fatal stroke, and vascular death at the end of trial. Fatal or 
non-fatal myocardial infarction was only recorded in five of the trials 
(Guiraud-Chaumeil et al. 1982; Bousser et al. 1983; The American-
Canadian Co-operative Study Group 1985; ESPS Group 1990; Diener 
et a/. 1996); and the rates of myocardial infarction were low in all the 
comparison groups. A composite outcome was created for all trials and 
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was based on non-fatal events of stroke and myocardial infarction, and 
vascular death at the end of trial. 
7.7.1 Type of intervention and formulation of 
dipyridamole 
All except one study (Acheson et a/. 1969) assessed the efficacy of the 
combination of dipyridamole and aspirin and compared this with aspirin, 
dipyridamole, or placebo. One trial had a control group instead of a 
placebo group (Guiraud-Chaumeil et a/. 1982). Three studies had more 
than two groups of patients (Guiraud-Chaumeil et a/. 1982; Sousser et 
al. 1983; Diener et al. 1996). Two formulations of dipyridamole were 
assessed in the trials; the majority of the trials used conventional 
formulation, and the remaining trial used modified release formulation 
(Diener et a/. 1996). The doses for dipyridamole and aspirin varied 
between the trials (Table 7.4). 
7.7.2 Timing of assessments and measures 
The follow-up assessments varied between the trials, ranging between 
3 and 72 months post-enrolment, and averaged at approximately 27 
months (Table 7.4). Also, in four of the trials the length of follow-up 
varied within the trials (Acheson et a/. 1969; Guiraud-Chaumeil et a/. 
1982; Caneschi et al. 1985; The American-Canadian Co-operative 
Study Group 1985). 
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Trial, year of Dipyridamole dose Aspirin dose Follow up 
publication (months) 
Acheson, 1969 100-200 mg qds - 15-37 
Guiraud-Chaumeil, 50 mg tds 300 mg tds 36-72 
1982 
AICLA,1983 75 mg tds 330 mg tds 36 
ACCSG,1985 75 mg qds 325 mg qds 24-60 
Caneschi, 1985 75 mg tds 300 mg od 22-34 
ESPS, 1990 75 mg tds 330 mg tds 24 
ESPS II, 1996 200 mg bd 25 mg bd 24 
ad once dally, bd twice dally, tds thrice dally, qds four times dally. 
Table 7.4 Doses of dipyridamole and aspirin and length of follow-up at the 
end of trial 
7.8 Analysis of the merged data set using summary 
data methods 
The data from the seven trials were merged into a single data set and 
involved 11,255 patients. The overall demographic characteristics were 
typical of an ageing stroke population, where the average age was 65 
years (standard deviation, SO 11.0), and 6,700 (60%) of patients were 
male. Time from stroke onset to recruitment into the trial averaged 33.8 
days (SO 64.7). 
7.8.1 Data analysis for subsequent stroke at the end of 
trial 
The proportion of patients with subsequent stroke for each treatment 
group within each trial was used as the primary outcome measure. The 
treatments were coded into four groups; dual treatment (aspirin and 
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dipyridamole), dipyridamole alone, aspirin alone or control/placebo. 
Comparisons were made to compare the efficacy of the dual treatment 
as compared to the other treatments. The odds ratios and variances for 
each trial were calculated as detailed in section 2.3.1.1. 
7.8.2 Results for subsequent stroke at the end of trial 
In a conventional fixed effect analysis as described in section 2.4.1, 
patients randomised to the dual treatment had significantly reduced 
risks of subsequent stroke as compared to patients that received 
dipyridamole alone (OR 0.72, 95% CI 0.58, 0.89), aspirin alone (OR 
0.78, 95% CI 0.65, 0.93), or control/placebo (OR 0.60, 95% CI 0.50, 
0.72). 
7.8.3 Results for secondary outcomes 
From a conventional fixed effect analysis as described in section 2.4.1; 
patients randomised to aspirin and dipyridamole had significantly 
reduced risks of non-fatal stroke (25%) and an event defined from the 
composite outcome (28%) as compared to those which received 
dipyridamole; reduced risks of non-fatal stroke (29%) and an event 
defined from the composite outcome (16%) as compared to patients 
receiving aspirin; and reduced risks of non-fatal stroke (41 %). fatal and 
non-fatal myocardial infarction (33%) and an event defined from the 
composite outcome (35%) as compared to control/placebo (Table 7.5). 
However, dual treatment of dipyridamole and aspirin was not 
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significantly associated with a reduction in the risk of vascular death at 
the end of trial as compared to dipyridamole, aspirin, or control/placebo 
(Table 7.5). 
AD vs. D AD vs. A AD vs. C 
Outcome OR (95% CI) OR (95% CI) OR (95% CI) 
Non fatal stroke 0.75 (0.57, 0.98) 0.71 (0.57, 0.88) 0.59 (0.48, 0.72) 
Ml,all 0.73 (0.47, 1.13) 0.98 (0.67, 1.43) 0.67 (0.46, 0.92) 
Vascular death 0.85 (0.62, 1.15) 1.09 (0.85, 1.38) 0.89 (0.72, 1.11) 
Composite 0.72 (0.60, 0.88) 0.84 (0.71, 0.98) 0.65 (0.56, 0.75) 
OR is the odds ratio for dual treatment relative to companson group, MI myocardial 
infarction, A aspirin, 0 dipyridamole, C control/placebo 
Table 7.5 Relationship between outcome measures and dual treatment 
with aspirin and dipyridamole at the end of trial, based on summary data 
7.9 Assessment of heterogeneity using summary 
data 
The conventional methods presented have assumed that the trials all 
have a common underlying estimate for the treatment effect for each 
pair wise comparison. An assessment of heterogeneity needs to be 
performed to evaluate whether this assumption is correct for each 
comparison. Visual and statistical assessments of heterogeneity were 
investigated for the primary outcome measure for each pair wise 
comparison. 
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7.9.1 Graphical assessment of heterogeneity 
Figure 7.3 shows the forest plot for subsequent stroke at the end of trial 
split by the comparison group. The forest plot indicates that there is 
very little heterogeneity between any of the estimates for each pair wise 
comparison. However, to formally assess the presence of heterogeneity 
between the estimates, statistical testing of heterogeneity was 
performed. 
7.9.2 Statistical assessment of heterogeneity using 
classical and Bayesian methods 
To formally assess whether there was evidence of heterogeneity 
between the trials estimates the Cochran's homogeneity Q test and 
Higgins and Thompson /2 were performed. Also, other analyses were 
used to quantify the heterogeneity between the trial estimates using un-
weighted and weighted MM, ML, REML, EB and FB (Table 7.6). 
Cochran's homogeneity test did not find evidence of heterogeneity 
between the trial estimates for the three pair wise comparisons (AD vs. 
D p =0.81; AD vs. A p =0.90; AD vs. C/P p =0.84). /2 was estimated 
as zero for all of the comparisons (Table 7.6) indicating that none of the 
differences between the trial estimates could be attributed to 
heterogeneity. 
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Figure 7.3 Forest plot for subsequent stroke at the end of trial split by type 
of comparison group 
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Dual treatment vs. Dipyridamole Dual treatment vs. Aspirin Dual treatment vs. 
I 
Control/Placebo 
Heterogeneity Test x2 [2 X2 [2 X2 [2 I 
Cochran's Q test 0.057 1.082 0.855 
[2 0 0 0 
Estimation methods Odds Ratio 95%CI ;2 Odds Ratio 95%CI e Odds Ratio 95%CI e 
MM, un-weighted 0.717 0.577, 0.891 0 0.776 0.647,0.930 0 0.604 0.510,0.716 0 
MM, weighted 0.717 0.577, 0.891 0 0.776 0.647, 0.930 0 0.604 0.510,0.716 0 
ML 0.717 0.577, 0.891 0 0.776 0.647, 0.930 0 0.604 0.510,0.716 0 
REML 0.717 0.577, 0.891 0 0.776 0.647, 0.930 0 0.604 0.510,0.716 0 
EB 0.717 0.577,0.891 0 0.776 0.647,0.930 0 0.604 0.510,0.716 0 
FB 0.727 0.131,4.108+ 0.844 0.801 0.606, 1.092+ 0.149 0.611 0.460, 0.608+ 0.141 
Odds ratio is the odds of subsequent stroke on dual treatment relative to the comparison group, :J: 95% credibility intervals 
Table 7.6 Heterogeneity test and analysis results for subsequent stroke at the end of trial based on summary data 
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From Table 7.6, the estimates for heterogeneity from the classical and 
EB methods were zero for all of the pair wise comparisons, and hence 
the estimates for the treatment effect were identical as to those from the 
fixed effect models and indicated that the dual treatment was 
associated with significant reductions in subsequent stroke by 28%, 
22%, and 40% as compared to dipyridamole alone, aspirin alone or 
control/placebo, respectively. 
The FB approach found heterogeneity in all of the pair wise 
comparisons, and hence the standard errors for the treatment effect 
were larger as compared to the estimates from the classical or EB 
models. Although the magnitudes of the treatment effect were similar 
for the comparisons as compared to the classical and EB models, only 
the comparison of dual treatment vs. control/placebo remained 
statistically significant. 
7.10 Exploring heterogeneity 
It appears that the differences in the estimates for the treatment effects 
between the trials may be due to sampling errors only and not due to 
heterogeneity. Although these tests did not find evidence of 
heterogeneity, it may still be advantageous to determine whether any 
prognostic factors either relating to patient characteristics, such as age 
and gender; or trial factors, such as dose of treatments, can explain 
some of the residual variation between the trials. Subgroup analyses 
were used to assess the influence of trial factors, and meta-regression 
analyses were used to assess the influence of patient characteristics. 
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Data relating to patient characteristics were unavailable for two of the 
trials due to lack of individual patient data from the authors and could 
not be included in the following analyses (Acheson et al. 1969; 
Caneschi et al. 1985); however, data relating to gender of the patient 
could be extracted from the publication of the Caneschi trial. 
7.10.1 Subgroup analyses 
Subgroup analysis was used to assess whether the trial level factors for 
the type of formulation used (conventional or modified release), were 
important for two of the three pair wise comparisons. The comparison of 
dual treatment against dipyridamole alone was not performed since only 
the trial relating to ESPS " would be included. 
7.10.1.1 Type of dipyridamole administration 
Dipyridamole may be given in two oral formulations, either 
conventionally in a standard tablet or as a modified release preparation 
which maintains blood levels longer. In four of the trials, dipyridamole 
was given conventionally, however in ESPS II the modified release 
formulation was given (Figure 7.4). The conventional formulation 
yielded a non-significant reduction in the risk of stroke recurrence when 
the dual treatment was compared to aspirin alone (OR 0.865, 95% CI 
0.628, 1.190); where as patients randomised to dual treatment had a 
significant 26% reduction in the risk of subsequent stroke as compared 
to patients which received aspirin alone when the modified release 
formulation was used (OR 0.736, 95% CI 0.591, 0.918). However, the 
p value for the change in heterogeneity was 0.418 indicating that there 
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does not appear to be evidence of a difference between the two 
estimates and their confidence intervals. 
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Figure 7.4 Subgroup analysis plot for recurrence at the end of trial by the 
formulation for dipyridamole for the comparison of dual treatment versus 
aspirin 
For the comparison of dual treatment against control/placebo (Figure 
7.5), similar reductions in the risk of subsequent stroke were seen for 
the two formulations, (conventional formulation OR 0.633, 95% CI 
0.479, 0.836; modified release formulation OR 0.589, 95% CI 0.476, 
0.728) (Figure 7.5). The p value for the change in heterogeneity was 
0.685 indicating that there does not appear to be significant evidence of 
a difference between the two estimates and their confidence intervals. 
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Therefore the method of formulation of dipyridamole does not appear to 
significantly modulate the effectiveness of the combination treatment on 
the risk of recurrence at the end of trial. This subgroup analysis also 
allowed for the effect of excluding ESPS II to be determined in light of 
the criticisms presented earlier regarding this trial relating to the dose of 
aspirin used (see section 7.1). 
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Figure 7.5 Subgroup analysis plot for recurrence at the end of trial by the 
formulation for dipyridamole for the comparison of dual treatment versus 
control/placebo 
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7.10.1.2 0050 of aspIrin 
With the exception of ESPS II and Caneschi trials. all of the other trials 
used relatively high lovol of dose for aspirin (range 900·1300 mg/day). 
When tho studios with low aspirin doses are excfuded from the analysis 
tho magnitudo for tho treatment oUeds are slighUy reduced (AD vs. A 
OR 0.88. 95% CI 0.63. 1.21; AD vs. CIP OR 0.63. 95% CI 0.48. 0.84) 
and only remain signifcanl for the comparison of dual treatment against 
controUplaccbo. Tho comparison between dual treatment and 
dipyridamolo alono \Y:aS not performed since both of the eligible trials 
had been oxcluded. 
7.10.2 Mela-regresslon analyses 
Tho patient characteristics of interest were assessed using the 
differenco between tho percentage of the factor between the dual 
treatment group and tho comparison groups of aspirin or 
conlroUplaccbo. Tho comparison against dipyridamole was not 
assessed using mota·regression since data from only two trials were 
availablo. Tho fadors considered wera ago. gender. and the type of 
qualifying evenl 
Although heterogeneity was only found in the FB model. random effect 
models wcro used to explore the relationships between subsequent 
stroko and tho CQvnriales (seo sedion 3.4). The methods used to 
ostimtlto heterogeneity woro the weighted and approximate MM. ML. 
REML. ED and FD. For the FB model assessments of convergence for 
tho parnmolers woro performed and found adequate when using a 
bum.fn of 10.000 iterntions nnd n sample chain of 40.000. 
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Method Odds ratio' 95%CI AgeO 95%CI "2 r 
MM, approx 0.780 0.647,0.940 0.963 0.438,2.120 0 
MM, weighted 0.780 0.647,0.940 0.963 0.438,2.120 0 
ML 0.780 0.647,0.940 0.963 0.438,2.120 0 
REML 0.780 0.647,0.940 0.963 0.436, 2.120 0 
EB 0.760 0.647, 0.940 0.963 0.436,2.120 0 
FB 0.790 0.545, 1.254* 1.013 0.894,1.139* 0.207 
Method Odds ratio' 95% CI Malau 95%CI i 1 I 
MM, approx 0.761 0.627, 0.923 1.022 0.948,1.103 0 
MM, weighted 0.761 0.627,0.923 1.022 0.946,1.103 0 
ML 0.761 0.627,0.923 1.022 0.946,1.103 0 
REML 0.761 0.627, 0.923 1.022 0.948, 1.103 0 
EB 0.761 0.627,0.923 1.022 0.948,1.103 0 
FB 0.787 0.532, 1.222* 1.018 0.920,1.123:1: 0.262 
Method Odds ratio' 95%CI StrokeO 95%CI i 2 
MM, approx 0.756 0.545, 1.049 0.926 0.665, 1.289 0.014 
MM, weighted 0.745 0.567, 0.978 0.935 0.683, 1.279 0 
ML 0.745 0.567, 0.978 0.935 0.683, 1.279 0 
REML 0.745 0.567,0.978 0.935 0.683, 1.279 0 
EB 0.745 0.567,0.978 0.935 0.683, 1.279 0 
FB 0.737 0.450, 1.293:1: 0.877 0.582, 1.329; 0.216 
§ Odds of subsequent stroke on dual treatment relative to aspirin when difference in percentage of covariate between the treatment groups 
equals zero, n Multiplicative increase in odds of subsequent stroke when the covariate is increased by 1 %, ; credibility intervals. 
Table 7.7 , Subsequent stroke at the end of the trial using summary data meta-regression methods for the comparison of dual 
treatment and aspirin alone 
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Method Odds rati0 3 95%CI AgeO 95%CI i 1 
MM, approx 0.622 0.497,0.778 1.063 0.771,1.466 0 
MM, weighted 0.622 0.497, 0.778 1.063 0.771,1.466 0 
ML 0.622 0.497,0.778 1.063 0.771,1.466 0 
REML 0.622 0.497,0.778 1.063 0.771,1.466 0 
EB 0.622 0.497,0.778 1.063 0.771,1.466 0 
FB 0.609 0.387, 1.007* 0.987 0.611,1.632* 0.213 
Method Odds ratio' 95%CI Malen 95%CI £2 
MM, approx 0.656 0.514,0.838 0.930 0.797, 1.086 0 I 
MM, weighted 0.656 0.514,0.838 0.930 0.797,1.086 0 
ML 0.656 0.514,0.838 0.930 0.797,1.086 0 
REML 0.656 0.514,0.838 0.930 0.797,1.086 0 
EB 0.656 0.514,0.838 0.930 0.797,1.086 0 
FB 0.626 0.451,0.883* 0.954 0.784, 1.160:1; 0.179 
Method Odds ratio' 95%CI Stroken 95%CI £2 
MM, approx 0.629 0.472,0.839 1.075 0.882,1.310 0.034 
MM, weighted 0.604 0.509,0.716 1.007 0.604, 1.091 0 
ML 0.604 0.509,0.716 1.007 0.604, 1.091 0 
REML 0.604 0.509,0.716 1.007 0.604,1.091 0 
EB 0.604 0.509,0.716 1.007 0.604, 1.091 0 
FB 0.626 0.448, 0.863* 1.074 0.875,1.366:1; 0.185 
§ Odds of subsequent stroke on dual treatment relative to aspirin when difference in percentage of covariate between the treatment groups 
equals zero, n Multiplicative increase in odds of subsequent stroke when the covariate is increased by 1 %, :1; credibility intervals. 
Table 7.8 Subsequent stroke at the end of the trial using summary data meta-regression methods for the comparison of dual 
treatment and control/placebo 
242 
Similar estimates for the treatment and covariate effects were seen 
from all of the classical and Bayesian models for each pair wise 
comparison (Tables 7.7 and 7.8). Slight differences between the 
magnitudes of the treatment and covariate effects from the FB 
models as compared to the classical and EB models is related to the 
estimates for the between trial heterogeneity. Also for the comparison 
of dual treatment against aspirin alone, the magnitude of 
heterogeneity found from the FB models impacted on the credibility 
intervals of the treatment effect so that they became non significant. 
In the age adjusted models, significant reductions in the estimated 
relative odds ratio for the treatment effect was seen in patients 
randomised to dual treatment as compared to either aspirin alone, or 
control/placebo. However, age did not appear to be an important 
predictor of the estimated relative odds ratio for the treatment effect in 
either of the comparisons (Tables 7.7 and 7.S). Also, in the gender 
adjusted models, gender did not appear to be an important factor on 
the estimated relative odds ratio for the treatment effect in either of 
the comparisons (Tables 7.7 and 7.8). 
When the models were adjusted for the type of qualifying event, the 
approximate MM method found small magnitudes of heterogeneity 
between the trials when the dual treatment was compared to aspirin 
alone and control/placebo, 0.014 and 0.034 respectively. The 
heterogeneity very slightly impacted on the odds ratio estimates by 
slightly reducing the importance of the dual treatment effect and 
emphasising the importance of the covariate effect; however, all of 
the models found that the covariate did not significantly impact on the 
estimated relative odds ratio for the treatment effect (Tab/es 7.7 and 
7.8). 
7.11 Individual patient data methods 
Using a classical fixed effect IPO model, patients randomised to dual 
treatment had significantly reduced risks of stroke at the end of trial 
by 26% (95% CI 7%, 31%) as compared to dipyridamole; by 22% 
(95% CI 4%, 36%) as compared to aspirin; and by 39% (95% CI 27%, 
50%) as compared to control/placebo (Table 7.9). 
Model method Odds ratio (SE) 95%CI 
Fixed effect modelling 
ADvs.D 0.744 {1.105} 0.593,0.933 
ADvs. A 0.782 {1.093} 0.640, 0.957 
ADvs. C 0.606 (1.087) 0.502,0.732 
Random effect modelling 
Classical REML 
ADvs.D 0.744 (1.105) 0.593, 0.933 
ADvs.A 0.782 (1.093) 0.640, 0.957 
ADvs. C 0.606 (1.087) 0.502, 0.732 
i 2 o (-) -
Full Bayesian 
ADvs.D 0.712 (1.228) 0.476, 1.065:t 
ADvs.A 0.736 (1.137) 0.572, 0.947; 
ADvs. C 0.576 (1.155) 0.434,0.764; 
i 2 0.118 (O.098) -
... .. SE Standard error, ~ ~ 95% credibility Intervals, A aspirin, D diPYridamole, C 
contrOl/placebo 
Table 7.9 Subsequent stroke at the end of trial using Individual patient 
data methodologies 
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7.12 Assessment of heterogeneity using individual 
patient data methods 
An interaction term between trial and treatment status was included in 
the above model to test whether there was heterogeneity between the 
trials. Allowing for this test having low power when a small number of 
trials are combined in the meta-analysis, there was no evidence of 
heterogeneity between the trial estimates (p =0.988). 
Classical and Bayesian random effect models were used where a 
common heterogeneity parameter was assumed. Additionally, for the 
FB models sample chains were run for a burn in of 5,000 iterations 
and monitored for 20,000 iterations. This length of chain was found to 
produce adequate assessments of convergence using techniques as 
described in section 2.5.3. 
The classical IPO model found that the heterogeneity was estimated 
as zero and hence the results for the treatment efficacies where 
identical to those yielded from the fixed effect IPD models; where dual 
treatment was associated with significant reductions in subsequent 
stroke as compared to dipyridamole alone, aspirin alone, and 
control/placebo by 26% (95% CI 7%,41%); 22% (95% CI 4%, 36%); 
and 39% (95% C127%, 50%), respectively (Table 7.9). 
Although the treatment estimates for the comparisons were similar to 
those estimated form the classical model, the FB model estimated a 
small amount of heterogeneity between the trial estimates. The 
heterogeneity impacted on the standard errors for the treatment effect 
making them slightly larger; however, the treatment effects only 
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became non-significant for the comparison against dipyridamole 
alone {Table 7.9}. 
7. 13 Exploring heterogeneity using individual 
patient data methods 
Although only the Bayesian model estimated some heterogeneity 
between the trial estimates, it may be advantageous to assess the 
impact of covariates on the treatment efficacies. Therefore trial level 
covariates, such as the dose of aspirin; and patient level covariates, 
such as the age, gender and type of qualifying event of the patients, 
were included in the random effect models. 
7.13.1 Trial level covariates using individual patient 
data 
The dose of aspirin was modelled using a classical random effect IPO 
meta-regression model as described in Section 3.5.1.3 to assess its 
impact on subsequent stroke at the end of trial. The daily dose of 
aspirin did not significantly affect the risk of subsequent stroke 
(p =0.840). 
7.13.2 Patient level covariates using individual 
patient data 
Classical and Bayesian models were performed to assess the impact 
of age, gender and type of qualifying events on subsequent stroke at 
the end of trial using random effects IPO models. Assessments of 
convergence were found to be adequate using a burn-in of 10,000 
iterations and sample chains of 40,000 iterations. 
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Initially, interaction terms between the covariate and treatment effects 
were introduced into the models to ascertain whether the treatment 
effects varied across the range of covariates. All of the models found 
no evidence of an interaction and hence the interaction terms were 
dropped from the models (age interaction p =0.99, gender interaction 
p =0.94, type of qualifying event interaction p =0.59). 
Models Classical REML Full Bayesian 
Odds ratio 95%CI Odds ratio 95%CI 
(SE) (SE) 
AD vs. D 0.740 (1.107) 0.607,0.903 0.796 (1.344) 0.446, 1.420+ 
ADvs. A 0.782 (1.094) 0.656, 0.933 0.847 (1.235) 0.560, 1.239+ 
AD vs. C 0.606 (1.088) 0.513,0.715 0.634 (1.223) 0.427,0.941:1: 
Age 1.034 (1.003) 1.027, 1.040 1.034 (1.003) 1.027, 1.040+ 
f2 0(-) - 0.105(-) -
AD vs. D 0.742 (1.106) 0.609, 0.903 0.808 (1.277) 0.500, 1.305+ 
ADvs.A 0.782 (1.093) 0.657,0.931 0.876 (1.220) 0.594, 1.294+ 
AD vs. C 0.607 (1.087) 0.515,0.715 0.646 (1.223) 0.435, 0.958+ 
Gender 1.052 (1.066) 0.929, 1.191 1.063 (1.067) 0.936, 1.207+ 
;2 0(-) - 0.232 (-) -
ADvs. D 0.741 (1.085) 0.632, 0.870 0.771 (1.310) 0.454, 1.310+ 
AD vs. A 0.783 (1.094) 0.656, 0.933 0.857 (1.228) 0.573,1.281+ 
ADvs. C 0.607 (1.088) 0.514,0.715 0.635 (1.213) 0.435, 0.922:1: 
QE 1.571 (1.084) 1.339, 1.843 1.543 (1.093) 1.297, 1.836+ 
f2 0(-) - 0.104 (-) -
Age, in years; Gender, male vs. female; QE qualifying event, stroke vs. TIA; ;2 is 
an estimate of heterogeneity; :l: 95% credibility intervals 
Table 7.10 Subsequent stroke at the end of trial using Individual patient 
data adjusted for patient level covariates 
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7.14 Discussion offindings 
The discussion of the findings from this systematic review is 
presented in six sections which relate to a summary of the overall 
findings, limitations of the data used in the review, comparison of the 
statistical methods, discussion of the results, practical implications of 
the results and suggestions for future research. 
7.14.1 Summary of the overall findings 
Seven randomised controlled trials of dipyridamole in strokerrlA 
patients were identified from a comprehensive search strategy which 
was performed up to December 2002. Individual patient data were 
available from five of these trials: data from the other two trials had 
been either previously discarded or we were unable to contact the 
authors of the trial. However, tabulated data from these two trials was 
extracted from the publications and merged with the individual patient 
data from the other trials. The data base comprised of data from 
11,255 stroke patients, and the patients from these trials were 
randomised to either a dual treatment of aspirin and dipyridamole, 
mono treatment with aspirin, mono treatment with dipyridamole or 
control/placebo. Baseline characteristics of the patients appeared to 
be balanced between the treatment groups from the individual trials. 
At the end of trial, patients randomised to the dual treatment of aspirin 
and dipyridamole had significantly lower risks of subsequent fatal or 
non-fatal stroke, non-fatal stroke, and an event as defined by the 
composite outcome (non-fatal stroke, non fatal myocardial infarction, 
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or death from a vascular event) as compared to either mono 
treatment with aspirin, mono treatment with dipyridamole or 
control/placebo. Additionally, patients randomised to the dual 
treatment had significantly lower risks of fatal or non-fatal myocardial 
infarction than compared to the control/placebo group. 
7.14.2 
7.14.2.1 
Limitations of the data used 
Number of studies included in the meta-analysis 
The search strategy used in this systematic review identified seven 
randomised controlled trials of dipyridamole given to strokelTlA 
patients for secondary prevention. Outcome data for these trials were 
available from all of the trials either through sharing individual patient 
data or extracted from the publications. However, the focus of the 
meta-analysis was based on assessing the efficacy of the combined 
treatment of aspirin and dipyridamole against mono treatment or 
control/placebo. The oldest trial by Acheson and colleagues only 
assessed the efficacy of the mono treatment of dipyridamole 
compared with placebo (Acheson et al. 1969), and hence this trial 
wasn't included in any of the analyses. 
7.14.2.2 Timings of the outcomes 
It was decided a priori to use the end of trial as the primary outcome 
assessment time. This timing was used to allow for a consistent end 
point to be specified and was thought preferable to using a particular 
time point such as one year, since there was a lack of data at a 
consistent time point across the trials. However, within some of the 
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trial proportions of patients weren't follow-up to the end of trial 
(Acheson et al. 1969; Guiraud-Chaumeil et al. 1982; Caneschi et al. 
1985; The American-Canadian Co-operative Study Group 1985). 
Generally, these patients were follow-up for a minimum length of 
time; however, it is acknowledged that this could have lead to biased 
estimates for these trials being estimated; where an over-estimate of 
the treatment effect would be yielded if the patients which dropped 
out early did so just before they suffered a subsequent event. 
It would have been more efficient to have used survival analysis to 
analyse the data for subsequent stroke, where not only the timing of 
the events are taken into consideration, but also allow for the data 
from the early drop out patients to be included in the analysis by 
censoring their data. However, data for the time to subsequent stroke 
was not available from these four trials and hence the analysis could 
not be undertaken. 
7.14.2.3 Extent of the shared individual patient data 
Although the original trials generally collected considerable amounts 
of data during the baseline and end of trial follow up times, the data 
shared with the collaboration was not consistent across the trials. For 
the ESPS and ESPS II trials, all recorded measurements taken 
throughout the trials duration were shared with the collaboration; 
however, for the other three trials (Guiraud-Chaumeil et al. 1982; 
Sousser et al. 1983; The American-Canadian Co-operative Study 
Group 1985) the individual patient data was shared from the 
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Antithrombotic Trialists Collaboration (Antithrombotic Trialists 
Collaboration 2002) and not from the original trialists. 
Bias may also result if data from some identified studies are 
unavailable, as occurred here with two studies (Acheson et al. 1969; 
Caneschi et al. 1985) although the missing data comprised <2% of 
the total data set. Tabulated data from the publications of these trials 
were included in the unadjusted analyses however, data for the 
exploration of heterogeneity were not available from the publications 
and hence these studies were not included in these analyses. Finally, 
we were not able to adjust for all potential prognostic factors, such as 
previous ischaemic heart disease and time from event to treatment; 
since these data were not available for most of the identified trials. 
Hence, some sources of heterogeneity will not have been explored in 
the analyses. 
7.14.2.4 Outcome assessments 
The primary and secondary outcome assessments used in this 
systematic review were selected a priori before the trials were 
identified and following discussion with the principal collaborators of 
the Dipyridamole in Stroke Collaboration (DISC). 
A trial was deemed eligible for inclusion into the systematic review if it 
recruited either TIA and/or stroke patients. This was to allow for trials 
with the widest definition of a cerebrovascular event to be included. 
Therefore, subsequent stroke was chosen as the primary outcome 
measure because it is the most common vascular events in patients 
with recent cerebrovascular events. This outcome assessment 
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appears to be a justified assessment to use to assess the efficacy of 
the dual treatment of aspirin and dipyridamole since it a component of 
the primary outcome measures used, either alone or with other 
events, in each of the identified trials. 
The secondary outcome measures specified included non-fatal 
stroke, combined fatal and non-fatal myocardial infarction, vascular 
death, and a composite outcome of non-fatal stroke, non-fatal 
myocardial infection, and vascular death to assess the impact of the 
dual treatment on all types of vascular outcomes. 
7.14.3 
7.14.3.1 
Comparison of the statistical methods 
Assessments of heterogeneity 
The impact of heterogeneity on the results was assessed using 
various statistical models for subsequent stroke at the end of trial. 
Initially, statistical assessments of heterogeneity were performed 
based on summary data methods, which consistently found no 
heterogeneity between the results, from using Cochran's 
homogeneity test and /2. No evidence of heterogeneity was also 
seen when using an individual patient data model by including a fixed 
effect interaction term between treatment and trial. Although, it is 
widely acknowledged that the power of both Cochran's homogeneity 
test and including an interaction term in an IPD model, are affected by 
having a small number of trials in the meta-analysis (Fleiss 1986; 
Whitehead et al. 1991; Brown et al. 1994; Thompson 1994), 12 has 
found to not be affected (Higgins et al. 2002); and therefore it appears 
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that the differences between the estimates from the individual trials 
may be due to sampling variation only. 
7.14.3.2 Impact of quantifying heterogeneity 
A range of estimation methods were used in random effect models to 
assess whether there were differences between the results. All of the 
classical summary and IPO models and the empirical Bayes models 
found no heterogeneity between the results; therefore the results for 
the treatment effect were identical from these models as compared 
with the fixed effect models. Conversely, the full Bayesian summary 
and IPO models consistently quantified small amounts of 
heterogeneity. This is not surprising since the nature of the full 
Bayesian models are to assume that all of the parameters to be 
estimated in the random effect models are random variables with pre-
specified distributions; hence it is inevitable that some heterogeneity 
will be estimated. 
Individual patient data models were then used to assess the impact of 
the dual treatment of aspirin and dipyridamole on subsequent stroke 
at the end of trial. From the classical models, patient randomised to 
the dual treatment were found to have significantly lower risks of 
subsequent stroke than compared to patients receiving aspirin alone 
(22% reduced), dipyridamole alone (28% reduced), or placebo/control 
(29% reduced). 
The significance of these findings were also seen in the full Bayesian 
models for two of the three pair wise comparisons, however, for the 
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comparison against dipyridamole the efficacy of the dual treatment 
was no longer significant. Also, the estimates for the treatment effects 
were slightly impact on by full Bayesian model estimating the 
heterogeneity making the magnitudes slightly larger by approximately 
4%. 
7.14.3.3 Impact of exploring heterogeneity 
Various estimation methods were then used in meta-regression 
models based on summary data to assess whether there were any 
treatment effect modifiers and whether there were any differences 
between the results from the estimation methods. All of the models 
yielded similar results for the treatment and covariate effect which 
implied that age, gender, and type of qualifying event did not modify 
the treatment effects. The lack of significance for the covariate in the 
summary data models was somewhat expected due to the small 
number of trials being assessed. The Cochrane Collaboration has 
suggested that meta-regression models should only be used where 
there are more than ten studies being assessed in the meta-analysis 
(The Cochrane Collaboration 2003). 
From the adjusted IPD models, although there no evidence of effect 
modifiers for any of the covariates assessed; several predictors of 
subsequent stroke were found. The included age and type of 
qualifying event; however gender did not appear to impact on the 
results. 
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Age suggested a small but significant effect were a 30% increase in 
the risk of subsequent stroke was seen for every 10 year increase in 
age. However, the single best predictor of subsequent stroke was 
based on the patients qualifying event. In this study, patients with 
stroke as their qualifying event were found to be at an increased risk 
of subsequent stroke by approximately 55% as compared to patients 
whose qualifying events was TIA. These findings are intuitive since 
stroke in known to be more common in the older population and in 
people who have already suffered a stroke (Johnston et al. 2003; Lee 
et al. 2004; Modrego et al. 2004). Although these predictors were also 
found in the full Bayesian models, the 95% credibility intervals 
suggested that the treatment effects were not significant in these 
models. 
Four of the trials randomised patients to more than two treatment 
groups (Guiraud-Chaumeil et al. 1982; Sousser et al. 1983; Caneschi 
et al. 1985; Diener et al. 1996); and having data at the IPD level 
enables contrasts to be specified for the type of treatment received. In 
the summary data models, separate analyses were conducted where 
the dual treatment of aspirin and dipyridamole were used repeatedly 
for each analysis. In this systematic review, since it was meaningless 
to combined the comparisons into an overall comparison group, the 
summary data analysis methods used were inefficient and assumed 
independence of the dual treatment group, which was used three 
times for the pair wise comparisons. 
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7.14.4 Discussion of the results 
This systematic review provides substantial evidence for the efficacy 
of dual treatment of aspirin and dipyridamole given to patients with 
recent cerebrovascular events. The aim of this systematic review was 
to estimate the magnitude of the efficacy of the dual treatment and 
also to identify which patients should be targeted for the dual 
treatment. 
7.14.4.1 Impact of dual treatment of aspirin and 
dipyridamole on subsequent stroke 
This meta-analysis of dipyridamole in patients with prior 
cerebrovascular events shows that a dual treatment of aspirin and 
dipyridamole is effective in reducing the risk of subsequent stroke. 
The risk of subsequent stroke was reduced with the combination of 
aspirin and dipyridamole as compared to aspirin alone (22%), or 
dipyridamole alone (28%). The combination of aspirin and 
dipyridamole gave twice the reduction (40%). These findings compare 
well with those of previous meta-analyses using aggregate data 
(Lowenthal et al. 1994; Diener 1998; Tijssen 1998). 
7.14.4.2 Impact of dual treatment of aspirin and 
dipyridamole on other outcomes 
A potential criticism of ESPS " and some other large trials such as 
Perindopril Protection Against Recurrent Stroke Study (PROGRESS 
Collaborative Group 2001) is their use of subsequent stroke, rather 
than the composite of non-fatal stroke, non fatal myocardial infarction, 
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and vascular death, as the primary outcome. Importantly, the dual 
treatment of aspirin and dipyridamole was found to reduce the risk of 
the composite outcome as compared with dipyridamole alone, as 
seen in the A IT (Antithrombotic Trialists Collaboration 2002): and as 
compared to aspirin alone or placebo/control. 
Dipyridamole in combination with aspirin did not alter the rate of 
myocardial infarction in patients with previous cerebrovascular events 
when compared against aspirin alone. In contrast, the addition of 
aspirin reduced the risk of myocardial infarction non-significantly by 
30% (AD vs. D), a findings that is compatible with the ATT findings for 
aspirin (Antithrombotic Trialists Collaboration 2002). 
The dual treatment of aspirin and dipyridamole did not alter the risk of 
vascular death when compared to aspirin alone or dipyridamole 
alone. This finding is probably related to a lack of power due to small 
number of events being recorded in the individual trials, since no 
effect was also seen when the dual treatment was compared to 
placebo/control. 
7.14.4.3 Differences between ESPS II and the other trials 
The ESPS " trial may have found that the dual treatment of aspirin 
and dipyridamole significantly reduces the risk of vascular events for 
several reasons (Diener et al. 1996). ESPS " provided 57% of the 
total data in this review and was positive in its outcome; it is possible 
that this trial is the primary driver for the findings reported here. 
However, when the data for ESPS II was excluded from the analyses, 
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the assessment of the dual treatment of aspirin and dipyridamole 
versus control remained positive whilst the comparison against 
aspirin became non-significant although the point estimates for the 
dual treatment support the efficacy of the dual agents. Earlier trials 
individually failed to find a positive effect of dipyridamole in stroke is 
unsurprising since they were all much smaller with lower statistical 
power (type II error). 
Another reason may be related to the dose of aspirin, since the 
additive effect of dipyridamole on aspirin would be relatively smaller 
for studies which had higher doses of aspirin than compared to the 
additive effect of dipyridamole on lower doses of aspirin, as used in 
the ESPS II trial. 
7.14.4.4 Impact of trial and patient characteristics 
Subgroup analyses indicated that trial characteristics such as the 
method of formulation for dipyridamole and the dose of aspirin 
appeared to have little effect on the overall conclusions. The dose of 
aspirin used in the ESPS \I trial has been previously criticised where 
the high stroke rates seen in the aspirin only group were thought to 
be related to the low level of dose (Davis et al. 1998). However, the 
lack of heterogeneity between the trial estimates and the results from 
the subgroup analyses suggested that the efficacy of the dual 
treatment was unrelated to the dose of aspirin. 
From individual patient data models, patients with stroke as their 
qualifying event were found to be more likely to suffer a subsequent 
stroke as compared to those with TIA; also, increasing age was found 
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to be an important predictor of subsequent stroke. However; there 
was no evidence that the dual treatment of aspirin and dipyridamole 
was not more beneficial in these patients. A lack of interaction may be 
related to suboptimal levels of power from the small number of trials 
included in the meta-analysis. 
7.14.4.5 Generalisability of the findings 
The findings contrast with the neutral results for dipyridamole in 
systematic reviews which included trials involving groups of patients 
other than just stroke, e.g. those with myocardial infarction 
(Antithrombotic Trialists Collaboration 2002; De Schryver et al. 2003), 
a situation which is unsurprising. First, the epidemiology of stroke and 
ischaemic heart disease are different; stroke patients are older and 
more likely to be female, also stroke has a stronger relationship with 
the risk factor hypertension, than seen in patients with myocardial 
infarction. Second, ischaemic stroke is of mixed cause (large artery 
disease, cardioembolic, and small vessel disease), where as 
myocardial infarction largely follows coronary artery plaque ruptures 
and thrombosis. Third, the main risk after stroke is of having a 
subsequent stroke, as seen in this analysis, whilst patients with a 
myocardial infarction are more likely to have a further cardiac event. 
Finally, trials of primary prevention have consistently shown a 
differential treatment effect so that reducing SP is more effective in 
reducing stroke than myocardial infarction: 40% versus 15% 
reduction for a 10/6 mm Hg reduction in SP. 
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Considerable discussion, largely based on the results of ESPS II, has 
focussed on whether dipyridamole has selective effects on stroke. 
These possible differential effects on vascular events have also been 
observed for antihypertensive agents, e.g. calcium channel blockers 
may reduce stroke more than myocardial infarction whilst angiotensin 
converting enzyme inhibitors appear to have the opposite effect 
(Blood Pressure Lowering Treatment Trialists' Collaboration 2000). 
The neutral rather than negative results for oral dipyridamole on 
myocardial infarction, as reported specifically in ESPS II (Diener et a/. 
1996), is reassuring in the view of this perception based on the use of 
intravenous dipyridamole in cardiac stress testing (Pfisterer 1992), 
that it might cause myocardial infarction. However, if one assumes 
that any platelet agent should have an affect on platelet mediated 
diseases wherever in the body it occurs, as assumed for aspirin and 
for clopidogrel; then the neutral result for dipyridamole on myocardial 
infarction found in ESPS II and this review can be explained in two 
ways. First, if we assume the above is true then as suggested 
previously the results from these studies focussed on stroke and so 
there were few cardiac events and so the failure to see such a 
reduction may be an issue of power. Or alternatively, if there is the 
possibility that there is a true discrepancy, and somehow 
dipyridamole stops cerebral platelet mediated events but not cardiac 
ones, then perhaps dipyridamole has a cardiotoxic effect that cancels 
out its platelet effect (Gladman Personal communication). This 
cardiotoxic effect could explain why many people can not tolerate 
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dipyridamole since the side effects they have nothing to do with the 
antiplatelet effect and may have something to do with the cardiotoxic 
effect. 
Systematic reviews are susceptible to missing unpublished trials or 
those which are published in non-English journals, so-called 
publication bias. Many such stUdies will be neutral or negative in 
outcome and reviews will then have positively biased results. We 
performed a comprehensive multilingual search strategy, utilised the 
publication lists of existing trials and reviews, and contacted the 
pharmaceutical company which manufactures dipyridamole to help 
identify relevant trials. Additionally, no statistical evidence of 
publication bias was seen for any of the methods, hence the trials 
identified in this review probably represent the totality of trial evidence 
relating to dipyridamole in patients with cerebrovascular disease, and 
it is unlikely that the results are biased by a failure to include relevant 
studies. 
7.14.5 Practical implications 
Dipyridamole in combination with aspirin reduces recurrence in 
patients with prior cerebrovascular events. The data are internally 
consistent between the trials and are broadly relevant to stroke 
patients external to the trials. Hence, this treatment has a place in 
secondary prevention after stroke or TIA, as recommended in current 
national and international guidelines (80gousslavsky et al. 2000; The 
Intercollegiate Working Party for Stroke 2002). 
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In depth analyses were performed in this review, however it appears 
that all patients with recent cerebrovascular events have equal benefit 
of the dual treatment, and no specific subgroups of patients where 
identified as effect modifiers. However, analyses did indicate that age 
was an important predictor of subsequent stroke and patients which 
suffered stroke as their qualifying cerebrovascular event had 
significantly higher risks of subsequent stroke at the end of trial. 
Surprisingly, although it is widely acknowledged that females are 
more likely to suffer an initial stroke; it appears from these analyses 
that females are not at a higher risk of subsequent stroke than males; 
however, the reasons for this finding remain unclear. However, the 
factors assessed in this meta-analysis were done so as part of post 
hoc analyses and there are open to bias. 
The results from this systematic review has important implications to 
service providers who need to ensure that patients which have 
recently suffered a cerebrovascular disease are offered the dual 
treatment of aspirin and dipyridamole. However, the administration of 
dipyridamole with aspirin will depend on patient-specific factors such 
as underlying risk, experience on existing antiplatelet drugs, and 
tolerance or allergies to each of the drugs. Since further analysis of 
the data revealed that patients were more likely to drop out of the 
individual trials or have significant headaches develop if they received 
dipyridamole (with or without aspirin) as compared to aspirin alone 
(p<O.001) or control/placebo (p<O.001). In contrast, the bleeding 
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rates were highest with aspirin treatment (with or without 
dipyridamole) (p <0.001) (Leonardi-Bee et al. 2005). 
From a public health perspective, clinicians are likely to use this 
combination treatment is it is deemed not only effective but also cost-
effective; however it is unsure at the present whether the cost of 
providing such treatments as specified in this review could be 
possibly met since although the cost of aspirin is minimal; the 
additional cost of dipyridamole may be difficult to meet; since minimal 
studies have been performed assessing this. 
7.14.6 Future research 
This review attempted to combine all of the available evidence and to 
estimate the benefit of a combined treatment of aspirin and 
dipyridamole in the secondary prevention of strokefTlA. However, it 
has not been able to fully explore which patients benefit the most 
from the combination treatment; this was primarily due to a lack of 
specific data being consistently shared across the trials. Also, if any 
significant effect modifiers had been found from this meta-analysis, 
the findings should be replicated in a subsequent sufficiently powered 
randomised controlled trial. 
Also, although this review has highlighted the combination of 
dipyridamole and aspirin is effective; the cost effectiveness of the 
combination treatment should be fully assessed. To do such a study 
would require health data and cost data, or data which generate 
costs, such as survival, stroke and disability. This type of analysis 
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could not be performed in this review due to a lack of data for specific 
cost generating outcomes for each of the individual trials. 
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CHAPTER 8 
GENERAL DISCUSSION 
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8.1 Introduction 
This thesis has described methods for conducting meta-analyses 
based on summary and individual patient data and has exemplified 
these methods using three meta-analyses of randomised controlled 
trials in stroke. The findings from these meta-analyses have been 
discussed in detail in the individual chapters. 
This chapter will be presented in five sections which relates to a 
summary of the advantages of meta-analyses, summary of the main 
limitations of meta-analyses, practical implications and 
recommendations for researchers, suggestions for future research, 
and conclusions. 
8.2 Summary of the advantages of meta-analyses 
Clinicians are repeatedly faced with questions of how best to treat 
patients; answers to these questions should be based on evidence 
based practice however, this evidence can provide advice that is 
diverse or conflicting. This diversity has lead to methodology being 
devised which attempts to combine the findings and produce 
generalisable conclusions. Meta-analyses based on systematic 
reviews are the most common method that is used since they have 
the advantage that they have increased power to perform analyses 
which can yield estimates for pooled intervention effects which are 
more generalisable, and therefore help clinicians and researchers to 
make more informed choices. 
Meta-analyses based on individual patient data have been described 
as the gold standard of systematic reviews and are quoted as 'a 
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yardstick against which other forms of systematic reviews could be 
measured' (Chalmers et al. 1993). This is because they remove some 
of the problems associated with meta-analyses based solely on data 
extracted from the literature, by allowing for detailed data checking 
and having access to data which was not originally published. 
However, they require considerable time and effort in contacting 
original trialists, merging of individual patient data into a single 
database, and often involve complex analyses (Clarke et al. 1994). At 
present there appears to be little evidence that the gains from 
performing a meta-analysis based on individual patient data are 
worthwhile and justified (Sutton et al. 1999). Since the late eighties, 
much collaboration has been achieved between trialists and much 
data has been shared to try to answer pressing questions that could 
not be answered alone from using summary data. 
So far very few individual patient data meta-analyses have been 
published in the research area of stroke and mostly centre in the 
medical research area of cancer and assess the relationship between 
treatment and time to event data. To date, within the research area of 
secondary prevention of stroke, apart from the meta-analyses 
conducted in this thesis only two other articles have been published 
which have performed a meta-analysis using individual patient data 
(Chen et al. 2000; Cornu et al. 2000). These meta-analyses were 
used to predict risks for outcomes and to allow for more in-depth 
subgroup analyses to be performed. 
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The findings from the meta-analyses considered in this thesis were 
very informative with regards to efficacy of specific interventions and 
highlighted which subgroups of patients should be targeted, and 
therefore allowed for a more balanced interpretation and wider 
endorsement of the available evidence in these three areas of 
controversy. 
Contacting the collaborators from the original trials enabled a fuller 
exploration of heterogeneity between the trials to be performed using 
both summary and individual patient data methods. This wouldn't 
have been possible if the data had been solely extracted from the 
original publications, as a considerable amount of the data were not 
presented in ways in which it could have been extracted. 
The findings from the meta-analyses considered in this thesis provide 
an insight into the gains that can be had through collaborations with 
other investigators and from the sharing of individual patient data. 
Therefore, these findings need to be widely disseminated to allow 
these revealing results to be available to clinicians, researchers and 
the wider stroke community so that it may inform them and if 
appropriate, change their clinical practice in line with these findings. 
8.3 Summary of the main limitations of meta-
analyses 
Systematic reviews and meta-analyses have distinct disadvantages 
associated with them (see Chapter 1); a summary of the main 
limitations which were apparent in the three meta-analyses from 
within this thesis are discussed. 
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8.3.1 Publication bias 
Evidence of publication bias is a common finding in meta-analyses of 
randomised controlled trials (Oxman et al. 1995), where a relatively 
large number of studies are combined; as seen in the Blood pressure 
in Acute Stroke Collaboration meta-analysis from this thesis. However 
publication bias is less likely to be found when a small number of 
studies are included in the meta-analysis due to a lack of power. 
Although an assessment of publication bias should always be made 
within a meta-analysis, evidence of publication bias may be seen due 
to other factors, such as methodological quality of the trials. 
Therefore, efforts should be taken to assess how publication bias 
could impact on the findings from the meta-analysis, either through 
performing a sensitivity analysis where poor quality studies are 
excluded, or by exploring reasons for publication bias through using 
subgroup or regression analyses. 
8.3.2 Extent of shared individual patient data 
All of the meta-analyses considered in this thesis suffered from 
problems due to the inability to get individual patient data for all of the 
trials. Therefore, data from the publications of the trials had to be 
sought and extracted. In the majority of cases the data not shared 
were from older studies which had been discarded previously. 
However, this limited the amount of exploratory analyses that could 
be performed. 
Additionally, missing data at study level can have a high impact of the 
results of the meta-analysis by introducing Significant biases in the 
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results, especially when exploring heterogeneity since these studies 
are then excluded from the analyses. Although the problems 
associated with data missing at study level are unique to meta-
analyses (Sutton et al. 1998), little research has been performed to 
date. 
Within the Blood pressure in Acute Stroke Collaboration meta-
analysis, due to a large number of studies not having data at the 
individual level, where possible the covariates in the adjusted 
individual patient data models for these studies were included using 
the study level value for each patient. Other researchers have 
suggested that where data is missing one can assume that the 
covariate is balanced between the two treatment groups, hence the 
difference between groups is set at zero (Higgins et al. 2001). 
However, this assumption is probably invalid in most cases, and 
would be hard to verify. Alternatively, a data index variable could be 
created where the covariate takes a value of 1 if it is observed and a 
zero if it is missing (Pigott et al. 1994). This would allow the 
researcher to assess whether this index variable is correlated with 
other covariates where there is no missing data. If a correlation is 
observed, then it appears that there some evidence that the reasons 
for the missing data could be dependent on the other covariates with 
no missing data (Pigott et al. 1994). These two methods thought 
could only be considered where there is a minority of studies with 
missing data. 
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8.3.3 Misleading meta-analyses 
Although each of the individual patient data meta-analyses 
considered in this thesis were conducted with a high methodological 
rigour, there is still the potential for the results from these meta-
analyses to be misleading and not replicated in a mega-sized tria\. 
Misleading results from meta-analyses have been systematically 
studied and found to only have fair agreement with large randomised 
control/ed trials (Ioannidis et al. 1998) this was also observed in this 
thesis in both the occupational therapy and dipyridamole meta-
analyses. A point worth mentioning is that meta-analyses should not 
be used as a solution instead of performing a large well designed 
randomised controlled trial since the results of a meta-analysis do not 
show how to treat individuals (Lau et al. 1998). Therefore, it is 
essential that large randomised controlled trials investigating any 
subsequent specific medical areas of debate identified from meta-
analyses are conducted and explored. 
8.3.4 Fixed effect or random effect model? 
At present, there does not appear to be a clear and simple answer to 
whether a fixed effect or random effect model should be used to 
combine the results from the individual trials. It has been argued that 
it is not the significance of the pooled p value that is important, but 
the estimates and their standard errors for the intervention effect 
(Sutton et al. 1998). It is clearly important that whichever method is 
used, a thorough analysis is emproyed to assess the impact of any 
heterogeneity between the studies. and to attempt to explore any 
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heterogeneity through the use of subgroup analysis or regression 
analyses. In the meta-analyses considered in this thesis, little 
differences were seen in the treatment estimates between the fixed 
effect and random effect models, which is probably due to low levels 
of heterogeneity being observed in these examples. 
Since meta-analysis is a tool that is used to combine studies which 
are thought to be comparable; it is only sensible to combine them if 
they are not too heterogeneous. A random effect model will allow for 
certain degrees of heterogeneity, however, there will come a point 
where the heterogeneity is so large that the random effect model will 
become inadequate, and the meta-analysis needs to be abandoned. 
However, it is unclear at present what the minimum level of 
comparability is before a judgement is made that the studies are too 
heterogeneous and therefore inappropriate to be combined in a meta-
analysis (Sutton et al. 1998). 
8.4 Practical implications and recommendations 
for researchers 
8.4.1 Involving the original trialists 
Researchers embarking on a systematic review and meta-analysis 
should ensure they perform a comprehensive search strategy to 
minimise the risk of not identifying all eligible studies. We contacted 
all of the original contact investigators from the trials to ask them to 
share their individual patient data with the specific collaboration. We 
found the investigators were more willing to share their data with the 
collaboration when they received reassurance of authorship status for 
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their contributions in providing data and editing of the draft manuscript 
of the systematic review. 
8.4.2 Summary or individual patient data 
methodologies? 
Stewart and Clarke have looked at the differences between meta-
analysis using literature data and individual patient data (Stewart et 
al. 1995). They conclude that differences in the effect estimates of the 
intervention may be seen when comparing the two methods. The 
combination of unpublished trials, excluded patients, short follow-ups, 
and fixed time-point analysis are thought to contribute to an over 
estimation of the effects in a meta-analysis of literature data. 
Therefore the authors concluded that a meta-analysis based on 
individual patient data gave the least biased result (Stewart et al. 
1995). 
80th summary and individual patient data methodologies were 
considered in this thesis and taking into account the findings of 
Stewart and Clarke, the data used from each of the trials was 
primarily based on individual patient data, and summarised where 
appropriate. No clinically important differences for treatment effects 
were seen between the two methods; therefore it is recommended 
that researchers which are less confident with using more complex 
analysis packages, such as SAS for Windows or MLWin, should use 
random effect summary data methods to perform their analyses. 
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8.4.3 Quantifying and exploring heterogeneity 
Within the thesis, methods for the testing of heterogeneity and a 
range of the most common estimation methods of estimating 
heterogeneity were considered. All of the estimation methods 
appeared to perform well when used in these three data sets; 
however, testing for heterogeneity seemed to be less important and 
the question of how much heterogeneity exists within the meta-
analysis appeared more important (Higgins et a/. 2002). 
It also seems essential to explore the reasons behind heterogeneity 
using appropriate analyses as described in this thesis; however, it is 
recommended that a random effect model is used to do this, 
especially where heterogeneity is present. This is to ensure that the 
importance of the explored covariate is not overtly emphasised as 
would be seen from using a fixed effect model (Thompson et a/. 
1999). 
A lower power has been associated with using meta-regression 
techniques are compared to using an individual patient data analysis 
(Lambert et al. 2002). They also found that the estimates for the 
patient level covariates rarely agreed between the methods as 
confirmed in this thesis. Therefore, it is recommended that a meta-
analysis based on individual patient data is needed when the meta-
analysis attempts to see how patient level covariates are related to 
the intervention. Lambert and colleagues stress that meta-regression 
is not a biased method and if an effect is detected then it is probably 
a large and important one. However, caution is needed since within 
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the Blood pressure in Acute Stroke Collaboration meta-analysis. 
systolic BP at baseline was found to be an important predictor of the 
relative estimate of the odds ratio for the treatment effect using meta-
regression methods. but not found to be an important effect modifier 
when an individual patient data model was considered. 
8.5 Suggestions for future research 
Although we were generally successful in obtaining the individual 
patient data from the majority of the studies included within two of the 
meta-analyses. problems were encountered with the Blood pressure 
in Acute Stroke Collaboration meta-analysis where a third of the 
studies did not have covariate data at the individual level and so the 
average trial level value was used for those particular trials in the 
individual patient data models. More research is needed in 
developing methodologies for combining summary and individual 
patient data covariates to allow for this lack of individual patient data 
from original trials. 
Within this thesis, some evidence of publication bias was seen in one 
of the meta-analyses; as yet. there has been little research into 
methods which adjust for publication bias during the analysis stage 
(Thompson et a/. 1999). Also. it has been suggested that since 
publication bias can lead to heterogeneity between the trials within a 
meta-analysis (Sutton et a/. 1998). then further research is needed 
into assessing the impact of publication bias on quantifying and 
exploring heterogeneity. 
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This thesis has focussed on whether there are clinically important 
differences between the heterogeneity assessment methods; 
however even though no clinically important differences were seen in 
these meta-analyses, there may be statistically important differences 
which could be evaluated using a series of simulation studies. 
8.6 Conclusions 
To conclude, collaborations within the area of stroke medicine can be 
successful and much data can be shared. The findings from meta-
analyses, if conducted with high methodological rigour, can be 
informative about the effectiveness of particular treatments and about 
which patients should be targeted for treatment. The findings from a 
well conducted review can also help steer the direction of future trials. 
Summary data meta-analyses are practically easier and can be very 
rewarding; however, assessments and explorations of heterogeneity 
should always be made. Meta-analyses based on individual patient 
data may be needed to allow for more in depth investigations of 
heterogeneity. especially of patient characteristics. However, they 
themselves are not the panacea to all difficulties since they are 
subject to particular problems, mainly related to obtaining individual 
patient data to enable in depth analyses. 
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